SPONSOR: The University of Chicago  
 
1 
Version 4Apr2019  
A phase II trial of nivolumab/nab -paclitaxel/carboplatin 
induction chemotherapy followed by response -stratified 
locoregional therapy for patients  with locoregionally 
advanced  HPV-related oropharyngeal c ancer  – the OPTIMA II 
Trial  
 
OPTIMA = O roPharyngeal Tumor Induction chemotherapy  and response -
stratified locoregional therapy  trial in order to Minimize long -term Adverse 
events  
 
 
 
 
 
UCCCC IRB Number:  IRB17 -0104  
 
Coordinating Center:  The University of Chicago  
 
Principal Investigator:  Everett Vokes   
    Section of Hematology/Oncology,  
University of Chicago Medical Center   
    5841 S Maryland Avenue ; MC6092 , Chicago, IL 60637  
    Phone: 773 -702-9306   
E-mail: evokes @medicine.bsd.uchicago.edu  
 
Co-Investigators:   Alexander T. Pearson  
Daniel Haraf  (Radiation  Oncology  PI) 
    Nishant Agrawal  (ENT  PI) 
    Michael Spiotto   
    Zhen Gooi   
Louis Portugal  
Elizabeth Blair  
Nicole Cipriani  
Mark Lingen  
Statistician:    Theodore Karriso n 
Research Nurse:   Courtney Mccampbell   
Study Coordinator:   Elaine Klema  
Data Manager:   Melody Jones  
 
  
SPONSOR: The University of Chicago  
 
2 
Version 4Apr2019  Table of Contents  
 
1 PROTOCOL SYNOPSIS & SCHEMATA ................................ ................................ ......6 
1.1 Brief Trial Schema  ................................ ................................ ................................ .6 
1.2 Brief Schema for Response -Stratified Locoregional Therapy  ........................... 6 
1.3 Brief Overview of Risk Classification  ................................ ................................ ..7 
1.4 Brief Trial Design Overview  ................................ ................................ ................. 7 
1.5 Brief Background and Rationale  ................................ ................................ .......... 8 
1.6 Brief Definition of Subject Populat ion ................................ ................................ .9 
1.7 Brief Overview of Objectives  ................................ ................................ ................ 9 
1.8 Key Inclusion Criteria  ................................ ................................ ......................... 10 
1.9 Brief Overview of Treatment Plan  ................................ ................................ .....10 
1.10  Brief Summary of Treatment Duration  ................................ ............................. 12 
1.11  Brief Overview of Statistical analysis  ................................ ................................ .12 
2 OBJECTIVES  ................................ ................................ ................................ .................. 14 
2.1 Primary Objective  ................................ ................................ ................................ 14 
2.2 Secondary Objectives  ................................ ................................ ........................... 14 
2.3 Laboratory Objectives  ................................ ................................ ......................... 15 
2.4 Exploratory Objectives  ................................ ................................ ........................ 15 
3 BACKGROUND  ................................ ................................ ................................ .............. 16 
3.1 Locally Advanced Head and Neck Cancer  ................................ ........................ 16 
3.2 Chemoradiotherapy  ................................ ................................ ............................. 16 
3.2.1  CRT Platforms: Concurrent Cisplatin -Radiation or TFHX  ........................... 17 
3.3 Induction Chemotherapy  ................................ ................................ .................... 18 
3.4 Human Papillomavirus (HPV) and HNSCC  ................................ ..................... 19 
3.5 Response -Adapted Volume De -escalation (RAVD)  ................................ .......... 20 
3.6 Dose De -escalation for HPV -related Oropharynx Cancer  ............................... 21 
3.7 Transoral Robotic Surgery (TORS)  ................................ ................................ ...21 
3.8 Positron Emission Tomography (PET) -Based Surveillance  ............................ 23 
3.9 Nivolumab / anti -PD-1 ................................ ................................ ......................... 23 
3.10  Study Rationale  ................................ ................................ ................................ ....24 
3.10.1  Risk Sta tus ................................ ................................ ................................ ............ 26 
3.10.2  Group A 1: Single -Modality De -escalation Arm (SDA) -- TORS B: Single -
Modality De -escalation Arm (SDA) –RT ................................ .......... 26 
3.10.3  Group A2: Single -Modality De -escalation Arm (SDA) –RT ............................ 26 
3.10.4  Group B: Intermediate De -escalation Arm (IDA) – Intermediate dose CRT  26 
3.10.5  Group C: Regular  Dose Arm (RDA) – Standard dose CRT:  .......................... 27 
SPONSOR: The University of Chicago  
 
3 
Version 4Apr2019  3.10.6  Adjuvant Treatment with Nivolumab/anti -PD-1 ................................ .............. 27 
4 SUBJECT SELECTION  ................................ ................................ ................................ .28 
4.1 Eligibility Criteria  ................................ ................................ ................................ 28 
4.2 Exclu sion Criteria  ................................ ................................ ................................ 29 
4.3 Criteria for discontinuation/withdrawal of informed consent  ......................... 31 
4.4 HPV testing  ................................ ................................ ................................ ........... 32 
5 TREATMENT PLAN  ................................ ................................ ................................ ......33 
5.1 General Considerations  ................................ ................................ ....................... 33 
5.2 Pre-treatment evaluation  ................................ ................................ ..................... 33 
5.3 Study evaluations  ................................ ................................ ................................ .34 
5.4 Induction Chemotherapy Details and Guidelines  ................................ ............. 35 
5.5 Surgical Details and Guidelines  ................................ ................................ .......... 35 
5.5.1  Indications for Adjuvant Radiation post -operatively  ................................ .......36 
5.6 Definitive Radiation/Chemoradiation Details and Guidelines ......................... 36 
5.6.1  Risk Status  ................................ ................................ ................................ ............ 36 
5.6.2  Response Stratified Grouping:  ................................ ................................ ........... 37 
5.6.3  Concurrent Cisplatin -Radiation: ................................ ................................ ........ 39 
5.6.4  TFHX Regimen:  ................................ ................................ ................................ ...39 
5.6.5  Radiation Therapy Guidelines  ................................ ................................ ............ 40 
5.6.6  Nodal Planning Target Volume Delineation:  ................................ .................... 43 
5.7 Adjuvant Immunotherapy Details and Guidelines  ................................ ........... 46 
5.8 Supportive Guidel ines................................ ................................ .......................... 47 
5.9 Post-therapy Follow -up ................................ ................................ ....................... 48 
5.10  Duration of Therapy  ................................ ................................ ............................ 49 
5.11  Late Toxicity Assessment  ................................ ................................ .................... 49 
5.11.1  Late Toxicity Assessment Schedule  ................................ ................................ ....49 
5.11.2  Assessment of Late Toxicity  ................................ ................................ ................ 49 
5.11.3  Quality of Life Assessments and Performance Measures  ................................ 50 
6 EXPECTED ADVERSE EVENTS, RISKS AND DOSE  MODIFICATIONS  .......... 51 
6.1 Expected Adverse Events  ................................ ................................ .................... 51 
6.1.1  Nab-Paclitaxel ................................ ................................ ................................ .......51 
6.1.2  Carboplatin  ................................ ................................ ................................ ........... 52 
6.1.3  5-Fluorouracil  ................................ ................................ ................................ .......52 
6.1.4  Paclitaxel (during TFHX concurrent chemoradiation)  ................................ ....53 
6.1.5  Hydroxyurea  ................................ ................................ ................................ ......... 54 
6.1.6  Cisplatin  55 
6.1.7  Filgrastim  ................................ ................................ ................................ .............. 55 
SPONSOR: The University of Chicago  
 
4 
Version 4Apr2019  6.1.8  Nivolumab  ................................ ................................ ................................ ............. 55 
6.1.9  Radiati on ................................ ................................ ................................ ............... 56 
6.2 Dose modifications  ................................ ................................ ............................... 56 
6.2.1  Induction Chemotherapy Dose Modifications  ................................ ................... 57 
6.2.2  Dose Modifications Immunotherapy/Nivolumab during Induction Phase  .....59 
6.2.3  Adverse Event Management Algorithms for Immunotherapy/Nivolumab  ....59 
6.2.4  Dose Modifications During Concurrent Chemoradiotherapy  ......................... 66 
6.2.5  Dose Modifications Immunotherapy/Nivolumab during Adjuvant 
Nivolumab Treatment  ................................ ................................ ......... 69 
7 AGENT FORMULATION AND PROCUREMENT  ................................ ................... 70 
7.1 Nab-paclitaxel  ................................ ................................ ................................ .......70 
7.2 Carboplatin  ................................ ................................ ................................ ........... 73 
7.3 Fluorouracil  ................................ ................................ ................................ .......... 73 
7.4 Hydroxyurea  ................................ ................................ ................................ ......... 73 
7.5 Paclitaxel  ................................ ................................ ................................ ............... 73 
7.6 Cisplatin  ................................ ................................ ................................ ................ 75 
7.7 Filgrastim (Neupogen ) Drug Information  ................................ ...................... 76 
7.8 Nivolumab  ................................ ................................ ................................ ............. 78 
8 CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ......... 81 
8.1 Objectives  ................................ ................................ ................................ .............. 81 
8.2 Correlative analysis ................................ ................................ .............................. 81 
8.2.1  Tissue:  81 
8.2.2  Blood:  82 
8.2.3  Radiological Correlatives  ................................ ........  Error! Bookmark not defined.  
8.3 Sample and Tissue  Procurement  ................................ ................................ ........ 83 
8.3.1  Archival tumor collection  ................................ ................................ .................... 83 
8.3.2  Tissue Biopsy  ................................ ................................ ................................ ........ 83 
8.3.3  Blood Isolation  ................................ ................................ ................................ ......83 
9 STUDY CALENDAR / FLOWCHART  ................................ ................................ ........ 85 
10 MEASUREMENT OF EFFECT  ................................ ................................ .................... 92 
10.1  Measurement of Target Lesions  ................................ ................................ ......... 92 
10.2  Measurement of Response  ................................ ................................ ................... 92 
10.2.1  Details about diagnostic imaging  ................................ ................................ ........ 92 
10.3  Progression -Free and Overall Survival ................................ .............................. 94 
11 REGULATORY AND REPORTING REQUIREMENTS  ................................ .......... 95 
11.1  Regulatory Guidelines  ................................ ................................ ......................... 95 
11.1.1  Food and Drug Administration (FDA) Approval  ................................ ............. 95 
SPONSOR: The University of Chicago  
 
5 
Version 4Apr2019  11.2  Expedited Adverse Event Reporting  ................................ ................................ ..95 
11.3  Adverse Event Definitions  ................................ ................................ ................... 95 
11.3.1  Adverse Event  ................................ ................................ ................................ .......95 
11.3.2  Serious Adverse Event (SAE) ................................ ................................ .............. 95 
11.3.3  Relatedness  ................................ ................................ ................................ ........... 96 
11.3.4  Adverse Reactions  ................................ ................................ ................................ 96 
11.4  Adverse Event Reporting  ................................ ................................ .................... 97 
11.4.1  Routine Adverse Event Reporting  ................................ ................................ ......97 
11.4.2  Serious Adverse Event Reporting  ................................ ................................ .......97 
11.4.3  Serious Adverse Event Reporting to BMS  ................................ ......................... 97 
11.4.4  Serious Adverse Event Reporting to Celgene  ................................ .................... 98 
11.5  Subject registration and data submission  ................................ .......................... 99 
11.5.1  Registration ................................ ................................ ................................ ........... 99 
11.5.2  Data management  ................................ ................................ ................................ 99 
11.6  Data and safety monitoring  ................................ ................................ ................. 99 
11.7  Auditing ................................ ................................ ................................ ................. 99 
11.8  Record Retention ................................ ................................ ................................ 100 
11.9  Obligations of Study Site Investigations  ................................ .......................... 100 
12 STATISTICAL CONSIDERATIONS  ................................ ................................ ......... 101 
12.1  Statistical methods  ................................ ................................ ............................. 101 
12.1.1  Primary Endpoint: Deep Response Rate (DRR)  ................................ ............. 101 
12.1.2  Secondary Endpoints  ................................ ................................ ......................... 101 
12.1.3  Exploratory Objectives/Endpoints/Analyses  ................................ ................... 103 
12.1.4  Laboratory/Translational Objectives  ................................ ............................... 103 
12.1.5  Visual Aid Objectives ................................ ................................ ......................... 103 
13 REFERENCES:  ................................ ................................ ................................ ............. 105 
APPENDIX A: Performance Status Criteria  ................................ ................................ .....112 
APPENDIX B: RTOG/NRG Early Toxicity Grading  ................................ ....................... 113 
APPENDIX C: RTOG Late Toxicity Grading  ................................ ................................ ...115 
APPENDIX D: Sample Transmission Form and Instructions  ................................ ......... 116 
APPENDIX E: Accepted Forms of B irth Control  ................................ ............................. 118 
APPENDIX F: Quality of Life Forms and Performance Measures  ................................ .119 
 
  
SPONSOR: The University of Chicago  
 
6 
Version 4Apr2019  1 PROTOCOL SYNOPSIS & SCHEMA TA 
1.1 Brief Trial Schema  
 
*For c oncurrent chemoradiotherapy  a choice of  either c isplatin -based  or a paclitaxel/5 -
FU/h ydroxyurea -based  backbone  is acceptable . Both regimens are considered equivalent 
choices and are dependent on physician/ subject  preference  (dealer’s choice) . 
1.2 Brief Schema for Response -Stratified Locoregional Therapy  
 
AUC= 6, d1  1. Carboplatin AUC=6, d1  
2. Nab -paclitaxel 100mg/m2   
    d1/d8/d15  
3. Nivolumab,  360mg(flat) , d1 
 
      21-day cycle for 3 cycles  
SPONSOR: The University of Chicago  
 
7 
Version 4Apr2019  1.3 Brief Overview of Risk Classification  
 
→ N3/bulky nodal disease is defined radiologically or on clinical exam . 
1.4 Brief Trial Design  Overview  
 A phase II trial in human papillomavirus (HPV) -positive oropharyngeal squamous 
cell cancer  (as determined by p16 immunohistochemistry with confirmatory ISH or PCR ) 
to determine r adiologic r esponse to induction chemotherapy  with nivolumab . Subject s will 
undergo evaluation by a multidisciplinary team prior to risk assessment. The subject s will 
be assigned to high or low risk groups based on tum or size, lymph node inv olvement, and 
smoking history. Subject s will be assigned to treatment with induction chemotherapy with 
carboplatin, nab-paclitaxel, and nivolumab. Radiologic response to induction 
chemotherapy according to R ECIST measurement of tumor  shrinkage will then be used 
for therapeutic stratification of locoregional therapy, consisting of either transoral robotic 
surgery (TORS) or radiation with or without chemotherapy  .  Subject s with low risk  disease 
(see table above)  and small volume tonsillar /BOT  disease  (T1-2 primary , non -bulky N2A -
N2B nodal status ) who have ≥50% reduction by RECIST following inductio n 
chemotherapy will undergo TORS for primary site resection and selective nodal 
dissection  as a definitive treatment if technically feasible  with adjuvant radiation for 
adverse pathologic features . Subject s with other low risk tumors  e.g. with higher volume 
disease, or who refuse surgery,  who also have ≥ 50% reduction by RECIST following 
inductio n chemotherapy will be given de -intensified treatment with radiation alone  to 50 
Gy (no chemotherapy) . Subject s with low risk features and <50% but ≥30% reduction OR 
high risk features  (T4, bulky N2B or N2C -N3, > 20 pack -years tobacco use)  with ≥50% 
reduction will  receive de -intensified chemoradiation with concurrent cisplatin -RT to 50 Gy 
(5 weeks)  or TFHX to 45 Gy  (3 cycles /6 weeks ). Subject s with low risk features and <30% 
reduction OR high risk disease with <50% reduction or any subject s with progr essive  
disease  during inducti on chemotherapy will undergo chemoradiotherapy with  concurrent 
cisplatin -RT to 70 Gy (7 weeks)  or TFHX to 75 Gy  (5 cycles/10 weeks) . Subject s with 
both high and low risk features who have ≥50% reduction  will receive locoregional therapy 
targeting the pre -chemotherapy extent of disease only. Adjuvant nivolumab will be offered 

SPONSOR: The University of Chicago  
 
8 
Version 4Apr2019  to all subject s for 6 -months post co mpletion of definitive therapy  (7 doses given as a flat 
dose of 480mg, every four weeks) . 
1.5 Brief Background and Rationale  
 The incidence of HPV -positive oropharyngeal cancer is rising rapidly in the United 
States and Europe.1 HPV-positive tumors occur in younger, healthier subject s often with 
higher socioeconomic status. Subject s with HPV -positive tumors have excellent 
prognosis and we may be currently over -treating this younger subject  population.2,3 
Recently, it has been shown that induction chemotherapy may be used for treatment 
stratification in HPV -positive subject s.4,5 A good response to induction chemotherapy 
indicates improved prognosis overall with decreased risks of locoregional and distant 
recurrence.6 As such, subject s with favorable response to induction chemotherapy may 
be candidates for de -intensified locoregional therapy . The goal of de -intensified 
locoregional therapy  is to decrease the late toxicity associated with treatment.  
 
In our recently published  response -adapted volume de -escalation (RAVD) trial, 
treatment was stratified based on response to induction chemotherapy.5 Subject s with 
favorable response to induction chemotherapy received concurrent chemotherapy and 
radiation targeted to only gross  disease. In this novel approach, elimination of elective 
nodal coverage did not compromise outcomes and resulted in significantly improved late 
toxicity. In a specific subset analysis of HPV -positive oropharynx subject s, outcomes were 
excellent with 2 -year locoregional control and progression -free survival rates of 100% and 
93%, respectively, in good responders to induction chemotherapy.   
 
In a subsequent study (OPTIMA I), we sought to further decrease the toxicity of 
definitive chemoradiation for HPV -positive oropharyngeal cancer by decreasing the 
radiotherapy dose.7 In this study, subject s were first stratified based on subject  and tumor 
characteristics. Treatment for each strata was then determined by response to an 
induction chemotherapy regimen consisting of nab -paclita xel and carboplatin. In this trial, 
low-risk subject s with favorable response to induction chemotherapy receive d definitive 
radiation and high -risk subject s receive d chemoradiation. Both low - and high -risk subject s 
with favorable response to induction chem otherapy receive d radiotherapy dose de -
escalation. Preliminary data based on post -treatment pathology specimens indicate a 
high degree of control using this approach although an analysis of the complete cohort is 
still pending . 
 
Monoclonal antibodies targeting the programmed death (PD) -1 immune 
checkpoint receptor have shown remarkable activity in multiple cancer types including 
head and neck c ancer .8,9 The goal of PD -1 blockade is to promote tumor recognition and 
destruction by the immune system. Nivolumab, a PD -1 inhibitor, is approved in 
melanoma,  Hodgkin lymphoma,  lung carcinoma , and renal cell carcinoma, and has 
recently been approved by the U.S. Food and Drug Administration (FDA)  for head and 
neck cancer.  Results of the phase III CheckMate -141 study investigating nivolumab after 
platinum -based chemotherapy were rec ently  published .8 In this trial, the ORR was 13. 3% 
with nivolumab and a 2.4 month  benefit in median overall survival (OS) was observed 
versus investigator’s choice of therapy ( P = 0.01).  
SPONSOR: The University of Chicago  
 
9 
Version 4Apr2019   
Given the above, we hypothesize that the addition of the checkpoint inhibitor 
nivolumab  to induction chemotherapy will increase the response rate to neoadjuvant 
therapy and therefore increase the proportion of subject s who may qualify for de -
intensified locoregional therapy. Additionally, we believe that  further  de-intensification of 
locoregional therapy compared to Optima I by limiting treatment  to only the pre -
chemotherapy extent of disease  (in subject s with ≥50% induction response)  will further  
reduce  the toxicity associated with curative -intent therapy  without compromising disease 
control . An additional goal of this trial will be to assess the co mparative efficacy and 
toxicity profiles of locoregional therapy with TORS versus RT in low -risk subject s with 
favorable induction response . 
 
1.6 Brief Definition of Subject  Population  
 
• Subject s with HPV-positive  HNSCC  
 
1.7 Brief Overview of Objective s 
 
Primary Objectives:  
• To measure the deep response rate ( DRR) to induction chemotherapy with 
carboplatin/nab -paclitaxel/nivolumab and determine its activity  compared to the 
DRR using carboplatin/nab -paclitaxel in the Optima I trial.  
 
• In the predecessor Optima  1 study , deep responses were defined as ≥50% tumor 
shrinkage by RECIST  1.1 and this is believed to approximate  a clinical complete 
response (CR) as utilized in the ECOG 1308 study (which was the primary 
outcome for E1308). Hence i n this study , deep responses are also defined as 
≥50% tumor shrinkage by RECIST 1.1.  Linked to this we will evaluate the overall 
percentage of subject s treated with dose -reduced radiotherapy or TORS.  
Secondary Objectives:  
• To determine the tolerability of the nivolumab/carboplatin/nab -paclitaxel  induction 
chemotherapy regimen and its impact on subsequent receipt of definitive 
chemoradiotherapy.  
 
• To determine  2-year progression -free survival (PFS) for the entire cohort and all 
arms and compar e them to the entire cohort and corresponding arms in Optima I.  
 
• To determine 2 -year overall survival (OS) for the entire cohort and all arms and 
compare them to the entire cohort and corresponding arms in Optima I.  
 
SPONSOR: The University of Chicago  
 
10 
Version 4Apr2019  • To determine 2 -year rates of locoregional and distant control for the entire cohort 
and all arms and compare them to the entire cohort and corresponding arms in 
Optima I.  
 
• To determine rates of acute and late toxicity and compare them to rates of G -tube 
dependency on the Optima I and RAVD trials.  
 
• To determine quality of life scores in subject s and compare them to quality of life 
scores on the RAVD trial.  
 
• To determine the comparative efficacy and toxicity profiles of TORS versus RT for 
management of low risk disease.  
 
1.8 Key Inclusion Cr iteria  
• Subject s with locoregionally  advanced HPV -positive  squamous cell carcinoma.  
HPV positivity will be determined by p16  IHC and HPV PCR for validation and HPV 
type determination . 
 
• Normal o rgan function  
 
• Measurable  disease  by RECIST  1.1 
 
• No previous radiation or chemotherapy for a head  and neck cancer  
 
• ECOG performance status 0 -1 (Karnofsky  80%) 
 
• Age ≥18 years  
 
• Ability to obtained informed consent  
 
• Availability of baseline tissue (as listed below in section 4.0)  
 
 
1.9 Brief  Overview of Treatment Plan  
Induction therapy : All enrolled subject s will receive three  21-day cycles  of 
chemotherapy consisting of nab -paclitaxel (100 mg/m2 on day s 1, 8, 15 ; 9 doses total ), 
carboplatin (AUC 5 on day 1; 3 doses total ), and nivolumab (3 60 mg on day s 1; 3 
doses total ). Growth factor support will be provided using G -CSF administered on  
days 16 -18 if clinically indicated . 
 
SPONSOR: The University of Chicago  
 
11 
Version 4Apr2019  TORS/RT/CRT : The subject s will be assigned to  treatment arms based on response 
to induction chemotherapy and  high or low risk status. High or low risk status is  based 
on tumor size, lymph node involvement, and smoking history at enrollment on study.  
 
Risk Status:  
 Low Risk  Status  (all of the below) : 
o T1-3 
o N0-N2B (unless N3 equivalent lymph nodal conglomerate *) 
o ≤20 pack year history tobacco use  
o HPV16  
 
 High Risk  Status  (any of the below) : 
o T4 
o N2C-N3 
o Bulky N2B disease with N3 equivalent  nodal conglomerate * 
o >20 pack year history tobacco use  
o Non-HPV16  HPV type (e.g. HPV31, 18, etc)  
 
*N3/bulky nodal disease is defined radiologically or on clinical exam . 
 
Response Stratified Group ing: 
 
Subject s will be assigned to TORS , RT, or CRT  based on respon se to induction 
chemotherapy  and risk category (see schemas 1.1 and 1.2) . Decision between RT or 
TORS in the single modality arm (SDA) will be individualized (see details below).  
Chemoradiation will be done using either outpatient  cisplatin (100mg/m2 every 3 
weeks ), or alternatively the inpatient  TFHX platform consist ing of 2-week  cycles of 
paclitaxel (100 mg/m2, day 1 ), 5-FU (continuous infusion at 600  mg/m2/day  5 days), 
and hydroxyurea (500 mg PO BID day s 0-5, 11 doses/cycle) with twice daily ra diation 
(150 cGy per fraction) . Both chemoradiation platforms are considered equivalent and 
treatment on either regimen will depend on subject  preference.  
 
Group A1: Single -Modality De -escalation Arm (SDA ) --TORS  
 
Subject s with low risk  and small volume tonsillar disease (T1-T2, non-bulky N2A -N2B 
with ≤2 non -lower neck lymph nodes measuring ≤5 cm in size ) or base of tongue 
disease (T1 -2 with lateralized primary ≤3  cm, non-bulky N2A -N2B with ≤2 non -lower 
neck  lymph nodes measuring ≤5 cm in size ) who have ≥50% reduction by RECIST 
following induction chemotherapy will undergo TORS and selective nodal dissection. 
De-intensified adjuvant RT will be given for adverse pathologic features.  Subject s may 
refuse TORS treatment (see treatment next paragraph ). 
 
Group A2: Single -Modality De -escalation Arm (SDA)  –RT 
Subject s with low risk , who do not qualify for TORS (due to volume of disease or poor 
visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following 
SPONSOR: The University of Chicago  
 
12 
Version 4Apr2019  induction chemotherapy will be  given de -intensified treatment with radiation alone to 
50 Gy  (see schema page 5) . 
 
Group B: Intermediate De-escalation  Arm (IDA)  – Low dose CRT  
Subject s who have low risk disease with <50% but ≥ 30% reduction of tumor by 
RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus 
cisplatin (x2 doses) or TFHX to 45 Gy  (3 cycles ). 
 
Subject s who have high risk  disease and ≥50% reduction of tumor by RECIST with 
induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 
doses) or TFHX to 45 Gy (3 cycles).  
 
Group C: Regular Dose Arm (RDA)  – Standard dose CRT : 
Subject s who have low risk  disease and < 30% reduction of tumor by RECIST with 
induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 
doses) or TFHX to 75 Gy (5 cycles) . 
 
Subject s who have high risk disease and < 50% reduction of tumor by RECIST with 
induction chemoth erapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 
doses) or TFHX to 75 Gy (5 cycles).  
 
Any subject  who has progressive disease will receive CRT to 70 Gy with concurrent 
bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).  
 
Adjuvant  therapy : Adjuvant nivolumab  480mg iv every 4 weeks  will be offered to all 
subject s for 6 -months post completion of locoregional  therapy  (= doses) . 
 
1.10 Brief Summary of Treatment Duration  
Induction chemotherapy: 9 weeks  
Definitive radiation therapy: 5 weeks  
Definitive chemoradiotherapy: 5-10 weeks  
Adjuvant radiation therapy (if indicated after TORS): 4 -4.5 weeks  
Adjuvant immunotherapy: 6 months (=7 doses)  
 
1.11 Brief Overview of Statistical analysis  
Subject s will receive induction chemotherapy for three cycles followed by radiologic 
evaluation  and response -based allocation to definitive locoregional therapy .  
Response will be assessed after completi on of induction chemotherapy by radiological 
examination.  
We expect to enroll  and start treatment in  3-5 subject s per month for a total of 56 
subject s over a period of approximately 18  months . This s tudy is designed to accrue 
SPONSOR: The University of Chicago  
 
13 
Version 4Apr2019  56 evaluable subject s for the primary endpoint to allo w sufficient statistical power.  
However the trial is to be extended to up to 74 patients to fulfull sufficient enrollment 
on the RT -alone (A1) and TORS (A2) arms ( at least 10 subjects each, unless the trial 
reaches N= 74 subjects  first).  
Overall Primary Objective:  To demonstrate an increased rate of deep response s (deep 
response rate=DRR ) to induction chemotherapy with the addition of nivolumab to the 
carboplatin/nab -paclitaxel backbone used in the Optima I trial.  
• In the predecessor Optima  1 study , deep responses were defined as ≥50% tumor 
shrinkage by RECIST  1.1 and this is believed to be equivalent to a clinical complete 
response (CR) as utilized in the ECOG 1308 study (which was the primary 
outcome for E1308). He nce in this study , deep responses are also defined as 
≥50% tumor shrinkage by RECIST 1.1.  
• We will employ a superiority  test in which the objective is to establish that the 
response rate to  carboplatin /nab-paclitaxel/ nivolu mab induction chemotherapy is 
15% higher than the response rate of 60%  in Optima I which utilized a  
carboplatin /nab-paclitaxel induction regimen.  
• We will test: H 0: DRR=60% (based on data from Optima  1 trial)  vs H A: DRR=75% 
with addition of nivolumab to the carboplatin/nab -paclitaxel induction regimen.  
• Using Power Analysis and Sample Size (PA SS v11) software, a sample of 56 
subject s will provide 87 % power to test this hypothesis using a (one -sided) type I 
error rate of 0.10. Essentially, H 0 will be rejected and nivolumab/carboplatin/nab -
paclitaxel  based induction regimen declared superior if the lower, one -sided 90% 
confidence limit for the response rate exceeds 75%. No interim analysis will be 
conducted.  
NB: A minimum of 10 patients will be  enrolled on the RT only and also TORS arm to 
allow for descriptive interpretation of the pathology results in tabular form. The overall 
trial may overenroll up to 18 patients (N=74)  to fulfill this enrollment goal for the RT -only 
and TORS arms.  
 
SPONSOR: The University of Chicago  
 
14 
Version 4Apr2019  2 OBJECTIVE S 
2.1 Primary Objective  
• To measure  the deep response rate ( DRR) t o induction chemotherapy  with 
carboplatin/nab -paclitaxel/nivolumab  and determine its activity  compared to the 
DRR using carboplatin/nab -paclitaxel  in the Optima I trial.  
 
• In the predecessor Optima  1 study , deep responses were defined as ≥50% tumor 
shrinkage by RECIST  1.1 and this is believed to approximate  a clinical complete 
response (CR) as utilized in the ECOG 1308 study (which was the primary 
outcome for E1308). Hence i n this study , deep responses are also defined as 
≥50% tumor shrinkage by RECIST 1.1.  Linked to this we will evaluate the overall 
percentage of subject s treated with dose -reduced radiotherapy or TORS.  
 
2.2 Secondary Objectives  
• To determine the tolerability of the nivolumab/carboplatin/nab -paclitaxel  induction 
chemotherapy regimen and its impact on subsequent receipt of definitive 
chemoradiotherapy.  
• To determine  2-year progression -free survival (PFS) for the entire cohort and all 
arms and compare  them to the entire cohort and corresponding arms in Optima I.  
• To determine 2 -year overall survival (OS) for the entire cohort and all arms and 
compare them to the entire cohort and corresponding arms in Optima I.  
• To determine 2 -year rates of locoregional and distant control for the entire cohort 
and all arms and compare them to the entire cohort and corresponding arm s in 
Optima I.  
• To determine rates of acute and late toxicity and compare them to rates of G -tube 
dependency on the Optima I and RAVD  trials.  
• To determine quality of life scores in subject s and compare them to quality of life 
scores on the RAVD trial . 
• To determine the comparative efficacy and toxicity profiles of TORS versus RT for 
management of low risk disease.  A minimum of 10 patients will be enrolled on the 
RT only and also TORS arm to allow for descriptive interpretation of the pathology 
results in tabular form. The overall trial may overenroll up to 18 patient s (N=74) to 
fulfill this enrollment goal for the RT -only and TORS arms.  
 
SPONSOR: The University of Chicago  
 
15 
Version 4Apr2019  2.3 Laboratory Objectives  
• To evaluate quantitative HPV titers pre -treatment, post -induction, and post -
definitive locoregional therapy  at defined intervals on blood and saliva samples.  
This will be used to assess treatment efficacy (e.g. during nivolumab based 
induction chemotherapy), as well as a potential marker for early recurrence.  
 
• To evaluate changes in the immune micro -environment at a) baseline and b) 
during combined anti -PD-1/chemotherapy induction (paired biopsies) . This will 
performed in an explorator y fashio n: 
o Multicolor IF to assess changes in the immune microenvironment  
o mRNA analysis (Nanostring)  
o Mutational Load  
o Blood based markers over time  
 
2.4 Exploratory  Objectives  
• To evaluate the efficacy and utility of a visual aid used during the consent 
process by anonymous and optional subject  and provider questionnaires.  
 
• To determine whether MRI (namely diffusion weighted imaging, and radiomics) 
can predict response to induct ion (chemotherapy + immunotherapy).  
SPONSOR: The University of Chicago  
 
16 
Version 4Apr2019  3 BACKGROUND  
3.1 Locally Advanced Head and Neck Cancer  
Approximately 50,000 new cases of head and neck cancer are diagnosed annually in the 
United States.10 The majority (90 -95%) of these cases are squamous cell carcinomas of 
the head and neck ( HNSCC) and approximately two -thirds are locoregionally advanced 
cancers (AJCC Stage III -IV). Despite advances in the multimodality treatment of 
locoregionally advanced  HNSCC (LA -HNSCC) over the past two decades, the se subject s 
still experience significant morbidity and mortality.  
 
Historically, locoregionally advanced tumors wer e treated with surgery, radiation therapy, 
or both. Locoregional failure rates were approxima tely 30% at 2 years and locoregional 
failures accounted for nearly 60% of failures. Survival at 5 ye ars was reported to be only 
40%. Approximately 20% of subject s developed metastatic disease and nearly one -fifth 
of these subject s died of distant metastase s without evidence of locoregional 
recurrence .11-14 
 
3.2 Chemorad iotherapy  
Given the discouraging outcomes with surgery and radiation, investigators became 
increasingly interested in the incorporation of chemotherapy for the treatment of LA -
HNSCC. The feasibility of a non -surgical, organ preservation approach with concomitant 
chemora diation was first established by the landmark Veterans Affairs Laryngeal Canc er 
Study .15,16 Since then, several randomized trials and meta -analyses have demonstrated 
improved disease -free and/or overall survival with concomitant chemoradiotherapy and 
confirmed its role as standard therapy for subject s with locoregionally advanced un -
resectable disease.17-22 The positive effects on disease -free and overall surviva l seem to 
be predominantly mediated through improved locoregional control, thus affecting the 
traditionally predominant pattern of failure for this disease.  
 
Concurrent chemoradiotherapy attempts to capitalize on both the radiosensitizing 
properties of chemotherapy at sites of known disease targeted by radiation in addition to 
delivering agents that function systemically to treat occult metasta tic disease. However, 
sensitizing effects are not tumor specific and exert both locoregional effec ts on adjacent  
normal tissues within the radiation field as well as systemic effects, particularly on the 
bone marrow and peripheral nervous system. Concurrent chemoradiotherapy trials have 
consistently reported an increased incidence of acute grade 3 and 4 toxic effect s, with 
muco sitis, dermatitis, and cytopenias being the most prominent .23 This rise creates 
concern about chronic toxic effects, including consequential late effects, which evolve 
from persistent severe acute toxic effects.  
 
Optimizing the therapeutic ratio of treatment benefit to toxicity has thus become a focus 
of recent inve stigation. Advances in the delivery of conformal radiation, including the 
development of intensity modulated radiation therapy (IMRT), have allowed significant 
improvements in sparing normal tissue struct ures. This is best exemplified by the 
SPONSOR: The University of Chicago  
 
17 
Version 4Apr2019  reduction in r ates of xerostomia with sparing of the parotid glands .24 However, other 
treatment -related morbidities such as dysphagia are still problematic . Rates of feeding 
tube dependence  at 1-year in the 3D -conformal era have been reported to be 
approximately  25%.25 This is particularly significant given recent data that quality of life 
among subject s with HNSCC treated with radiotherapy is substantially affected by 
swallowing dysfunction and the need for enteral nutrition support .26 In the IMRT -era, 
efforts have been  focused on decreasing the dose of radiation to dysphagia -related 
structures, particularly the pharyngeal constrictors, which are prone to stricture formation 
with doses ≥50 Gy.27 Single -institution reports of treatment of oropharyngeal cancer in 
the IMRT -era demonstrate long -term feeding tube dependence rates of approximately 5 -
10%.28 
 
3.2.1  CRT Platforms: Concurrent  Cisplatin -Radiation  or TFHX  
Chemoradiotherapy with concurrent bolus cisplatin (100 mg/m2 delivered q3weeks) and 
conventionally fractionated radiotherapy remains the commonly accepted standard of 
care for the treatment of LA-HNSCC . This is due to the prevalence of randomized studies, 
including the Head and Neck  Intergroup trial and RTOG 91 -11, which  observed that 
concurrent chemoradiotherapy  with every -3-weeks cisplatin improved locoregional 
control  and overall survival  for unresectable HNSCC  and resectable laryngeal cancers, 
respectiv ely.29,30  
 
At the University of Chicago, we hav e investigated multiple intensive concomitant 
chemoradiotherapy regimens. We initially studied the interaction of 5 -FU, hydroxyurea 
and radiotherapy (FHX) .31,32 Both chemotherapy agents have known systemic activity and 
have been shown to act as radiation enhancers in vitro and in vivo.14,33,34 Cytotoxic activity 
is synergistic as hydroxyurea modulates the activity of 5 -FU by depleting cellular pools of 
deoxyuridine monophosphate (dUMP) and facilitating binding of the  5-FU metabolite 5 -
FdUMP to its target enzyme thymidylate synthase.35 Paclitax el was subsequently added 
to the FHX regimen (TFHX) and the radiation scheme changed to twice daily to further 
intensify the treatment.36-39  
 
The TFHX regimen was demonstrated to be a highly active and tolerable concomitant 
chemotherapy and hyperfractionated radiation regimen: overall survival and locoregional 
control rates at 3 years were 60% and 86%, respectively .38,40 Since surgery was used 
primarily a s a salvage procedure, excellent organ preservation was also achieved. Acute 
toxicities were severe in a majority of subject s but were considered tolerable overall. 
Mucositis (84% grade 3/4), “in -field” dermatitis (38% grade 3/4), leukopenia (34% grade 
3/4), and anemia (22% required tr ansfusion) were the most common serious side effects. 
At 1 year post -treatment, 61% of subject s had severe xerostomia and 4 7% had 
compromised swallowing; the rate of feeding tube dependence was 20% . 
 
In an attempt t o decrease the toxicity of concomitant chemoradiation , we conducted 
prospective investigations into reducing the radiation dose in sequential cohorts to areas 
at risk for microscopic disease.6,41 The cohort receiving 75 Gy to gross disease (high risk), 
54 Gy to intermediate -risk volumes, and 39 Gy to low -risk volumes experienc ed the best 
SPONSOR: The University of Chicago  
 
18 
Version 4Apr2019  therapeutic ratio. Again, high locoregional and distant control rates were seen, though the 
rate of dermatitis (45%) was significantly  lower . 
 
With improved locoregional control, the systemic control of micrometastatic disease 
emerged as an imp ortant treatment goal that was not achieved optimally with the 
chemotherapy doses applied during concomitant chemoradiotherapy. Indeed, 
approximately 20% of subject s were noted to recur distantly, despite the addition of 
cytotoxic chemotherapy to radiation  therapy as part of the TFHX regimen . 
 
3.3 Induction Chemotherapy  
On the basis of  the aforementioned studies, induction chemotherapy was investigated as 
a method of successfully eradicating micrometastatic disease. At the University of 
Chicago, carboplatin and paclitaxel were initially chosen as an induction chemotherapy 
regimen becaus e they are typically well -tolerated with low rates of mucositis. The first 
report of this regimen demonstrated both high locoregional control and improved distant 
control.42 Systemic disease progression was noted in 7% of subjects; this translated into 
improved 3 -year progression -free and overall survival rates of 80% and 77%, 
respectively.  
 
Currently, the triplet combination of a taxane (docetaxel or paclitaxel), cisplatin, and 5 -FU 
(TPF) is considered one standard induction regimen (if induction therapy is considered). 
This is largely based on the results of a meta -analysis demonstrati ng a 5% increase in 
survival for cohorts using a cisplatin/fluorouracil (5 -FU) combination  and published phase 
III trials demonstrati ng the superiority of induction docetaxel, cisplatin, and 5 -fluorouracil 
over cisplatin and 5 -fluorouracil when followed by radiotherapy or 
chemoradiotherapy .21,43 -45  
 
Controversy still exists regarding the overall survival benefit of adding induction TPF to 
chemoradiotherapy . Recent studies demonstrating no additional survival benefit are 
limited by methodological deficiencies .46-48 Additionally, recent data demonstrate that TPF 
and carboplatin/ paclitaxel seem to have equivalent activity while  the latter platform is 
associated with decreased toxicity.49 Two studies ev aluating carboplatin/paclitaxel 
induction demonstrated 82% and 87% response rates compared to our De CIDE trial 64% 
response to TPF.41,42,50  
 
Paclitaxel and nab -paclitaxel have the same activity  based on response rates  with better 
delivery and  a favorable  toxicity profile  (especially  with nab -paclitaxel ). Compared with 
solvent -based paclitaxel, nab -paclitaxel  delivers 33% higher drug concentration to tumors 
in preclinical xenograft models, and demonstrates enhanced transport acr oss endothelial 
cell monolayers.51 The Cremophor -free medium enables nab -paclitaxel to be given in a 
shorte r duration without the need for premedication to prevent solvent -related 
hypersensitivity reactions.   Standard IV bags and tubing may be used for the delivery of 
nab-paclitaxel. Preliminary data from our Optima I trial using a nab -paclitaxel/carboplatin 
induction backbone indicate a high degree of tolerability and efficacy with a deep 
response  rate of approximately 60%.  Importantly with relation to immunotherapy , nab-
SPONSOR: The University of Chicago  
 
19 
Version 4Apr2019  paclitaxel can be administered without steroid premedication, and concerns exist for 
immun otherapy efficacy with steroid pre -medication.  
 
3.4 Human Papillomavirus (HPV) and HNSCC  
Both epidemiologic and molecular evidence have elucidated the  causative role of HPV in  
oropharynx SCC  over the past decade . The incidence of oropharyngeal cancer has risen 
dramatically over the past two decades and it is now the most common HNSCC .1 Both 
seropositivity and  oral infection with high -risk type HPV (HPV -16) have been shown to 
increase the risk of developing oropharyngeal cancer (OPC).52,53 HPV-positive tumors 
have a unique molecular profile: wild -type p53, upregulated p16, and downregulated 
pRb.54 There is direct evidence that HPV -16 is oncogenic, mechan istically driving the 
development and viability of cancer cells.55-57 
 
There is concern for an HNSCC -epidemic due to HPV. Extrapolating recent trend s, the 
annual number of HPV -positive OPC is expected to surpass the annual number of 
cervical cancers by the year 2020 .1,58 This is especially concerning in light of the fact that 
subject s with HPV -related OPC are approximately ten years younger on average than 
their HPV -negative OPC counterparts.59 
 
Recently, studies have demonstrated that subject s with HPV -related OPC have superior 
response to ther apy and survival  compared to HPV -negative OPC. In retrospective 
analyses of survival and HPV status from three pha se III trials, unprecedented overall 
survival of approximately 80 -90% at three years was obtained .2,60,61  Improved survival in 
these studies was largely due to markedly improved local -regional control as a biologic 
consequence of the HPV -origin of these tumors. With the improvement in locoregional 
control, distant metastasis is now gaining recognition as a l eading cause of death in HPV -
positive subject s and the rate of distant relapse is the same for both HPV -related OPC 
and non -HPV related  tumors .2,3,62 
 
Recursive partitioning analysis has helped to stratify HPV -related OPC subject s for both 
risk of death and distant relapse. In a retrospective analysis of the association between 
tumor HPV status and survival among subject s with stage III/IV OPC who were enrolled 
in a randomized trial comparing accelerated -fractionation r adiotherapy  with standard -
fractionation radiotherapy as part of concomitant chemoradiation with cisplatin, HPV 
status of the tumor was the major determinant of overall survival, followed by the number 
of pack -years of tobacco  smoking (≤10 vs  >10), and then nodal stag e (N0 -N2A vs N2B -
N3) for HPV -positive tumors .2 In another retrospective analysis of  the association 
between tumor HPV status and distant metastatic risk in a prospectively assembled 
cohort of OPC subject s treated with radiotherapy alone or concurrent chemoradio therapy, 
the distant control  rates for H PV-positive, low -risk N0 -2A or less than 10 pack -year N2B  
subject s were similar for RT alone and CRT, b ut the rate was lower in the N2C  subset 
managed by RT alone .3 Subsequent studies however have found a higher threshold of 
20-pack years, which is now commonly used, and other studies have found no 
relationship with tobacco use at all, and hence  tobacco use was not integrated into the 
SPONSOR: The University of Chicago  
 
20 
Version 4Apr2019  new staging system for HPV -positive OPC subject s (ICONS -S / AJCC 8th edition) for that 
reason.3,64 
 
Preliminary results of our Optima I trial indicate that risk stratification using nodal stage 
(N0-N2B vs N2C -N3), t umor size (T0 -3 vs T4), and tobacco use history (≤10 vs  >10 pack 
years) appropriately selected subject s for de -intensified locoregional therapy with out 
compromising outcomes. Additionally, this risk stratification is echoed in recent proposals 
for a new staging classification for HPV -related OPC as part of the AJCC 8th edition.63,64 
In a multi -institutional development and val idation study, adjusted hazard ratio methods 
were found to best model a proposed staging system in which T1 -T2/N0 -N2B is classified 
as stage I (5 -year survival 85%), T3/N2C is classified as stage II (5 -year survival 78%), 
and T4/N3 is classified as stage I II (5-year survival 53%).64 Additionally, there are recent 
data demonstrating the prognostic significance of HPV -genotype, with superior survival 
outcomes for subject s with HPV -16.65 
 
3.5 Response -Adapted Volu me De -escalation  (RAVD)  
It has been shown that subject s with favorable response to IC have superior prognosis 
and are less likely to e xperience locoregional failure after definitive chemoradiation .6 
Strategies to decrease the late toxicity associated with CRT have focused on rad iotherapy 
(RT) dose reduction  and const raints for organs at risk . It has also been shown that the 
majority of locoregional failures  after CRT are “in -field” and occur within the highest -risk 
RT treatment volu me.66 
 
Conventional head and neck RT elective nodal volumes are based on historic surgical 
data regarding the risk of occult LN involvement.  Several series have investigated 
decreasing elective nodal RT coverage. For subject s with limited tonsillar cancer, 
elimin ation of contralateral elective nec k RT has shown to be feasible.67 Additionally, it 
has recently been shown that elimination of elective RT to the retropharyngeal and high 
level II lymph nodes in the contralateral uninvolv ed neck is feasible and results in 
decreased toxicity.68 In our  RAVD  trial, we utilized radically reduced RT volumes entirely 
omitting elective nodal coverage in good responders  to IC and significantly decreasing 
coverage in non-responders .5  
 
Outcomes  of the RAVD  trial were specifically investigated in subjects with HPV+ 
oropharyngeal SCC. 2 -year PFS and OS  for HPV+ oropharynx good responders  were 
93.1% and 92.1%, respectively. 2 -year PFS and OS for HPV+ oropharynx non -
responders  were 74.0% and 95.2%, respectively.  The majority of locoregional failures  
(12/13 —92.3%) in this trial were in -field failures within the RT treatment volume and  11/12 
(91.7%) occurred in the highest -risk PTV1.  With respect to late toxicity, non -responders  
were significantly more likely to undergo G -tube placement during treatment (50.0% GR 
vs 73.5% NR, P = 0.040) and be G -tube dependent at 3 -month (22.9% GR vs 57.1% NR, 
P = 0.002) and 6 -month follow -up (5.7% GR vs 32.6% NR, P = 0.005).  On multivariate 
analysis, good response  to IC was the only significant predictor of G -tube de pendency on 
treatment (OR 0.36 , P = 0.028) and at 3 -month (OR 0.22 , P = 0.002) and 6 -month follow -
up (OR 0.12 , P = 0.009).  
SPONSOR: The University of Chicago  
 
21 
Version 4Apr2019   
 
 
3.6 Dose De -escalation for HPV -related Oropharynx Cancer  
Given the excellent  cancer control and survival in HPV -associated oropharynx cancer , 
there has been a wave of recent efforts to  decrease the intensity of treatment without 
compromising cancer control . Alternative dose de -intensification strategies have been 
recently published or presented.  
 
In the University of North Car olina/University of Florida experience, subject s with 
favorable -risk HPV -associated oropharynx cancer were treated with weekly cisplatin and 
60 Gy RT (10 Gy dose de -escalation) followed by pathologic evaluation.69 The pathologic 
complete response rate was 86% and non -inferior to the null hypot hesis of 87%. In the 
ECOG 1308 trial, subject s with resectable stage III/IV disease received induction 
chemotherapy followed by risk -stratified locoregional therapy (54 Gy with cetuximab for 
complete responders versus 69.3 Gy for partial responders).4 Preliminary results of this 
trial indicate a 2-year progression -free survival of 84% and locoregional control greater 
than 90%. Additionally, preliminary results of our Optima I trial significantly de -escalating 
dose for both high and low risk HPV -related oropharynx cancer after favorable response 
to induction chemotherapy indicate a high degree of control without compromised 
efficacy.  
 
3.7 Transoral Robotic Surgery (TORS)  
Compared to traditional open surgical approaches, transoral robotic surgery ( TORS ) has 
been shown to improve  Quality of Life (QOL) ou tcomes and  functional outcomes in 
speech and swallowing, while maintaining good oncologic outcomes.70 Favorable 
gastrostomy tube rates (0 -9,5% at one  year and 0% at 2 years after treatment) have been 

SPONSOR: The University of Chicago  
 
22 
Version 4Apr2019  reported following TORS. T1-2 tumors of the oropharynx , especially those ar ising within 
the tonsillar fossa and lateral pharyngeal wall, glossopharyngeal sulcus, and lateral 
tongue bas e, are amenable to TORS when adequate oral access can be obtained.  
 
There are limited retrospective and no randomized data comparing TORS versus RT/CRT 
for definitive treatment of oropharynx cancer. A recently published meta -analysis 
suggest s equivalent efficacy of both TORS and RT  in terms of disease control for early 
stage oropharyngeal SCC .71 A small retrospective analysis of quality of life outcomes 
published by the UCLA group showed s imilar quality of life among subject s treated by 
transoral surgery or chemora diotherapy.72 The currently accruing ORATOR phase II 
study which randomize s subject s with early -stage SCC of the oropharynx to RT of TORS 
will provide valuable prospective data.73 
 
A novel approach using induction chemotherapy followed by transoral surgery was 
recently published by the George Washington University group.74 In this series of 17 
subject s with advanced oropharyngeal  cancer who were treated with neoadjuvant 
chemotherapy followed  by transoral surgery of the pre -chemotherapy extent of disease 
plus selective neck dissection, 16/17 subject s were alive without recurrence at median 
follow -up of 31 months (3 -year disease -specific survival 94.1%).  
 
Additionally, multiple trials are currently examining the role of adjuvant therapy de -
intensification for subject s with HPV -related oropharynx cancer after TORS.  Standardly, 
post-operative RT is delivered to a dose of 60 -66 Gy for adverse features including 
extracapsular extension (ECE), positive surgical margins, per ineural invasion (PNI), or 
lymphovascular invasion (LVI). Concomitant chemotherapy is a lso added for subject s 
with ECE or positive margins, based on joint analysis of the EORTC and RTOG trials 
demonstrating a significant survival benefit for this subset.75   
 
The Eastern Cooperative Group (ECOG) 3311 trial is examining transoral surgery 
followed by low -dose of standard -dose RT with or without chemotherapy for subject s with 
HPV-related stage III/IVA oropharynx cancer.76 Subject s with intermediate adverse 
features ( ≤1 mm ECE, 2 -3 involved nodes, PNI, or LVI) are randomized to RT alone to 50 
Gy versus 6 0 Gy. Subject s with high risk adverse features (positive margins, >1 mm ECE, 
or ≥4 involved nodes) are treated to 66 Gy with concurrent cisplatin (40 mg/m2). In the 
phase II trial from the Mayo Clinic, subject s with p16 -positive oropharynx cancer  with less  
than a ten pack -year smoking history who have had a complete surgical resection  are 
also treated with de -intensified adjuvant therapy.77 Subject s with intermediate risk 
disease (≥T3, ≥N2, LVI, or PNI) are treated with 30 Gy RT (1.5 Gy BID) and concurrent 
weekly docetaxel while subject s with ECE  receive a similar treatment regimen but also 
have the nodal level with positive ECE concurrently boosted to 36 Gy in 1.8 Gy twice -
daily fractions.  
 
In this trial we are seeking to use TORS as a substitution for XRT in good prognosis cases 
with excellent response to induction with reduced longterm toxicities  (such as fibrosis, 
xerostomia, dental issues, and dysphagia , etc (see 5.11.2 ).  
 
SPONSOR: The University of Chicago  
 
23 
Version 4Apr2019  3.8 Positron Emission Tomography (PET) -Based Surveillance  
Post-chemoradiotherapy neck dissection can be associated with significant morbidity  
because of the associated scarring and fibrosis . In our published experience at the 
University of Chicago, 10% of subject s developed wound healing complications  and o ther 
complications occurred in 16% of  subject s and included need for tracheotomy, nerve 
transection and paresis, and permanent hypocalcem ia.78 
 
Computed tomography (CT) has been previously shown to spare subject s with 
radiographic complete response from post -RT neck dissection, regardless of initial nodal 
stage.79 This has been ad opted as the routine post -CRT surveillance at the University of 
Chicago over the past decade. Recently, positron emission tomography (PET) -CT has 
been adopted at several institutions as a method of avoiding neck dissection after 
definitive chemoradiotherap y.  
 
A prospective, randomized, controlled trial, assessing  the noninferiority of PET-CT guided 
surveillance (performed 12 weeks after the end of chemoradiotherapy, with neck 
dissection performed only if PET -CT showed an incomplete or equivocal response) t o 
planned neck dissection in subject s with stage N2 or N3 disease  was recently published.80 
The hazard ratio for death slightly favored PET -CT–guided surveillance and indicated 
noninferiority . Survival  was similar among subject s who underwent PET -CT–guided 
surveillance and those who underwent planned neck dissection, but surveillance resulted 
in considerably fewer operations and it was more cost -effective.  
 
3.9 Nivolumab  / anti -PD-1 
Nivolumab is a fully humanized, IgG4 (kappa) isotype monoclonal antibody (mAb) that 
binds the programmed death receptor -1 (PD -1).81 PD-1 is a transmembrane protein 
primarily expres sed on activated immune cells.  In its usual function, the binding of PD -1 
(found on activated T -cells) to its ligands PD -L1 (B7 -H1) and PD -L2 (B7 -DC) inhibits T -
cell proliferation and activation.  Upregulation of PD -1 ligands can occur in tumors and is 
thought to serve as a means o f immune evasion by the tumor.82 Nivolumab blocks the 
interaction of the PD -1 T-cell receptor with its ligands, potentially enabling the reactivation 
of immunosurveillance and cancer eradication.  
 
Nivolumab  is approved by the U.S Food and Drug Administration (FDA) in melanoma, 
Hodgkin lymphoma, lung carcinoma, an d renal cell carcinoma. It has received approval  
for head and neck cancer based on the results of the CheckMate 141 study.8 In this phase 
III randomized trial, eligibility criteria included recurrent/metastatic HNSCC of the oral 
cavity, pharynx, or larynx with progression on or within 6 months of the last dose of 
platinum -based thera py (irrespective of number of prior lines of therapy or PD -L1 status. 
Subject s were randomized to receive nivolumab (3 mg/kg IV q2week) versus 
investigator’s choice of therapy. Approximately one -quarter of subject s enrolled were p16 
positive. Median overal l survival was 7.5 months for nivolumab versus 5.1 months for 
investigator’s choice therapy (HR 0.70, P=0.01). The 1 -year overall survival rate was 
36.0% for nivolumab versus 16.6% for investigator’s choice. The objective response rate 
SPONSOR: The University of Chicago  
 
24 
Version 4Apr2019  with nivolumab was 1 3.3% (2.5% complete, 10.8% partial). For subject s with p16 positive 
disease, the HR for overall survival was 0.56 (95% CI 0.32 -0.99).  Overall, nivolumab was 
well-tolerated with  3.8% of subject s not continuing treatment due to study drug toxicity 
and 13.1% of subject s experiencing any treatment -related grade 3 -4 adverse event. The 
most common grade 3 -4 treatment related adverse events were fatigue (2.1%), anem ia 
(1.3%), and asthenia (0.4%).  
 
Currently, there is great interest in integrating nivolumab into th e curative -intent setting. 
The Radiation Therapy Oncology Group (RTOG) will soon activate a phase III trial with a 
phase I dose finding lead -in study to evaluate whether the addition of nivolumab will 
improve the overall survival for subject s with newly di agnosed intermediate -risk or high -
risk HNSCC  when treated with radiation therapy and cisplatin -based or cetuximab -based 
chemotherapy or with radiation alone .83  
 
Chemotherapy leads to tumor lysis and release of tumor antigens, which may prime the 
immune system for checkpoint inhibitor s. The combination of a taxane and  immune 
checkpoint inhibitor has been reported to improve response in non -small cell lung cancer  
(NSCLC). In a recently presented p hase I study of nivolumab with nab -paclitaxel and 
carboplatin  in advanced NSCLC  (ABI-007-ST-001), subject s received 4 cycles of nab -
paclitaxel  (100 mg/m2 on days 1, 8, 15 ), carboplatin (AUC 6 on day 1 of a 21 -day cycle), 
and nivolumab  (5 mg/kg on day 15 starting at cycle 1 ).84 No dose -limiting toxicities  were 
observed. The most frequent grade ≥3 treatment -related adverse events  were 
neutropenia ( 28.6%) and anemia (19%). No pneumonitis has been reported to date.  
 
3.10 Study Rationale  
HPV-positive  oropharynx cancer  is a distinct clinical entity based on differing 
demographics, biology, and prognosis. The overall survival benefit in subject s with HPV -
related oropharynx cancer is due largely to a marked improvement in locoregional control. 
Given the yo unger demogr aphic and the significant long -term morbidity incurred with 
standard locoregional therapy , treatment de -intensification is currently an area of active 
investigation.  
 
Multiple approaches for treatment de -intensification of HPV -positive oropharynx cancer 
have r ecently been presented or are currently under investigation in multi -institutional 
settings. These strategies may be classified as follows:  
 
1. Chemotherapy and RT dose de -escalation for select subject s with low -risk 
disease (UNC/UF study69, NRG HN00285) 
2. Substitution of cetuximab in place of cisplatin as the concurrent agent (RTOG 
101686, TROG 12.0187) 
3. Transoral surgical resection followed by de -intensified adjuvant therapy (ECOG 
331176) 
4. Induction chemotherapy followed by response -stratified locoregional therapy 
(ECOG 13084, University of Chicago RAVD5 and Optima I88 studies)  
 
SPONSOR: The University of Chicago  
 
25 
Version 4Apr2019  Our published results using induction chemotherapy to stratify subject s for receipt of 
radic al radiotherapy volume de -escalation demonstrate excellent locoregional control and 
significantly improved  treatment toxicity and quality of life outcomes .5 Notably, subject s 
with both high - and low -risk HPV -positive oropharynx cancer, as well as HPV -negative 
HNSCC, were candidates for radical vo lume de -escalation in this trial. In the subset 
analysis of HPV -positive oropharynx subject s, outcomes were excellent with 2 -year 
locoregional control and progression -free survival rates of 100% and 93%, respectively, 
for subject s with favorable response t o induction chemotherapy in whom elective nodal 
coverage was omitted. Preliminary results of our subsequent study investigating 
significant RT dose de -escalation in subject s with response to induction chemotherapy 
also indicate a high degree of control wit hout compromised outcomes.  
 
Increasing  the response rate to neoadjuvant therapy is an important endpoint to increase 
the proportion of subject s who qualify for de -intensified locoregional therapy . Monoclonal 
antibodies targeting the programmed death (PD) -1 immune checkpoint receptor have 
shown remarkable activity in multiple cancer types including head and neck cancer. The 
goal of PD -1 blockade is to promote tumor recognition and destruction by the immune 
system.  Nivolumab has received breakthrough designation for head and neck cancer 
based on phase III results demonstrating a survival benefit with an objective response 
rate of 13.3%.8  
 
Chemotherapy leads to tumor lysis and release of tumor antigens, which may prime the 
immune system for checkpoint inhibitors. Synergy of anti -PD-1 with chemotherapy is 
supported by early data  combining nivolumab with  nab-paclitaxel and carboplatin.84 
These data suggest a marked increase in the response rate and depth of response, 
perhaps related to the use of steroid sparing chemotherapy (in particular steroid sparing 
nab-paclitaxel) which allows for synergy with PD-1/PD -L1 checkpoint blockade.  
 
Given the above, we hypothesize that the addition of a checkpoint inhibitor, nivolumab, 
to induction chemother apy will increase the response rate to neoadjuvant therapy and 
therefore increase the proportion of subject s who may qualify for de -intensified 
locoregional therapy . Additionally, we  hypothesize that de-intensified locoregional 
therapy for subject s with fa vorable response to induction chemotherapy (including TORS 
or dose - and volume - de-escalated C/RT) will not compromise control outcomes but will 
result in significantly decreased treatment toxicity.  
 
In this study, we will specifically evaluate subject s with locoregionally advanced  HPV-
positive squamous cell cancer of the oropharynx. Subject s will be given 3 cycles of 
neoad juvant nivolumab, carboplatin , and nab -paclitaxel followed by clinical and 
radiographic assessment of response. T he subject s will be assigned to  treatment arms 
based on response to induction chemotherapy and  high or low risk status, as outlined 
below:  
 
SPONSOR: The University of Chicago  
 
26 
Version 4Apr2019  3.10.1  Risk Status  
3.10.1.1   Low Risk  Status (all of the below) : 
o T1-3 
o N0-N2B (unless N3 equivalent lymph nodal conglomerate *) 
o ≤20 pack year history tobacco use  
o HPV16  
 
3.10.1.2   High Risk  Status (any of the below) : 
o T4 
o N2C-N3 
o Bulky  N2B disease with N3 equivalent  nodal conglomerate * 
o >20 pack year history tobacco use  
o Non-HPV16  HPV type (e.g. HPV18, HPV31, etc)  
  
*N3/bulky nodal disease is defined radiologically or on clinical exam  
 
3.10.2  Group A 1: Single -Modality De -escalation Arm (SDA) -- TORS : Single -
Modality De-escalation Arm ( SDA ) –RT 
Subject s with low risk and small volume tonsillar disease (T1 -T2, non -bulky N2A -
N2B with ≤2 non -lower neck lymph nodes measuring ≤5 cm in size) or base of 
tongue disease (T1 -2 with lateralized primary ≤3 cm, non -bulky N2A -N2B with ≤2 
non-lower neck lymph nodes me asuring ≤5 cm in size) who have ≥50% reduction 
by RECIST following induction chemotherapy will undergo TORS and selective 
nodal dissection. De -intensified adjuvant RT will be given for adverse pathologic 
features. Subject s may refuse TORS treatment .  
 
3.10.3  Grou p A2: Single -Modality De -escalation Arm (SDA)  –RT 
Subject s with low risk, who do not qualify for TORS (due to volume of disease or 
poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST 
following induction chemotherapy will be given d e-intensified treatment with 
radiation alone to 50 Gy (see schema page 5).  
 
3.10.4  Group B: Intermediate De -escalation Arm (IDA) – Intermediate dose 
CRT 
Subject s who have low risk disease with <50% but ≥30% reduction of tumor by 
RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent 
bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).  
 
SPONSOR: The University of Chicago  
 
27 
Version 4Apr2019  Subject s who have high risk disease and ≥50% reduction of tumor by RECIST with 
induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin 
(x2 doses) or TFHX to 45 Gy (3 cycles).  
  
3.10.5  Group C: Regular Dose Arm (RDA)  – Standard dose CRT : 
Subject s who have low risk  disease and <30% reduction of tumor by RECIST with 
induction chemotherapy will receive CRT to 70 Gy with concurrent bo lus cisplatin 
(x3 doses) or TFHX to 75 Gy (5 cycles).  
      
Subject s who have high risk disease and <50% reduction of tumor by RECIST with 
induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin 
(x3 doses) or TFHX to 75 Gy (5 cycles).  
      
Any subject  who has progressive disease will receive CRT to 70 Gy with 
concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles).  
 
3.10.6  Adjuvant Treatment with Nivolumab/anti -PD-1 
Adjuvant nivolumab will be offered to all subject s for 6 -months post completion of 
locoregional  therapy for additional systemic activity.  
 
SPONSOR: The University of Chicago  
 
28 
Version 4Apr2019  4 SUBJECT  SELECTION  
4.1 Eligibility Criteria  
• Subject s must have pathologically confirmed HPV -positive head and neck 
squamous cell carcinoma  of the oropharynx. Confirmed HPV -positive disease of 
other subsites  are uncommon but also eligible .  
 
• HPV testing mus t be compliant with the following criteria:  
• p16 IHC positivity is sufficient to enroll  and initiate treatment (p16 IHC 
interpretation  to follow  guidelines by Jordan and Lingen et al89).   
• p16 IHC positivity is  to be  validated using an  HPV PCR during the induction 
phase . This is essential as HPV genotype inf luences treatment arm 
allocation, with non-HPV16 HPV strains being considered high risk . 
 
• Availability  of ≥10 unstained 5 micron slides (to be provided to HTRC  at the 
University of Chicago) . Subject s who cannot fulfill this requirement  will need to  
undergo a new biopsy prior to enrollment on study.  
 
• Subject s must be at least 18 years of age.  
 
• Subject s with AJCC (7th edition, 2010) N2 -N3 nodal disease or T3-T4 primary 
tumor.  Those with AJCC (8th edition 2018) TXNX are also allowed.  
 
• Measurable disease (either primary site and/or nodal disease)  by RECIST  1.1 
criteria .  
 
• No previous radiation or chemotherapy for a head and neck cancer.  
 
• No complete surgical resection for a head  and neck cancer within 8 weeks of 
enrollment (although lymph node biopsy including excision of an individual node 
with presence of residual nodal disease , or surgical biopsy /excision  of the tumor  
with residual disease is acceptable).  
 
• ECOG performance status 0 -1 (Karnofsky 80%). 
 
• Normal Organ Function  
• Leukocytes ≥3000/m m3,  
• platelet s ≥100,000/mm3,  
• absolute neutrophil count ≥1,500,  
• hemoglobin  >9.0 gm/dL,  
• AST and ALT <2.5 X ULN   
• alkaline phosphatase <2.5 X ULN   
• albumin > 2.9 gm/dL,  
• total bilirubin ≤1.5 mg/dl,  
SPONSOR: The University of Chicago  
 
29 
Version 4Apr2019  • creatinine clearance > 45 mL/min  (or SCr <1.5 mg/dL) , normal within 2 
weeks prior to start of treatment.  
→The standard Cockcroft and Gault formula or the measured 
glomerular filtration rate must be used to calculate CrCl for enrollment 
or dosing  
• Subject s must sign a study -specific informed consent form prior to study entry. 
Subject s should have the ability to understand and the willingness to sign a written 
informed consent document.  
 
• Age, Sex, and Reproduct ive Status :  
a) Men and women, ages ≥ 18. 
b) Women of childbearing potential (WOCBP =premenopausal woman capable of 
becoming pregnant ) must have a negative serum or urine pregnancy test 
(minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior 
to the start of study drug.   
c) Women must not be breastfeeding.   
d) WOCBP must agree to follow instructions for method(s)  of contraception for 
the duration of treatment with study drug(s) plus 5 half -lives of study drug(s) 
plus 30 days (duration of ovulatory cycle) for up to 5 months post-treatment 
completion.   
e) Men who are sexually active with WOCBP must agree to follow instructions for 
method(s) of contraception for the duration of treatment with study drug(s) plus 
5 half -lives of study drug(s) plus 90 days (duration of sperm turnover) for up to 
7 months  post treatment completion.   
f)  Azoospermic males and WOCBP who ar e continuously not heterosexually 
active are exempt from contraceptive requirements. However, they must still 
undergo pregnancy testing as described in this section.   
 
Investigators shall counsel WOCBP and male subjects who are sexually active 
with WOCBP on the importance of pregnancy prevention and the implications of 
an unexpected pregnancy. Investigators shall advise WOCBP and male subjects 
who are sexually active wit h WOCBP on the use of highly effective methods of 
contraception. Highly effective methods of contraception have a failure rate of 
<1% when used consistently and correctly.  
 
At a minimum subjects must agree to the use of one method of highly effective 
contraception as  listed in Appendix E . In addition, male subjects are expected to 
use a con dom as noted in  Appendix E .  
  
4.2 Exclusion Criteria  
• Unequivocal demonstration of distant metastases (M1 disease) . 
 
• Unidentifiable primary site.  
SPONSOR: The University of Chicago  
 
30 
Version 4Apr2019   
• Intercurrent medical illnesses which would impair subject  toleranc e to therapy or 
limit survival. Including but not limited to ongoing or active infection, 
immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, 
cardiomyopathy, unstable angina pe ctoris, cardiac arrhythmia , or psychiatric 
illness/social situations that would limit compliance.  Once clinically stable, as 
defined by the PI, they are eligible.  
 
• Pregnant and nursing women are excluded because of the potential teratogenic 
effects and pot ential unknown effects on nursing newborns (please see above  
paragraph under inclusion criteria  regarding WOCBP)  
 
• Prior surgical t herapy other th an incisional/excisional biopsy or  organ -sparing 
procedures such as debulking of airway -compromising tumors . Residual 
measurable tumor is r equired for enrollment on study  as outlined above  
 
• Subject s receiving other investigational agents.  
 
• Peripheral neuropat hy >grade 1  
 
• Has a diagnosis of immunodeficiency or is receiving systemic ster oid therapy in 
excess of physiologic dose or any other form of immunosuppressive therapy within 
7 days prior to the first dose of trial treatment.   
• Has a known history of active tuberculosis (Bacillus Tuberculosis infection)  
 
• Has hypersensitivity to nivolumab or any other drug used in this protocol.  
• Has had a prior systemic anti -cancer treatment within the last 8 weeks  
• Has a known additional malignancy that is progressing or requires active 
treatment.  Exceptions include basal cell  carcinoma of the skin or squamous cell 
carcinoma of the skin that has undergone potentially curative therapy or in situ 
cervical cancer or any tumors that are not likely to influence live expectancy in the 
subsequent 3 years without active treatment (e.g.  low grade prostate cancer in 
absence of therapy).  
• Has active autoimmune disease that has required systemic treatment in the past 
year (i.e. with use of steroids or immunosuppressive drugs). Replacement therapy 
e.g. levothyroxine, insulin, or physiologic corticosteroid doses for adrenal or 
pituitary insuff iciency, etc. are not considered a form of systemic treatment.  
• Has known history of, or any evidence of active, non -infectious pneumonitis.  
• Has a history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).  
SPONSOR: The University of Chicago  
 
31 
Version 4Apr2019  • Has known active Hepatitis B (e.g., HBsAg  reactive) or Hepatitis C (e.g., HCV RNA 
[qualitative] is detected). However, if eradicated subject  is eligible.  
• Has received a live vaccine within 28 days of planned start of study therapy.  
o Note:  Seasonal influenza vaccines for injection are generally in activated 
flu vaccines and are allowed; however intranasal influenza vaccines (e.g., 
Flu-Mist®) are live attenuated vaccines, and are not allowed within 28 
days prior to initiation of treatment.  
 
4.3 Criteria for discontinuation/withdrawal of informed consent  
Subject s may be discontinued from trial treatment at any time, at the discretion of the 
investigator(s).  Specific reasons for discontinuing a subject  from study treatment include:  
 
• Objective progression of disease  if deemed inappropriate  for further study 
treatment.  
 
• Unacceptable adverse events.  
 
• Protocol non -compliance.  
 
• Study closure.  
 
• Subject  decision to withdraw from the study.  
 
• In the judgment of the investigator, further treatment would not be in the best 
interest of the subject . 
 
All deaths that occur within the trial period or within 100 days after administration of the 
last dose of trial drug are to  be reported  as SAEs . 
 
All trial treatment -related toxicities and SAEs must b e followed up until resolution. All 
subject s who have new or worsening CTC AE grade 3 or 4 laboratory values at the time 
of withdrawal must have additional testing performed  for up to 12 months , and the results 
must be recorded in the subject ’s medical record. In these cases, the investigators must 
record  their opinions regarding relationship to study treatment in the subject ’s medical 
record. Laboratory abnormalities should not be reported as adverse eve nts unless a 
criterion for an SAE is fulfilled, the laboratory abnormality causes the subject  to 
discontinue from the study, or the investigator insists the abnormality should be reported 
as an AE.   
 
SPONSOR: The University of Chicago  
 
32 
Version 4Apr2019  4.4 HPV testing  
As this trial makes treatment decision s based on HPV status , the specificity of the HPV 
test used is of critical importance. Therefore , certain HPV testing requirements have to 
be met that take into account varying HPV performance characteristics in oropharyngeal 
primary tumors .  
 
• p16 IHC positivity is sufficient to enroll  and initiate treatment (p16 IHC 
interpretation  to follow guidelines by Jordan and Lingen et al89).   
• p16 IHC positivity is  to be  validated using an  HPV PCR during the induction 
phase. This is essential as HPV genotype influences treatment arm 
allocation, with non -HPV16 HPV strains being c onsidered high risk . 
 
SPONSOR: The University of Chicago  
 
33 
Version 4Apr2019  5 TREATMENT PLAN  
5.1 General Considerations  
Induction chemotherapy will be administered on an out patient  basis . Subject s receiving 
radiation therapy alone will be treated as out patient s whereas chemoradiotherapy may 
be admi nistered on an inpatient  basis  (using the TFHX regimen) or outpatient  basis (with 
cisplatin) . Subject s receiving adjuvant nivolumab will receive this on an outpatient  basis. 
All subject s will be evaluated by surgical, medical , and radiation oncologists pri or to trial 
entry to determine optimal local treatment. Subject s will start induction chemotherapy 
within 4 weeks of signing consent . Three cycles  of carboplatin, nab-paclitaxel , and 
nivolumab  induction chemotherapy will be followed by response -adjusted locoregional 
therapy.   
 
Subject s in Group A 1 (Single -Modality De-escalation Arm) will undergo either TORS  (with 
adjuvant radiation therapy 40 -44 Gy for adverse features) . Subject s in Group A2 will 
receive  radiation  therapy  alone  to 50 Gy in standard daily fractionation. Subject s in Group 
B (Intermediate De -escalation Arm) and Group C (Regular Dose Arm) will receive  
concurrent chemoradiation consist ing of cisplatin  100mg/m2 for two (intermediate)  or 
three (regular) doses with daily radiation, OR twice daily rad iation with paclitaxel, 5 -FU, 
and hydroxyurea (TFHX) given on an al ternating week basis. Subject s should have a pre -
induction chemotherapy CT simulation (or PET -CT simulation if available) performed . 
Cisplatin -radiation will be given to a total dose of 50 Gy for subject s in Group  B and 70 
Gy for subject s in Group C. TFHX will be given to a total dose of 45 Gy for subject s in 
Group B and 75 Gy for subject s in Group C. Adjuvant nivolumab will be offered to all  
subject s for 6 months  on an out patient  basis.   
 
5.2 Pre-treatment evaluation  
Subject s must have completed the following within 4 weeks of signing consent  unless 
noted  (also see study calendar in section 9 for additional details) : 
 
• Inclusion and e xclusion criteria reviewed.  
 
• Physical examination to define measurable disease.  
 
• Pan-endoscopy with biopsy, tumor mapping, and documentation  (if clinically 
indicated at PI’s d iscretion) . 
 
• Biopsy proven squamous cell carcinoma of the oropharynx  with HPV testing  (IHC 
is sufficient for enrollment, but PCR needs to be completed during the first cycle of 
induction to confirm IHC) . 
 
• Baseline diagnostic CT or MRI scans of the head and neck that includes entire 
disease extent within 4 weeks  before study entry.  
SPONSOR: The University of Chicago  
 
34 
Version 4Apr2019   
• PET/CT  scan is recommended  prior to start of induction chemotherapy , 
though not required . 
 
• 10 days  prior to chemotherapy, CBC with differential and platelet count, and 
complete metabolic profile.  
 
• Ultrasound or CT imaging of the liver if chemistries (SGOT, SGPT, and bilirubin) 
are above upper limit of normal . 
 
• Additional studies (bone scan, barium swal low, etc.) to exclude distant metastases 
or second primaries as clinically indicated.  
 
• Complete dental evaluation  before the end of induction . 
 
• Speech and swallowing consultation  during the first cycle of induction . 
 
• Informed consent.  
 
Refer to section 9 for a complete list of required baseline evaluations.   
 
5.3 Study evaluations  
Subject s will have the following exams and tests throughout the study at specified time 
points  (please see study chart):  
 
• Physical examination . 
 
• Performance status evaluation . 
 
• CBC with differential and platelet count.  
 
• Complete metabolic panel.  
 
• Toxicity and quality of life evaluations . 
 
• Head and Neck staging evaluation and imaging  with either MRI or CT  within 4 
weeks prior to induction chemotherapy . 
 
• Repeat imaging  of the head and neck after the 3rd cycle of induction chemotherapy  
week for stratification of locoregional therapy.  In the case of TORS candidates, this 
can be delayed up to 3 weeks.  
 
• Follow -up imaging with head and neck CT/MRI at 4 weeks post -locoregional 
therapy with or without  re-staging PET/CT at 12 weeks post -locoregional therapy.  
SPONSOR: The University of Chicago  
 
35 
Version 4Apr2019  5.4 Induction Chemotherapy  Details an d Guidelines   
Induction chemotherapy will be administered on an outpatient  basis and concurrent 
chemoradiation will be administered on an inpatient  basis. Expected adverse events 
(AEs) and appropriate dose modifications for these agents are described in Se ction 6. No 
other investigational agents or therapies other than those described below may be 
administered with the intent to treat the subject ’s malignancy.  
  
Carboplatin, nab -paclitaxel , and nivolumab  combination will be administered for three 
cycles of three  weeks duration each. TORS or RT/CRT  will be performed  after induction 
chemotherapy (i.e. day 64 of therapy). Dose delays and dose modifications should take 
place as outlined.   In no case should th e three cycles of induction chemotherapy be 
given over a period exceeding twelve (12) weeks.  
 
Pre-medications: Premedication with dexamethasone should not be  given due to the 
possibility of counteracting the effect of nivolumab , unless absolutely clinicall y necessary 
(after discussion with the PI) . 
 
Nivolumab:  360 mg flat dose on day 1 , q21 days  (3 doses total ) 
 
Nab-Paclitaxel: 100 mg/m2 in 250 ml of NS (or similar per institutional standard) over 30 
minutes on d ays 1, 8, and 15 (9 doses total)  
 
Carboplatin: Start after completion of nab-paclitaxel , AUC 5 in 250 ml  of D5W (or 
similar per institutional standard) over 30 -60 minutes  on day 1 (3 doses total)  
 
A baseline creatinine level should be drawn within 1 week prior to starting chemotherapy.  
 
Antiemetics:  Pre-treatment with a 5 HT -3 antagonist [eg ondansetron  hydrochloride 
(Zofran), dolasetron mesylate (Anzemet ), or granisetron  
 
Hydrochloride (Kytril)] prior to chemotherapy on Day 1 is  recommended. The use of 
additional antiemetics and the p revention of delayed  emesis are left to the discretion o f 
the tr eating physician.  Dexamethasone/steroids as anti -emetic therapy should be 
avoided, and only should be given after discussion with the study PI.  
 
Hydration:  Hydration is left to the discretion of the treating physician.  
 
For each cycle :  Filgrastim (neupogen) is to be given at the discretion of the treating 
physician as clinically indicated . 
 
5.5 Surgical Details and Guidelines   
Subject s with low risk and small volume tonsillar disease (T1 -T2, non -bulky N2A -N2B 
with ≤2 non -lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease 
(T1-2 with lateralized primary ≤3 cm, non -bulky N2A -N2B with ≤2 non -lower neck lymph 
SPONSOR: The University of Chicago  
 
36 
Version 4Apr2019  nodes me asuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction 
chemotherapy will undergo TORS and selective nodal dissection. De -intensified adjuvant 
RT will be given for adverse pathologic features. Subject s may refuse TORS treatment 
(see tr eatment next paragraph).  
 
Subject s with low risk, who do not qualify for TORS (due to volume of disease or poor 
visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following 
induction chemotherapy will be given de-intensified treatment with radiation alone to 50 
Gy (see schema page 5).  
 
Before induction chemotherapy, subject s will undergo examination under anesthesia 
and direct laryngoscopy to tattoo and photograph the primary tumor to plan the post -
induction res ection.  Surgical resection should be performed within 2 weeks and no later 
than 4 weeks after completion of the third cycle of induction chemotherapy.  
 
Primary site resection by TORS will be limited to the pre -induction extent of 
tumor (as defined with ma pping and documentation at the time of pre -induction 
direct laryngoscopy).  Selective nodal dissection of  levels 2 -4 and any other  
previously involved nodal levels  as well as nodal levels that are clinically felt to 
be at risk  will be performed.  
 
5.5.1  Indication s for Adjuvant Radiation post -operatively  
In the absence of adverse pathologic features, subject s will not receive radiation 
based therapy.  
 
Post-operative radiation will be given for adverse pathologic features as follows:  
 
(1) 40 Gy in 2 Gy once daily fractions for PNI or LVI.  
(2) 44 Gy in 2 Gy once daily fractions for ECE or positive surgical margins.  
 
Post-operative RT volumes will be at the discretion of the treating physician, with appr oval 
from the Radiation PI , but generally will be targeted  toward th e surgical bed site with 
adverse pathology.  
 
Post-operative RT should begin within 4 weeks and no later than 6 weeks after surgical 
resection.   
 
5.6 Definitive Radiation/Chemoradiation  Details and Guidelines   
5.6.1  Risk Status  
5.6.1.1  Low Risk  Status (all of the below) : 
o T1-3 
SPONSOR: The University of Chicago  
 
37 
Version 4Apr2019  o N0-N2B (unless N3 equivalent lymph nodal conglomerate *) 
o ≤20 pack year history tobacco use  
o HPV16  
 
5.6.1.2  High Risk  Status (any of the below) : 
o T4 
o N2C-N3 
o Bulky N2B disease with N3 equivalent  nodal conglomerate * 
o >20 pack year history tobacco use  
o Non-HPV16  HPV type (e.g. HPV18, HPV31 etc)  
 
*N3/bulky nodal disease is defined radiologically or on clinical exam . 
 
5.6.2  Response Stratified Group ing: 
Subject s will be assigned to TORS, RT,  or CRT  based on respon se to induction 
chemotherapy.  
 
Chemoradiation wil l be given with concurrent cisplatin or on the TFHX platform 
based on physician and subject  preference, and  are considered interchangeable.  
 
• Cisplatin will be given at a dose of 100mg/m2, every 21 days for 2 (IDA arm, 
see below) or 3 doses (RDA arm, see below).  
 
• Chemoradiation on the TFHX platform will consist of 14 -day cycles of 
paclitaxel (100 mg/m2 day 1 over 1 hour), 5 -FU (continuous infusion at 
600 mg/m2/day  5 days), and hydroxyurea (500 mg PO BID days 0 -5, 11 
doses/cycle) with twice daily radiation (150 cGy per fraction). Cisplatin -
based chemoradiation on an outpatient  basis will be offered as an 
alternative treatment platform.  
 
 
5.6.2.1   Group A 1: Single -Modality  De-escalation Arm ( SDA) – TORS  
Subject s with low risk tumors and small volume tonsillar disease (T1 -T2, up to 
N2B) OR  base of tongue disease (T1 -2 with primary ≤3cm, up to N2B)  who have 
≥50% reduction by RECIST following induction chemothe rapy will undergo 
TORS and selective nodal dissection. De-intensified adjuvant RT will be given 
for adverse pathologic features.  Subject s may refuse TORS treatment (see 
treatment next paragraph).  
 
Subject s with low risk, who do not qualify for TORS (due to  volume of disease or 
poor visualization/access) or refuse TORS, who have ≥50% reduction by 
SPONSOR: The University of Chicago  
 
38 
Version 4Apr2019  RECIST following induction chemotherapy will be given de -intensified treatment 
with radiation alone to 50 Gy (see schema page 5).  
 
Surgical resection should be perf ormed within 2 weeks and no later than 4 weeks 
after completion of the third cycle of induction chemotherapy.  
 
Primary site resection by TORS will be limited to the pre -induction extent of tumor 
(as defined with mapping and documentation at the time of pre -induction direct 
laryngoscopy). Selective nodal dissection of at least the previously involved 
nodal levels will be performed.  
 
Post-operative radiation will be given for adverse pathologic features as follows:  
 
• 40 Gy in 2 Gy once daily fractions for PNI or LVI.  
• 44 Gy in 2 Gy once daily fractions for ECE or positive surgical margins.  
 
Post-operative RT volumes will be at the discretion of the treating physician, with 
approval from the Radiation PI , but generally will be directed to ward the involved 
disease site.  
 
Post-operative RT should begin within 4 weeks and no later than 6 weeks after 
surgical resection.   
 
5.6.2.2  Group A2: Single -Modality D e-escalation Arm (S DA) – RT 
Subject s with low risk, who do not qualify for TORS (due to volume of disease or 
poor vis ualization/access) or refuse TORS, who have ≥50% reduction by 
RECIST following induction chemotherapy will be given de -intensified treatment 
with radiation alone t o 50 Gy (see schema page 5).  
 
5.6.2.3  Group B: Intermediate De -escalation Arm (IDA) – Low dose CRT  
Subject s who have low risk disease with <50% but ≥ 30% reduction of tumor by 
RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent 
cisplatin (x2 doses) or 45 Gy  on the TFHX platform (3 cycles ). 
 
Subject s who have high risk  disease and ≥50% reduction of tumor by RECIST with 
induction chemotherapy will receive CRT to CRT to 50 Gy with concurrent cisplatin 
(x2 doses) or 45 Gy on the TFHX platform (3 cycles).  
 
5.6.2.4   Group C: Regular Dose Arm (RDA)  – Standard dose CRT : 
Subject s who have low risk  disease and < 30% reduction of tumor by RECIST with 
induction chemotherapy will receive CRT to 70 Gy with concurrent cisplatin (x3 
doses) or 75 Gy on the TFHX platform (5 cycles) . 
SPONSOR: The University of Chicago  
 
39 
Version 4Apr2019        
Subject s who have high risk disease and < 50% reduct ion of tumor by RECIST with 
induction chemotherapy will receive CRT to CRT to 70 Gy with concurrent cisplatin 
(x3 doses) or 75 Gy on the TFHX platform (5 cycles).  
      
Any subject  who has progressive disease will receive CRT to 70 Gy with 
concurrent cispl atin (x3 doses) or 75 Gy on the TFHX platform (5 cycles).  
 
Expected AEs and appropri ate dose modifications for nab -paclitaxel, carboplatin,  
nivolumab,  5-FU, hydroxyurea, and radiation are described in s ections 6.1 and 6.2 
and Appendices  B and C. No invest igational or commercial agents or therapies 
other than those described below may be administered with the intent to treat the 
subject 's malignancy.  
 
5.6.3   Concurrent Cisplatin -Radiation:  
Cisplatin  will be given on an every -3-weeks basis at a do se of 100mg/m2 IV over  
3-4 hours day 1 (or 2) and 22 (or 23)  for subject s on the Intermediate Dose Arm , 
and additionally on  day 43 (or 44) for subject s on the Regular Dose Arm . 
Mannitol should be  given  to decrease risk of toxicity if clinically appropriate.  
  
5.6.4  TFHX Regimen:  
Subject s on the I ntermediate or Regular  Dose Arms will receive chemoradiation 
for 3-5 cycles (6 -10 weeks) and c hemotherapy should be administered during all  
weeks of radiotherapy.   
 
Day 0  
P.M.:  start hydroxyurea at 500 mg PO q 12 hours  6 days 
(11 doses).  The firs t daily dose of hydroxyurea on d ays 
1 – 5 is given 2 hours prior to the first fraction of daily 
radiotherapy.  
 
  
6:00 P.M.:  start continuous infusion of 5 -FU at 600  mg/m2/day  5 
days (120 hours).  
 
Day 1 – 5 dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior 
to paclitaxel  
 famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to 
paclitaxel  
 diphenhydramine 50 mg PO (IV) in  am Day 1, 30 mins 
prior to paclitaxel  
  
SPONSOR: The University of Chicago  
 
40 
Version 4Apr2019  Start paclitaxel 100 mg/m2 after first RT fraction on day 
1 of each cycle. Paclitaxel should be administered in 
250 ml 0.9% NaCl over 60 minutes.  
 
Radiation therapy is administered twice daily at 
150 cGy per fractio n. 
 
Days 6 – 13:  No chemoradiotherapy. Subject s should be seen 
once on an out patient  basis during these non -
treatment days to monitor for toxicity.   
 
For each cycle:  Administer 5 g/kg subcutaneously (SQ) of G -CSF 
(filgrastim) daily, beginning on Day 6 through Day 12 
at a minimum of 24 hours after completion of 5 -FU in 
subject s who develop grade 3 neutropenia or who have 
neutropenia  grade 2 on Day 0 of any cycle.  In these 
subject s, G-CSF should be utilized in all subsequent 
cycles. G -CSF can be utilized prophylactically from the 
start of chemoradiotherapy in all cycles at the 
discretion of the treating physician.  
 
Chemoradiotherapy cycles are repeated every 14 days until the compl etion of 
radiotherapy.  
 
5.6.5  Radiation Therapy Guidelines  
1. All subject s will have a complete dental evaluation prior to the start of radiation 
therapy, ideally prior to the start of chemotherapy.  
 
2. Treatment approaches will use Intensity Modulated Radiotherapy (IMRT) and, in 
selected cases, 3D conformal radiotherapy will be used alone or in combination 
with IMRT.  In both instances , the physician will attempt to deliver an even dose 
to the target tis sue and minimize doses to surrounding normal struct ures.  The use 
of customized blocks or multileaf collimation for field shaping is strongly 
recommended.  
 
3. Localization requirements: All subject s will be immobilized and simulated in the 
treatment  position prior to the start of induction chemotherapy and after induction 
chemotherapy within 1 -2 weeks after the last cycle of chemotherapy. A contrast 
enhanced CT  simulation scan (or PET -CT simulation scan) with immobiliza tion is 
required for planning. Slice thickness should be optimally 3  mm and no greater 
than 5 mm. The pre - and post -chemotherapy diagnostic scans will be fused to 
define the targets below.  Subject s must be reproducibly immobilized. Radio -
opaque markers may be used whenever possible to d elineate the surgical scars, 
extent of nodal disease, skin involvement, and any gross disease.  
 
SPONSOR: The University of Chicago  
 
41 
Version 4Apr2019  4. Target volumes:  Appropriate volumes  will be delineated  at the time of simulation 
to treat the pre -chemotherapy extent of gross disease and areas of potential 
microscopic disease.  
 
GTV will be all gross tumor identified by physical exam, additional clinical 
information , and radiographic studies prior to induction chemotherapy.  
 
CTV1  will be an isotropic expansion of the GTV by 1.0 cm and may be modified 
at the discretion of the treating physician to respect anatomic boundaries to 
spread of tumor (e.g., bone or air).  
 
PTV1  will be an isotropic expansion of the CTV1 by 0.5 cm . 
 
CTV2  will include CTV1  plus the next echelon of uninvolved but at risk lymph 
nodes  that include  the nodal stations at risk for microscopic spread a s described 
in the tables below . Inclusion of the retropharyngeal nodes will be at the discretion 
of the treating ra diation oncologist. CTV2 may be modified at the discretion of the 
treating physician to respect anatomic boundaries to spread of tumor (e.g., bone 
or air).  
 
PTV2 will be an isotropic expansion of the CTV2 by 0.5 cm . 
 
5. Dose and fractionation:  
 
For subject s treated with RT alone :  
 
i. Single -Modality De-escalation Arm  (SDA ) -- RT:  PTV1 will be 
treated to 50 Gy  (2 Gy QD ) with radiation alone  over 5 consecutive  
weeks . There will be no PTV2 volume.  
 
For subject s treated with  CRT on the TFHX platform:  
 
i. Intermediate De -escalation Arm  (IDA) : PTV1 will be treated to 45 Gy  
(1.5 Gy BID)  over the course of 3 cycles . PTV2 will be treated to 30 Gy  
(1.5 Gy BID)  during the first 2 cycles of CRT  for low -risk subject s with 
<50% response. There will be no PTV2 volume for high -risk subject s 
with ≥50% response.  Chemoradiation will b e given on an alternating 
week  basis. There should be a minimum of 6 hours between fractions. 
All fields will be treated each day. In the case of me chanical failure or a 
holiday, one day of BID radiotherapy can be replaced wi th a single QD 
fraction of 2 Gy. Accordingly, the final cumulative dose will be slightly 
less. 
ii. Regular Dosing Arm  (RDA) : PTV1 will be treated to 7 5 Gy (1.5 Gy 
BID) over the course of 5 cycles and PTV2 will be treated to 45  Gy (1.5 
Gy BID)  during the first 3 cycles of CRT . Chemoradiation will b e given 
on an alternating week  basis. There should be a minimum of 6 hours 
SPONSOR: The University of Chicago  
 
42 
Version 4Apr2019  between fractions. All fields will be treated each day. In the case of 
mechanical failure or a holiday, one day of BID radiotherapy can be 
replaced with a single QD fraction of 2 Gy. Accordingly, the final 
cumulative dose will be slightly less.  
 
For subject s treated with CRT with cisplatin, RT do se, fractionation,  and volume 
delineation will be as follows:  
 
i. Intermediate De -escalation Arm (IDA) : PTV1 will be treated to 50  Gy 
(2 Gy QD ) over the course of 5 consecutive weeks . PTV2 will be treated 
to 30 Gy  (2 Gy QD ) during the first 3 weeks of CRT  for low -risk subject s 
with <50% response . There will be no PTV2 volume for high -risk 
subject s with ≥50% response.  
ii. Regular Dosing Arm (RDA): PTV1 will be treated to 70 Gy  (2 Gy QD ) 
over the course of 7 consecutive weeks. PTV2 will be treated to 50 Gy  
(2 Gy QD ) during the first 5 weeks of CRT.  
 
6. Field Size:  Appropriate volumes  will be determined at the time of simulation to 
treat gross disease and areas of  potential microscopic disease  as indicated . The 
optimal field arrangement will be determined based on the treatment planning 
techniques employed. All fields must be treated during each treatment session.  
 
7. Treatment technique:  Blocking will be individualiz ed for each subject .  Either 
custom Cerrobend blocks or multileaf collimator will be acceptable.  
 
Intensity Modulated Radiotherapy:  Optimal IMRT planning will depend on the 
planning system employed.  We anticipate the optimal plan will use 7 to 11 gantry 
positions.  Acceptable plans will encompass the PTV with the 95% isodose line.  
No more than 1% of the PTV should receive less than 95% of the prescribed dose .  
Plans should be reviewed to e nsure that any part of the PTV getting less than 
95% of the prescribed dose is at the edge of the volume.  In no case should a 
central area of the PTV receive less than 95% of the prescribed dose.  No more 
than 1% of the PTV should receive more than 110% of the prescribed dose.  
 
3D Conformal Radiotherapy:  The neck should be treated with opposed lateral 
fields using a half -field technique.  The lower neck should be treated with an 
anterior field prescr ibed to a depth of 3 cm. Opposed fields for the lower neck are 
permitted in order to improve PTV coverage and increase homogeneity.  Wedges, 
tissue compensators , or segmented fields should be used to e nsure uniformity of 
PTV coverage. Electron boosts of th e posterior neck are permitted to limi t the 
dose to the spinal cord. Electron fields shall be prescribed to the depth of 
maximum dose with the energy and field size chosen so that the target volume is 
encompassed within 90% o f the prescribed isodose line. A cord block is permitted 
on the anterior or lateral fields provided it does  not block tumor. Feathering the 
match line is permitted in cases where a cord block would block tumor. For 3D 
techniques, acceptable plans will encompass the PTV within the 95% isodose 
SPONSOR: The University of Chicago  
 
43 
Version 4Apr2019  line. The dose variation in the PTV will be +7% and -5% of the prescription point 
dose.  
 
8. Normal Tissue Constraints/Dose Volume Histograms: Isodose calculations in 
the axial, sagittal, or coronal planes are required. In addition, dose volume 
histogr ams for the planning treatment volumes  and the spinal cord are required.  
The dose limit to the spinal cord will vary dep ending upon the technique used. 
Attempts should be made to limit the spinal cord dose to <45 Gy in all cases.  
 
9. Adaptive Re -planning:  Subjects on the Regular Dose Arm  treated on the  TFHX 
platform will undergo repeat CT simulation during cycle 3 for adaptive re -planning 
of treatment volumes.  
 
10. Surrounding critical normal structures  should be outlined for study purposes, 
including the brainstem, spinal cord, superior/ inferior  constrictor muscles, optic 
nerves/chiasm, parotid and submandibular glands, temporo -mandibular (T -M) 
joints and cochlea, oral cavity, mandible, eyes, lens, brac hial plexus, esophagus 
(including postcrico id pharynx) and glottic larynx. The normal tissues will be 
contoured and considered as solid organs. DVH  plots  must be generated for 
relevant critical normal structures, any corresponding PRVs, and the unspecified  
tissues. Institutions that use PRVs must clearly define them as such. Ultimate 
inclusion of the normal structures and exceptions from the above guidelines will 
be made at the discretion of the  treating radiation o ncologist.  
 
11. Special situations:  3D conformal treatment techniques may be preferable to  
IMRT in certain situations.  Some large primary tumors and some large neck  
nodes may extend up to the skin.  In these situations,  it may not be possible to  
add a sufficient margin to the GTV to accoun t for variability in the subject  set up. 
In such a situation , 3D conformal treatment techniques may be preferable to 
IMRT.  
 
5.6.6  Nodal Planning Target Volume  Delineation:  
 
Lateralized Base of Tongue  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, 
II IA,
II IB, 
III II, 
IV II, III 
SCV II, 
III IA, 
IB, 
II II II II II II 
Contralateral  IA  II II II II II IB II IB II, 
IV II, III 
SCV II, 
III 
 
SPONSOR: The University of Chicago  
 
44 
Version 4Apr2019  Base of Tongue Crossing Midline  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, II IA,
II IB, 
III II, 
IV II, 
III, 
SCV II, 
III IA, 
IB, 
II II II II II II 
Contralateral  IA  II II II II II IB IA, 
II IB, 
III II, 
IV II, III, 
SCV II, 
III 
 
Soft Palate  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, II IA, 
II IB, 
III II, 
IV II, 
III, 
SCV II, 
III IA, 
IB, 
II II II II II II 
Contralateral  IA  II II II II II IB IA, 
II IB, 
III II, 
IV II, 
III, 
SCV II, 
III 
 
Lateralized Tonsil  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, II IA, 
II IB, 
III II, 
IV II, 
III, 
SCV II, 
III IA, 
IB, 
II II II II II II 
Contralateral  IA --- --- --
- --- --
- IB IA, 
II IB, 
III II, 
IV II, 
III, 
SCV II, 
III 
 
SPONSOR: The University of Chicago  
 
45 
Version 4Apr2019  Tonsil with Base of Tongue I nvasion  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, II IA,
II IB, 
III II, 
IV II, 
III, 
SCV II, 
III IA, 
IB, 
II II II II II II 
Contralateral  IA  II II II II II IB II IB, 
III II, 
IV II, 
III, 
SCV II, 
III 
 
Oropharynx involving Larynx  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, II IA,
II  III II, 
IV II, 
III, 
SCV II, 
III IA, 
IB, 
II II II III III II 
Contralateral  IA  II II II II II IB IA, 
II IB,
III II, 
IV II, III, 
SCV II, 
III 
 
Oropharynx involving Oral Cavity (L ateralized)  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, 
II IA, 
II IA, 
IB, 
III IA, 
IB, 
II, 
IV IA, 
IB, 
II, 
III, 
IV, 
SCV IA, 
IB, 
II, 
III IA
, 
IB
, 
II IA, 
IB, 
II IA, 
IB, 
II IA, 
IB, 
II IA, 
IB, II IA, 
IB, 
II 
Contralateral  IA, 
IB --- --- --- --- --- IB
, 
II IA, 
II IA,
IB, 
III IA, 
IB, 
II, 
IV IA, 
IB, 
II, 
III, 
SCV II, 
III 
 
SPONSOR: The University of Chicago  
 
46 
Version 4Apr2019  Oropharynx involving Oral Cavity (Crosses M idline)  
 Adenopathy Level  
 Ipsilateral  Contralateral  
Involved 
Nodes  IA IB II III IV V IA IB II III IV V 
CTV2             
Ipsilateral  IB, 
II IA, 
II IA, 
IB, 
III IA, 
IB, 
II, 
IV IA, 
IB, 
II, 
III, 
IV, 
SCV IA
, 
IB
, 
II, 
III IA, 
IB, 
II IA, 
IB, 
II IA, 
IB, 
II IA, 
IB, 
II IA, 
IB, II IA
, 
IB
, 
II 
Contralateral  IB, 
II IB, 
II IB, 
II IB, 
II IB, II IB
, 
II IB, 
II IA, 
II IA,
IB, 
III IA, 
IB, 
II, 
IV IA, 
IB, II, 
III, 
SCV II, 
III 
 
Oropharynx involving Nasopharynx  
 Adenopathy Level  
 Ipsilateral  
Contralateral  
Involved 
Nodes  IA IB II III IV 
V IA IB II III IV V 
CTV2             
Ipsilateral  IB, 
II, 
VA IA, 
II, 
VA IB, 
III, 
VA II, 
IV, 
VA II, 
III, 
VA, 
SCV II, 
III IA, 
IB, 
II, 
VA II, 
VA II, 
VA II, 
VA II, VA  II, 
VA 
Contralateral  IA  II II II II II IB, 
VA IA, 
II, 
VA IB, 
III, 
VA II, 
IV, 
VA II, III, 
SCV,
VA II, 
III, 
VA 
 
5.7 Adjuvant Immunotherapy Details and Guidelines  
Nivolumab:  480 mg flat dose every 28 days (7  doses total  = 6 months adjuvant 
treatment). The goal is to potentially re -activate a potential antitumor response 
triggered during the induction phase after immunosuppressive RT or CRT 
treatment and eradicate micro -metastatic residual disease.  
 
SPONSOR: The University of Chicago  
 
47 
Version 4Apr2019  5.8 Supportive Guidelines  
• Antiemetics will be ordered at the discretion of the attending physician.  
 
• Use of growth factor s upport (G -CSF) on days 16/17/18  of induction  if counts drop 
and Physician -recommended. . During the TFHX week -on week -off regimen G -
CSF may be used during the off week at the treating physician ’s discretion.  
 
• A double lumen venous access device (e.g., Port -a-Cath) is recommended prior 
to initiation of therapy , although peripheral IV access i s acceptable . 
 
• Use of a feeding device is recommended for high -risk subject s. Placement of a 
feeding device is left to the discr etion of the treating physician/investigator. 
Commonly applied criteria for feeding device placement include : 
i. Loss of > 10% of body weight from the start of therapy  
ii. Dehydration or inability to main tain adequate oral hydration  
iii. Inability to maintain intake of >25 kcal/kg of ideal body weight  
 
• During chemoradiotherapy subject s should receive instructions for oral hygiene 
and prescrip tions to include  standard of care treatment typical for the care of HNC 
subject s undergoing radiation or chemoradiation : 
i. Oral nystatin or fluconazole (100mg QD)  
ii. Viscous lidocaine HCl (Xylocaine ) solution) and/or Grade I 
mouthwash 10  mL QID, swish and spit  
 
Table: Grade I mouthwash  
Lidocaine, Viscous (2%)  50 mL  
Diphenhydramine elixir (12.5 mg/5 mL)  50 mL  
Sodium bicarbonate injection  100 mL  
Normal saline irrigation  500 mL  
Total volume  700 mL  
 
iii. Normal saline mouthwash 10ml QID swish and spit  
 
iv. Natural Care Gel (or similar product) BID during chemoradiotherapy 
and TID during rest week.  
 
v. Vigilon (or similar product) to be applied to open wounds during 
chemoradiother apy. 
 
vi. Silvadene cream to open wounds followed by zinc oxide cream and 
then Telfa dr essings BID during rest week ( N.B.: discontinue Silvadene 
and zinc oxide creams 1 day prior to radiotherapy) . 
 
SPONSOR: The University of Chicago  
 
48 
Version 4Apr2019  vii. Aquaphor (or similar brand) cream to lips PRN.  
 
viii. Adequate analgesia is essential to maintain oral intake and subject  
comfort. Narcotic analgesics are usually necessary and should be used 
at the physician/investigator discretion.  
 
ix. Therabite for trismus if appropriate.  
 
x. Replacement for electrolyte imbalances when applicable.   
 
• Prior to discharge of the subject s after a cycle of chemoradiation, a CBC and 
platelet count, and determination of serum electrolytes, including creatinine will be 
performed.  
 
• A visit to the treating physician is strongly recommended between cycles of  
chemoradiation (i.e., days 6 -14)   
 
• Use of intravenous home hydration is strongly recommended in subject s with 
inadequate oral intake: normal saline 1000ml IV QD during rest week (days 6 -14). 
 
• If Hgb < 10, subject s should generally be transfused an amount sufficient to 
increase Hgb to 10.  The H gb level should be maintained > 10 mg/dl for the 
duration of chemoradiotherapy in all subject s.  
 
• The use of peg -filgrastim is described in section 6 and G -CSF (filgrastim) is 
described in section 5.8.  
 
• The use of amifostine during chemoradiotherapy is not permitted . 
 
5.9 Post -therapy F ollow -up 
Every subject should be followed clinically until taken off study. Subject s will be 
seen in clinical evaluation approximately 4 weeks after completing locoregional 
therapy with repeat imaging of the head and neck at that time. PET-CT at 12 weeks 
post-completion of locoregional therapy may also be optionally performed for 
surveillance of indeterminate findings at 6 -week imaging. Salvage surgical 
intervention may be indicated by either 6 - or 12 -week post -treatment imaging 
findings (upon review in multidisciplinary tumor board).  
 
Subject s should undergo clinical and radiographic disease evaluation every 3 
months in year 1, every 6 months in years 2 and 3, and annually in years 4 and 5. 
Radiographic assessment sho uld include imaging of the head, neck , and chest. 
Laboratory evaluation should  consist of at least a CBC, serum electrolytes, serum 
creatinine, liver enzymes (AST, ALT, alkaline phosphatase), serum calcium, and 
serum albumin. TSH should be measured at least annually.  This schedule can be 
SPONSOR: The University of Chicago  
 
49 
Version 4Apr2019  altered according to the physician’s discreti on. Suspicion of progressive disease 
should be evaluated by radiographic studies whenever possible.  
 
In addition, in an exploratory manner, we will draw blood for cell free circulating 
tumor DNA extraction and evaluation of HPV titers as an exploratory mar ker of 
early detection of potential recurrences. This is a research /exploratory evaluation 
and will not be used for clinical decision making at this point.  
 
5.10 Duration of Therapy  
In the absence of treatment delays due to adverse events, treatment may continue 
for the allotted treatment time period (as described above)  or until one of the 
following criteria applies:  
  
• Disease progression.  
 
• Intercurrent illness that prevents further administration of treatment.  
 
• Unacceptable adverse event(s).  
 
• Subject  decides to withdraw from the study.  
 
• General or specific changes in the subject ’s condition render the subject  
unacceptable for further treatment in the judgment of the investiga tor. 
 
5.11 Late Toxicity Assessment  
5.11.1  Late Toxicity Assessment Schedule  
 Swallowing function and speech will be assessed pre -treatment, after induction 
chemotherapy, at first follow -up after completion of definitive locoregional therapy, 
and then at 3, 6, 12, and 24 months post -treatment.  
 
5.11.2  Assessment of Late Toxicity  
Performance measures will be assessed by determining swallowing function and 
speech. Voice will be assessed as a simple yes/no response from subject s as to 
whether their  voice has returned to normal. Swallowing will be determined by  a 
subject ’s ability to swallow table food. A formal swallow evaluation will be done on 
subject s experiencing dysphagia. Additionally, late toxicity will be determined by 
evaluating presence and degree of xerostomia, dental decay, osteoradionecrosis, 
as well as th e presence of G -tube or tracheotomy dependence .  
 
SPONSOR: The University of Chicago  
 
50 
Version 4Apr2019  5.11.3  Performance Measures  
The proposed regimen aims to  decrease treatment toxicity without compromising 
outcomes. Thus, QoL and performance are  important treatment endpoints. The 
objective is to  describe these dimensions prospectively, pre -treatme nt, through 
treatment, to long -term follow -up. Specific aims are to document subject ’s 
experience of treatment effects; evaluate  changes in QoL and performance as a 
function of treatment regimen; determine extensiveness  and persistence of QoL 
and function -related treatment effects; and describe the pattern, timing  and extent 
of recovery of function and QoL.  
 
Performance measures to be used in this protocol include  (Appendix F ): 
• Performa nce Status Scale for Head and Neck Cancer Patient s (PSS -
HN) 
• Functional Assessment of Cancer Therapy - Head and Neck Version 4  
(FACT -H&N)  
• Selected questions from the McMaster University Head and Neck 
Radiotherapy Questionnaire Performance Status Scale fo r Head and 
Neck Cancer ( MRQ )  
 
The PSS -HN is a clinician  rated instrument consisting of three subscales: 
Normalcy of Diet, Eating in Public, and  Understandability of Speech. It has been 
demonstrated to be reliable and valid in head and  neck cancer subject s. 
 
Functional Assessment of Cancer Therapy -Head and Neck V ersion 4 (FACT -
H&N). The FACT -H&N is a multidimensional, self -report QoL instrument 
specifically designed for use with head and neck cancer subject s. The core scale 
(FACT-G) con sists of 27 core items assessing subject  well-being in four areas: 
Physical, Social/Fam ily, Emotional, and Functional. The Core scale is 
supplemented with site -specific modu les, of which the head and neck version (12 
items) will be employed here.  
 
McMaster  Radiotherapy Questionnaire. This subject  self-report instrument (can be 
clinician  administered) quantifies subject s' perception of the frequency  and 
severity (troublesomeness) of radiation related side effects.  
 
These instruments will be administered pre -treatment (pre -induction),  post-
induction chemotherapy,  at first follow -up (4 weeks) after completion of definitive 
locoregional therapy , and then at 3, 6, 12, and 24 months  post-treatment.  
 
SPONSOR: The University of Chicago  
 
51 
Version 4Apr2019  6 EXPECTED ADVERSE EVENTS, RISKS AND DOSE 
MODIFICA TIONS  
6.1 Expected Adverse Events  
6.1.1  Nab-Paclitaxel  
• Cardiovascular: ECG abnormal (60%; 35% in subject s with a 
normal baseline). Edema /fluid retention (10%), hypotension (5%), 
cardiovascular events (grades 3/4: 3%; included chest pain, 
cardiac arrest, supraventricular tachycardia, thrombosis, 
pulmonary thromboembolism, pulmonary emboli, and 
hypertension)  
• Dermatologic: Alopecia (90%)  
• Gastrointestinal: Nausea (30%; grades 3/4: 3%), diarrhea (27%; 
grades 3/4: <1%), vomiting (18%; grades 3/4: 4%), mucositis (7%; 
grades 3/4: <1%)  
• Hematologic: Neutropenia (80%; grade 4: 9%), anemia (33%; 
grades 3/4: 1%), myelosuppression (dose -related), bleeding (2%), 
neutropenic fever (2%), thrombocytopenia (2%; grades 3/4: <1%)  
• Hepatic: AST increased (39%), alkaline phosphatase increased 
(36%), GGT increased (grades 3/4: 14%), bilirubin increased (7%)  
• Neuromuscular & ske letal: Sensory neuropathy (71%; grades 3/4: 
10%; dose dependent; cumulative), weakness (47%; severe 8%), 
myalgia/arthralgia (44%), peripheral neuropathy (grade 3: 10%)  
• Ocular: Vision disturbance (13%; severe [keratitis, blurred vision]: 
1%)  
• Renal: Creatin ine increased (11%; severe 1%)  
• Respiratory: Dyspnea (12%), cough (7%)  
• Miscellaneous: Infection (24%; primarily included oral candidiasis, 
respiratory tract infection, and pneumonia) Hypersensitivity 
reaction (4%, includes chest pain, dyspnea, flushing, hy potension; 
severe: <1%)  
 
SPONSOR: The University of Chicago  
 
52 
Version 4Apr2019  6.1.2  Carboplatin  
• Dermatologic: Alopecia (includes other agents in combination with 
carboplatin)  
• Endocrine & metabolic: Hypomagnesemia, hypokalemia, 
hyponatremia, hypocalcemia; less severe than those seen after 
cisplatin (usually asympt omatic)  
• Gastrointestinal: Nausea, vomiting, stomatitis, diarrhea, anorexia  
• Hematologic: Myelosuppression is dose related and is the dose -
limiting toxicity; thrombocytopenia is the predominant manifestation, 
with a reported incidence of 37% in subject s rece iving 400 mg/m2 as 
a single agent and 80% in subject s receiving 520 mg/m2; leukopenia 
has been reported in 27% to 38% of subject s receiving carboplatin as 
a single agent (nadir: ~21 days following a single dose)  
• Hepatic: Alkaline phosphatase increased, AST  increased (usually mild 
and reversible)  
• Otic: Hearing loss at high tones (above speech ranges, up to 19%); 
clinically -important ototoxicity is not usually seen  
• Renal: Increases in creatinine and BUN have been reported; most of 
them are mild and they are c ommonly reversible; considerably less 
nephrotoxic than cisplatin  
• Neuromuscular & skeletal: Peripheral neuropathy (4% to 6%; up to 
10% in older and/or previously -treated subject s) 
• <1% (Limited to important or life -threatening): Neurotoxicity, urticaria, 
rash, nephrotoxicity, secondary malignancies, anaphylaxis, malaise, 
hypertension  
 
6.1.3  5-Fluorouracil  
Common toxicities include:  
• Gastrointestinal – diarrhea, mucositis, nausea, and vomiting  
• Hematologic – myelosuppression  
• Dermatologic – photosensitivity, skin dryness, hand -foot syndrome, 
increased pigmentation of skin, increased pigmentation of veins used for 
infusion, nail changes  
SPONSOR: The University of Chicago  
 
53 
Version 4Apr2019   
Less commonly observed toxicities include  
• Cardiac – myocardial ischemia, arrhythmias  
• Allergic reactions  
• Neurologic – acute cerebellar syndrome, disorientation, headache  
• Eye – lacrimal duct stenosis, lacrimation, photophobia, and visual 
changes  
 
5-FU may cause birth defects and should not be used in pregnant women.  It is a 
known radiation sensitizer and may potentiate side effects of radiation.  
 
6.1.4  Paclitaxel  (during TFHX concurrent chemoradiation)  
 Common toxicities include  
• Myleosuppression  
• Anemia  
• Alopecia  
• Myalgias and arthralgias  
• Peripheral neuropathy  
• Nausea and vomiting (usually mild)  
• Diarrhea  
• Mucositis  
• Hyper sensitivity reaction  - fever, facial flushing, chills, shortness of 
breath, or hives after Taxol is given.   The majority of these 
reactions  occur within the first 10 minutes of an infusion.   Notify your 
healthcare provider immediately (premedication regim en has 
significantly decreased the incidence of this reaction).   
 
Less common side effects  
• Peripheral edema  
• Abnormal liver function tests  
SPONSOR: The University of Chicago  
 
54 
Version 4Apr2019  • Hypotension  
• Skin reactions/darkening of the skin  
• Nail changes/discoloration  
• Electrocardiogram (ECG) abnormalities with bradycardia, heart block, bundle 
branch block, and ventricular tachycardia,  
 
The following are less common side effects (occurring in 10 -29%) for subject s 
receiving Taxol:  
• Swelling of the feet or ankles (edema).  
• Increases in blood tests measuring liver function.   These return to normal 
once treatment is discontinued. (see liver problems).  
• Low blood pressure (occurring during the first 3 hours of infusion).  
• Darkening of the skin where previous radiation treatment has been given 
(radiation recall - see skin reactions).  
• Nail changes (discoloration of nail beds - rare) (see skin reactions)  
 
6.1.5  Hydroxyurea  
Common side effects include:  
• Myelosuppression (mainly leukopenia)  
• Nausea, vomiting  
• Diarrhea or constipation  
• Stomatitis  
 
It may aggravate the inflammation of mucous membranes secondary to irradiation.   
 
Less common side effects include:   
• Dysuria or impairment of renal tubular function  
• Rare neurologic disturbances, e.g., headaches, dizziness, disorientation, 
hallucination a nd convulsion.  
 
SPONSOR: The University of Chicago  
 
55 
Version 4Apr2019  6.1.6  Cisplatin  
 Common side effects include:  
• Nausea and vomiting  
• Renal toxicity  
• Electrolyte wasting (magnesium, calcium, potassium)  
• Myelosuppression  
• Anemia  
Less common side effects include:  
• Peripheral neuropathy  
• Hearing loss  
• Anorexia  
• Dysguesia, metallic taste  
• Elevated liver function tests  
• Alopecia  
 
6.1.7  Filgrastim  
Common side effects may include chest pain , elevated white count , fatigue, 
dizziness, skin rash, elevated LDH, nausea, thrombocytopenia, bone aches, 
epistaxis, fever  
 
6.1.8  Nivolumab  
Immuno -Oncology (I -0) agents such as PD -1 inhibitors  (e.g. Nivolumab) are 
associated with adverse events that can differ in severity and duration than adverse 
events caused by other therapeutic classes.  Nivolumab is considered an immune -
oncology  agent in this protocol.  Early recognition and management of adverse 
events associated with immune -oncology agents may mitigate severe toxicity.  For 
further details please refer to the nivolumab investigator brochure  and tables below . 
Management guidelin es are provided under 6.2.2.  
SPONSOR: The University of Chicago  
 
56 
Version 4Apr2019  Common side effects include:  
• Fatigue  
• Nause a 
• Anemia  
• Diarrhea  
• Asthenia  
• Endocrinopathies (e.g. hypothyroidism)  
 
Less common side effects include:  
• Hepatic (e.g. transaminase elvation)  
• Pulmonary (e.g. pneumonitis)  
• Renal  
• Skin 
• Hypersensitivity/Infusion Reactions  
 
6.1.9  Radiation  
Radiation to the head and neck will cause skin irritation, dry mucous membranes due to 
salivary gland dysfunction, mucositis and stomatitis.  The concomitant administration of 
chemotherapy will aggravate these side effects.  Long -term side effects include myelitis, 
osteoradionecrosis, hoarseness, hypothyroidism, trismus, swallowing dysfunction, and 
fibrosis of soft tissues.  
 
6.2 Dose modifications  
This study will utilize the CTC AE (NCI Common Termino logy Criteria  for Adverse Events ) 
Version 4 for toxicity and Adverse Event reporting.  A copy of the CTC AE Version 4.0 can 
be downloaded from the CTEP home page 
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  
).This section  discusses the general dose modifications in the setting of the most 
commonly observed adverse events with systemic therapy.  These are general guidelines 
to be followed, but deviations from the listed dose modifications are allowed at the 
discretion of th e treating physician.  
. 
SPONSOR: The University of Chicago  
 
57 
Version 4Apr2019   
6.2.1  Induction Chemotherapy  Dose Modifications  
No more than two dose modifications should be allowed for any subject . If a subject  
requires a third dose -reduction study treatment should be discontinued.  If such a 
subject  is clinically benefiting from treatment, and, if the physician believes the toxicity 
will be alleviated sufficiently with dose modification, further treatment will be permitted at 
the discretion of the Principal Investigator.  In no case should the three cycles of 
induction chemotherapy be given over a period exceeding eleven  (11) weeks  and 
treatment with surgery, radiation, or chemoradiation (as appropriate) should be initiated .   
 
Hematologic toxicity  
• Subject s should not begin a new cycle of induction therapy  unless 
the ANC is > 1500 cells/mm3 and the platelet count is > 100,000 
cells/mm3. Repeat counts should be obtained weekly until 
resolved . In the setting of low blood counts as specified above, 
dose reductions on subsequent cycles are provided in the table 
below.  
• A delay in therapy of up to 2 weeks is permitted for count 
recovery.   
• If ANC  is <1,500 or platelets <100,000 on day 8  or 15  of each 
cycle , reduce all subsequent doses of nab -paclitaxel and 
carboplatin ( if any) to one dose reduction of the previous dose. 
Withhold treatment until counts recover to an absolute neutrophil 
count of at least 500 cells/mm3  and a platelet count of at  least 
50,000 cells/mm3 on days 8 or 15 of the cycle.  Growth factor 
support should then be used with subsequent cycle s. 
 
Dose Modification  Table:  
 
 
Neurotoxicity (Peripheral)  
• Subject s with grade 1 peripheral neuropathy should be carefully watched 
for progression of symptoms. A dose reduction is not necessary in this 
setting.  
100,000/mm3  
SPONSOR: The University of Chicago  
 
58 
Version 4Apr2019  • In the setting of grade 2 peripheral neuropathy – nab-paclitaxel should be 
dose reduced according to the table below.   
• Withhold albumin -bound paclitaxel for grade 3 -4 peripheral neuropathy.  
Resume albumin -bound paclitaxel at reduced doses (see table) when 
peripheral neuropathy improves to Grade 1 or completely resolves.  
 
 
 
Ototoxicity:  
• For grade 3 ototoxicity discontinue carboplatin.  
 
Hypersensitivity : 
• Albumin -bound paclitaxel (Nab -paclitaxel):    
o  For grade 3 reactions manage the reaction according to institutional 
guidelines. For subsequent doses, use steroid and anti -histamine 
pretreatment and increase the infusion time to 60 minutes . For 
documented grade 4 hypersensitivity reactions, manage the reaction 
according to institutional guidelines and discontinue nab -paclitaxel.  
 
Liver : 
• Albumin -bound paclitaxel (Nab -paclitaxel):   
• Mild impairment (AST or ALT <10 times ULN or bilirubin ≤1.25 
times ULN): No adjustment required.  
• Moderate impairment (AST or ALT <10 times ULN or bilirubin 
1.26-2 times ULN): Reduce dose to 75 mg/m2. 
• Severe impairment: AST or ALT <10 times ULN or bilirubin 2.01 -
5 times ULN: Reduce dose to 50 mg/m2. May increase up to 
75mg/m2 in subsequent cycles if liver impairment improves to 
either moderate or mild impairment (based on individual 
tolerance).  
• AST or ALT >10 times ULN or bilirubin >5 times ULN: Discontinue 
nab-paclitaxel.  
 
• No dose adjustment required for Carboplatin  
 Other  Toxicities  
• For all other grade ≥ 2 toxicities (except alopecia, nausea, 
vomiting, fatigue and anorexia), reduce carboplatin and albumin -

SPONSOR: The University of Chicago  
 
59 
Version 4Apr2019  bound paclitaxel by 25% for all subsequent doses during 
induction.  
• In the event of recur rent grade 3 or 4 toxicity attributed to 
chemotherapy (excluding transaminase elevation, nausea, 
vomiting, and alopecia) reduce carboplatin and nab -Paclitaxel by 
a further 25% during induction.  
 
6.2.2  Dose Modifications Immunotherapy/Nivolumab  during Induction Phase   
There will be no dose adjustments for nivolumab, however treatment can be held or 
discontinued based on occurrence of immune related adverse events. Please refer to the 
below tables/guidelines for guidance as  well as investigator brochure for most up to date 
detailed management guidelines.  
Guidelines for permanent discontinuation or withholding of doses are described in Tables 
below (derived from the IB). Detailed guidelines for the management of immune -relate d 
adverse reactions are described in the IB).  
6.2.3  Adverse Event Management Algorithms for Immunotherapy/Nivolumab   
 

SPONSOR: The University of Chicago  
 
60 
Version 4Apr2019   
 

SPONSOR: The University of Chicago  
 
61 
Version 4Apr2019   
 

SPONSOR: The University of Chicago  
 
62 
Version 4Apr2019   
 
 

SPONSOR: The University of Chicago  
 
63 
Version 4Apr2019   
6.2.3.1  Nivolumab Dose Delay Criteria  
Because of the potential for clinically meaningful nivolumab -related AEs requiring early 
recognition and prompt intervention, management algorithms have been developed for 
suspected AEs of selected categories.   These algorithms are specified above.   
 
Dose delays will occur when nivolumab -related AEs have not resolved upon the next 
cycle of tr eatment or the subject  remains on an equivalent of 10 mg prednisone or 
higher. In the setting of an a dverse event  likely due to nivolumab, the treating physician 
has the option to continue induction therapy with carboplatin and nab -paclitaxel w hile 
holdin g nivolumab .  
 
In the event there are adverse events related to carboplatin or nab -paclitaxel that 
require holding treatment, nivolumab must also be held and delayed until chemotherapy 
can resume.  
 
Nivolumab  should also be permanently discontinued for Gra de 2 or 3 immune -related 
adve rse reactions that persist despite treatment modifications or for inability to reduce 
corticosteroid dose to 10 mg prednisone or equivalent per day  
 
 
SPONSOR: The University of Chicago  
 
64 
Version 4Apr2019   
 
6.2.3.2  Treatment of Infusion Reaction  
Since Nivolumab contains only human IgG protein sequences, it is unlikely to be 
immunogenic and induce infusion or hypersensitivity reacitons.  However, if such a 
reaction were to occur, it might manifest with fever, chills, rigors, headache, rash 
pruritus, athralgias, blood pressure shifts, bro nchospasms, or other symptoms.  All 
Grade 3 ,4, or 5 infusion reacitons should be reported within 24 hours to the primary 

SPONSOR: The University of Chicago  
 
65 
Version 4Apr2019  investigator and reported as an SAE if criteria are met.  Infusion reactions should be 
graded according to NCI CTCAE v 4.0 guidelines.  
 
Treatment recommendations are provided below and may be modified based on local treatment 
standards and guidelines as appropriate:  
 
For Grade 1 symptoms:  (Mild reaction; infusion interruption not indicated; intervention 
not indicated)  
 
Remain at bedside a nd monitor subject until recovery from symptoms. The following 
prophylactic premedications are recommended for future infusions: diphenhydramine 50 
mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 
minutes before additional n ivolumab administrations.  
 
For Grade 2 symptoms : (Moderate reaction requires therapy or infusion interruption 
but responds promptly to symptomatic treatment [eg, antihistamines, non -steroidal anti-
inflammatory drugs, narcotics, corticosteroids, bronchodila tors, IV fluids]; prophylactic 
medications indicated for  24 hours).  
 
Stop the nivolumab infusion, begin an IV infusion of normal saline, and treat the subject 
with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg 
(acetaminophen); remain at bedside and monitor subject until resolution of symptoms. 
Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the 
infusion is interrupted, then restart the infusion at 50% of the original infusion  rate when 
symptoms resolve; if no further complications ensue after 30 minutes, the rate may be 
increased to 100% of the original infusion rate. Monitor subject closely. If symptoms 
recur then no further nivolumab will be administered at that visit. Admin ister 
diphenhydramine 50 mg IV, and remain at bedside and monitor the subject until 
resolution of symptoms. The amount of study drug infused must be recorded on the 
electronic case report form (eCRF). The following prophylactic premedications are 
recommend ed for future infusions: diphenhydramine 50 mg (or equivalent) and/or 
paracetamol 325 to 1000 mg (acetaminophen) should be administered at least 30 
minutes before additional nivolumab administrations. If necessary, corticosteroids 
(recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be used.  
 
For Grade 3 or Grade 4 symptoms:  (Severe reaction, Grade 3: prolonged [ie, not 
rapidly responsive to symptomatic medication and/or brief interruption of infusion]; 
recurrence of symptoms following ini tial improvement; hospitalization indicated for other 
clinical sequelae [eg, renal impairment, pulmonary infiltrates]). Grade 4: (life 
threatening; pressor or ventilatory support indicated).  
 
Immediately discontinue infusion of nivolumab. Begin an IV infu sion of normal saline, 
and treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg 
of a 1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 
solution injected slowly for IV administration, and/or diphenh ydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored 
SPONSOR: The University of Chicago  
 
66 
Version 4Apr2019  until the investigator is comfortable that the symptoms will not recur. Nivolumab will be 
permanently discontinued. Investigators should follow thei r institutional guidelines for 
the treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from 
symptoms. In the case of late -occurring hypersensitivity symptoms (eg, appearance of a 
localized or generalized pruritis within 1 week af ter treatment), symptomatic treatment 
may be given (eg, oral antihistamine, or corticosteroids).  
 
6.2.4  Dose Modifications During Concurrent Chemoradiotherapy  
Hematologic Toxicity Dose Modifications for Hydroxyurea:  
Neutropenia :  
If the absolute neutrophil count (ANC) is between 500 and 1000 on day 0 – 5 of each 
cycle, decrease hydroxyurea to 50% of the full dose. On subsequent cycles, a reduced 
starting dose of hydroxyurea should be used.  
For ANC of  500/l on Day 0 – 5 of any cy cle, omit hydroxyurea, and administer 600 
mg/m2/day of 5 -FU and radiotherapy only.  On subsequent cycles, a reduced starting 
dose of hydroxyurea by 50% should be used.  
Thrombocytopenia :  
For a platelet count  of 50,000/ l to 74,000/ l on Day 0 – 5 of each cycle, decrease 
hydroxyurea to 50% of full dose.  On subsequent cycles, a reduced starting dose of 
hydroxyurea may be used.  
For a platelet count  50,000/l on Day 0 – 5 of any cycle, omit hydroxyurea, and 
administer 600 mg/m2/day of 5 -FU and radiothe rapy only.  On subsequent cycles, a 
reduced starting dose of hydroxyurea by 50% should be used.  
Hematologic Dose Modifications for Paclitaxel:  
Dose Level  Paclitaxel 
(mg/m2) 
  0 100 
–1 75 
 -2 50 
-3 Discontinue  
 
SPONSOR: The University of Chicago  
 
67 
Version 4Apr2019  Neutropenia and Thrombocytopenia :  
For ANC ≤ to 1000 or platelet count of 50 -74 on day 0 -5 of each cycle: decrease 
paclitaxel by  one dose level.  
 
For ANC </= 500 or platelet count of less than 50 on day 0 -5 of any cycle:  hold 
paclitaxel for that cycle and decrease by one dose level in subsequent cycles.    
 
Non-Hematologic Dose Modifications  for 5 -FU, Hydroxyurea, and Paclitaxel : 
Mucositis, Dysphagia, Dermatitis, Diarrhea  
 
Treatment cycles should not be delayed for mucositis, dysphagia, dermatitis or 
diarrhea.  
 
For grade 4 mucositis, dysphagia, and dermatitis  exceeding 7 days duration or 
persisting on Day 1 of a subsequent cycle, decrease 5 -FU to 500 mg/m2/day.   
 
For grade 4 diarrhea exceeding 7 days duration or persisting on Day 1 of a 
subsequent cyc le, decrease 5 -FU to 500 mg/m2/day.  
 
Doses will not be increased again on subsequent cycles.  
 
Nephrotoxicity  
 
Grade 2 renal toxicity  – administer 50% dose hydroxyurea  
 
Grade 3, 4 renal toxicity  – Hold hydroxyurea  
 
Hepatotoxicity on day 0:  Grade 3, 4 – Hold hydroxyurea and adjust paclitaxel per package 
insert  
Peripheral neuropathy:  
For Grade 2 peripheral neuropathy, decrease paclitaxel  by one dose level per CRT 
dosing schedule (see hematologic toxicity chart).  
For Grade 3 or greater peripheral neuropathy, discontinue paclitaxel.  
Other Non -hematological Toxicity  
Chemoradiotherapy sh ould not be interrupted for non -hematologic toxicity except as 
judged necessary on a case -by-case basis by the treating radiation, medical oncologists, 
and Principal Investigator.  
In the presence of a persisting fever  38C or other clinically apparent inf ection a cycle 
can be postponed for 1 week or interrupted (if treatment cycle has already started) if this 
is necessary in the opinion of the treating medical and radiation oncologists.  
SPONSOR: The University of Chicago  
 
68 
Version 4Apr2019  Cutaneous vasculit ic toxicities, including vasculitic ulcerations and gangrene, have 
occurred in subject s with myeloproliferative disorders during therapy with hydroxyurea. 
These vasculitic toxicities were reported most often in subject s with a history of, or 
currently rece iving, interferon therapy. Due to potentially severe  clinical outcomes for 
the cutaneous vasculitic ulcers reported in subject s with myeloproliferative disease, 
hydroxyurea should be discontinued if cutaneous vasculitic ulcerations develop.  
 
Geriatric Use:  Elderly subject s may be more sensitive to the effects of hydroxyurea, and 
may require a lower dose regimen. This drug is known to be excreted by the kidney, 
and the risk of toxic reactions to this drug may be greater in subject s with impaired renal 
functi on. Because elde rly subject s are more likely to have decreased renal function, 
care should be taken in dose selection, and it may be useful to monitor renal function.  
 
Dose Modifications  for Cisplatin : 
Cisplatin  
Renal Toxicity  
CrCl 46 -60 – 25% dose reduction  
CrCl 31 -45 – 50% dose reduction  
Myelosuppression  
If the absolute neutrophil count (ANC) is < 1000 on day 1 of each cycle, hold cisplatin and 
when count recover > 1000 ANC, then decrease cisplatin 25% . On subsequent cycles, a 
reduced starting dose of cisplatin  should be used.  
Peripheral neuropathy  
If Grade 2 neuropathy  on day 1 of each cycle, then decrease cisplatin 25% . On 
subsequent cycles, a reduced starting dose of cisplatin  should be used.  
If Grad e 3 or greater neuropathy  on day 1 of each cycle, hold cisplatin and when 
neuropathy recovers to grade 2 or better, then decrease cisplatin 25% . On subsequent 
cycles, a reduced starting dose of cisplatin  should be used.  
General Toxicity Information  
 
Any ot her significant toxicity that is felt to be potentially drug related should be discussed 
between the PI and the treating physician and dose reduction can be implemented for the 
benefit and safety of the subject .  
SPONSOR: The University of Chicago  
 
69 
Version 4Apr2019  Radiotherapy should not be interrupted for non-hematologic toxicities except when judged 
necessary on a case -by-case basis by the treating radiation and medical oncologist in 
consultation with the PI.  
All interruptions or changes to study drug administration must be recorded.  
It will be documented whether or not each subject  completed the clinical study. If for any 
subject  either study treatment or observations were discontinued the reason will be 
recorded. Reasons that a subject  may discontinue participation in a clinical stud y are 
considered to constitute one of the following:  
1. adverse event(s)  
2. abnormal laboratory value(s)  
3. abnormal test procedure result(s)  
4. disease progression  
5. protocol violation  
6. subject withdrew consent  
7. lost to follow -up 
8. administrative problems  
9. death  
 
6.2.5  Dose Modifications Immunotherapy/Nivolumab  during Adjuvant 
Nivolumab Treatment  
There will be no dose adjustments for nivolumab, however treatment can be held or 
discontinued based on occurrence of immune related adverse events. Please refer to 
section s/treatment algorithms  above for adverse event management  during induction for 
further details (management of adverse events and dose delays will be analogous to the 
induction phase for immunotherapy with nivolumab).  
 
SPONSOR: The University of Chicago  
 
70 
Version 4Apr2019  7 AGENT FORMULATION AND PROCUREMENT  
7.1 Nab-pacli taxel  
Classification:  
Antineoplastic Agent, Antimicrotubular; Natural Source (Plant) Derivative; Taxane 
Derivative  
Mode of Action:  
Albumin -bound paclitaxel nanoparticle formulation. Paclitaxel promotes microtubule 
assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and 
inhibiting their disassembly, interfering with the late G 2 mitotic phase, and inhibiting cell 
replication. May also distort mitotic spindles, resulting in the breakage of chromosomes. 
Paclitaxel may also suppress cell proliferation and modulate immune response.  
How Supplied:  
Injection, powder for reconstitution: Abraxane®: 100 mg [contains albumin (human)]  
Storage:  
Store in vials in original cartons at room temperature (20oC -25oC; 68oF to 77oF). Retain 
in the original package to protect from bright light.  
Stability:  
Unopened vials of nab -paclitaxel are stable unt il the date indicated on the package when 
stored at the above temperature in the original package. Reconstituted vials of albumin -
bound paclitaxel may be refrigerated at 2oC to 8oC (38oF to 46oF) for a maximum of 8 
hours and should be protected from bright  light 
Dose Specifics:  
Albumin -bound paclitaxel 100mg/m2 IV over 30, minutes on day 1 , 8, and 15  of each 21 -
day cycle of induction chemotherapy (total of 3 cycles)  
Preparation:  
Reconstitute each vial with 20 mL of 0.9% sodium chloride injection, USP inject ed over 
at least 1 minute. Direct the NaCl onto the inside wall of the vial, and not directly onto the 
lyophilized cake, as this will result in foaming. Following reconstitution, allow the vial to 
sit for a minimum of 5 (five) minutes to ensure proper wett ing of the lyophilized 
cake/powder. Gently swirl and/or invert the vial slowly for at least 2 minutes until complete 
dissolution of any cake/powder occurs.  
Rapid agitation or shaking will result in foaming. If foaming or clumping occurs, stand 
solution for  at least 15 minutes until foam subsides. The reconstituted suspension should 
appear milky and homogeneous without visible particulates. If unsuspended powder is 
visible, the vial should be gently inverted again to ensure complete resuspension, prior to 
SPONSOR: The University of Chicago  
 
71 
Version 4Apr2019  use. Each ml of reconstituted product will contain 5 mg of paclitaxel. Withdraw the desired 
volume and inject the suspension into an empty sterile PVC container.  
Route of Administration  
Albumin -bound paclitaxel will be administered as an IV infusion over 30 minutes. On days 
when carboplatin is given, albumin -bound paclitaxel will be administered first. Filters are 
not required for preparation or administration of albumin -bound paclitaxel. If filters are 
used as part of institutional procedures, the pore size must be ≥ 15 micron.  
Drug Return and Destruction   
Study drug will be disposed of as per the University of Chicago Medical Center 
Investigational Pharmacy drug destruction policy/procedure. The following information 
must be recorded on the site’s pharmacy d rug accountability log:  
Quantity of vials destroyed.  
Expiration date  
Lot number.    
 
The pharmacist must document that the study drug was destroyed in accordance with 
their institution’s drug destruction policy or SOP.   A drug destruction memo and the site’s 
drug destruction SOP/policy should be sent to Celgene Medical Operations Dept.   A copy 
of the drug destruction memo should be retained at the clinical site.   In the event of study 
completion or termination, a copy of all pharmacy records (drug dispe nsing log, drug 
accountability log and any destruction memos) must be mailed to Celgene Medical 
Operations.   
a) Supplier  
Celgene Corporation  
86 Morris Avenue  
Summit, NJ  07901  
 
Industry Contact:  
Martha Kennedy  
Manager, Medical Operations  
Celgene Corporation  
400 Connell Drive, 7th Floor  
Connell Corporate Park  
Berkeley Heights, NJ 07922  
Mobile: 908 -723-6919  
Fax: 908 -673-2779  
Email: Mkennedy@celgene.com   
SPONSOR: The University of Chicago  
 
72 
Version 4Apr2019  b) Drug Distribution  
ABRAXANE® will be distributed by Celgene Corporation .  No supplies will be 
shipped to any site until regulatory approval has been obtained.  Investigational 
sites will be supplied with ABRAXANE® upon identification and screening of a 
potential trial subject.   
Upon identification of a potential subject, sit es must fax a completed Drug 
Request Form to Celgene Corporation .  Allow at least 5 working days for drug 
shipment.  There are no shipments on Fridays or holidays.  
For re -supply of drug, please complete and fax the Drug Request Form to 
Celgene Corporation at 908 -673-2779.  
c) Drug Return and Destruction  
If the investigational site does not have a policy, procedure or SOP detailing 
the process to follow for study drug destruction, the study drug must then be 
returned to Celgene using the Drug Return Form provide d in the package 
containing the study drug.  The following information must be recorded on the 
site’s pharmacy drug accountability log: quantity of vials to be returned, 
expiration date and lot number.  A copy of the Drug Return Form and the study 
drug sho uld be returned to Celgene Clinical Supplies Dept. using the mailing 
address on the packaging slip that came with the original study drug order.  A 
copy of the Drug Return Form should be retained at the clinical site.  In the 
event of study completion or t ermination, a copy of all pharmacy records (drug 
dispensing log, drug accountability log and any destruction memos) must be 
mailed to Celgene Medical Operations.  
If the investigational site has a policy, procedure or SOP detailing the process 
to follow for  study drug destruction, the pharmacist or designee can choose to 
destroy the study drug on site.  The following information must be recorded on 
the site’s pharmacy drug accountability log: quantity of vials destroyed, 
expiration date and lot number.  The pharmacist must document that the study 
drug was destroyed in accordance with their institution’s drug destruction policy 
or SOP.  A drug destruction memo and the site’s drug destruction SOP/policy 
should be sent to Celgene Medical Operations Dept.  A copy  of the drug 
destruction memo should be retained at the clinical site.  In the event of study 
completion or termination, a copy of all pharmacy records (drug dispensing log, 
drug accountability log and any destruction memos) must be mailed to Celgene 
Medic al Operations.  
 
SPONSOR: The University of Chicago  
 
73 
Version 4Apr2019  7.2 Carboplatin  
 Carboplatin: supplied commercially as a sterile lyophilized powder available in single -
dose vials containing 50 mg, 150 mg and 450 mg of carboplatin. Each vial contains equal 
parts by weight of carboplatin and mannitol. Please refer to package insert for information 
on preparation.  
Side effects: listed in section 9.3. Please refer to the package insert for full prescribing 
information.  
Preparation: Immediately before use, the content of each vial must be reconstituted with 
eithe r sterile water for injection, USP, 5% dextrose in water, or 0.9% sodium chloride 
injection, USP to produce a carboplatin concentration of 10 mg/ml. When prepared as 
directed, carboplatin solutions are stable for 8 hours at room temperature. Since no 
antib acterial preservative is contained n the formulation, it is recommended that 
carboplatin solutions be discarded 8 hours after dilution.  
Storage and Stability: Unopened vials of carboplatin are stable for the life indicated on 
the package when stored at con trolled room temperature and protected from light.  
Administration: Administer over  30-60 minutes  after completing the nab-paclitaxel 
infusion. The Calvert Equation (Dose=AUC (CC+25) will be used to achieve the desired 
dose where CC = Wt*(140 -age)/72/creati nine (if female use 85%).  
 
7.3 Fluorouracil  
5-Fluorouracil (Adria, OH) : commercially available as 10 ml ampules containing 
500 mg/10 ml.  No dilution is necessary for administration, but it may be further diluted in 
D5W or normal saline.  It is stored at room temperature and is stable for 24  hours.  It will 
be administered by intravenous continuous infusion  as described in section 5.6.4 .  Please 
refer to the package insert for full prescribing information.   
 
7.4 Hydroxyurea  
Hydroxyurea (Bristol -Myers Squibb, Princeton, NY):  commercially available as 500  mg 
capsules.  It is stored at room temperature and will be administered orally  as described 
in section 5.6.4 .  Please refer to the package insert for solution preparation and expected 
AE.  Please refer to the p ackage insert for full prescribing information.  
 
7.5 Paclitaxel  
Chemistry : Paclitaxel is a natural product with antitumor activity. The chemical name for 
paclitaxelis 5,20 ‐Epoxy‐1,2 hexahydroxytax ‐11‐en 9‐one 4, 10 diacetate 2 ‐
benzoate 13 ‐ester with (2R,3S)‐N‐benzoyl‐3‐phenylisoserine. Paclitaxel is a white 
SPONSOR: The University of Chicago  
 
74 
Version 4Apr2019  to off‐white crystall ine powder with the empirical formula C47H51NO14 and a molecular 
weight of 853.9. It is extremely lipophilic and melts at around 216 ‐217°C. Paclitaxel is 
highly insoluble in water.  
 
Mechanisms of Action : Microtubules have been demonstrated to be very strat egic targets 
for antineoplastic agents; however, few antimicrotubule agents have been discovered and 
encompassed into standard chemotherapeutic regimens. Paclitaxel, a diterpenoid plant 
product extracted from the bark of the western yew (Taxus brevifolia) , has a unique 
mechanism of action. Unlike other antimicrotubule agents in clinical use (e.g. colc hicine, 
vincristine, and vinblastine) that shift the equilibrium between microtubules and tubulin 
subunits toward microtubule disassembly, paclitax el promotes assembly of microtubules 
from tubulin dimers and stabilizes microtubules by preventing depolymerization. These 
microtubules are stable even when treated with low temperatures or calcium, conditions 
that usually promote disassembly. This unusual  stability results in the inhibition of the 
normal dynamic reorganization of the microtubule network that is essential for vital 
interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays 
or "bundles" of microtubules during mitosis.  
 
Human Toxicology : The dose limiting toxicities and MTD of paclitaxel administered on a 
variety of schedules to subject s with solid neoplasms were previously evaluated in phase 
I trials. In these studies, paclitaxel was infused over 1, 3, 6, and 2 4 h, but severe acute 
reactions, characterized by bronchospasm, hypotension, stridor, tachy ‐ and 
bradyarrhythmias, and death, resulted in the temporary discontinuation of all trials. These 
reactions were attributed to paclitaxel's Cremophor vehicle, since identical reactions were 
observed with other drugs formulated with it and when the vehicle a lone was administ ered 
to animals. Since a higher incidence of these acute reactions was observed with shorter 
durations of infusion, studies that used shorter infusions were permanently discontinued, 
and trials that evaluated longer infusion durations (24 h) were resumed u sing antiallergic 
pre‐medications consisting of corticosteroids, H1 ‐ and H2‐ histamine antagonists. 
These modifications were associated with a marked reduction in the incidence of acute 
reactions. Neutropenia was the major dose ‐limiting to xicity for paclitaxel in phase I solid 
tumor trials. In addition, a sensory neuropathy, characterized by a glove ‐and‐sock 
distribution of numbness and paresthesias, was observed at higher doses. Nausea and 
vomiting, myalgias, mucositis, total ‐body alopecia , diarrhea, and phlebitis were also 
observed.  
 
Pharmaceutical Data:   
Formulation:  Paclitaxel (TAXOL®) for Injection Concentrate is a clear colorless to slightly 
yellow viscous solution. It is supplied as a solution in a nonaqueous medium. It is intended 
for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is 
available in 30 mg (5mL) vials. Each mL of sterile non ‐pyrogenic solution contains 6 mg 
paclitaxel, 527 mg of Cremophor®EL (polyoxyethylated castor oil) and 49.7% (v/v) 
dehydrated alcohol, USP.  
 
SPONSOR: The University of Chicago  
 
75 
Version 4Apr2019  Storage and Stability : Unopened vials of Paclitaxel for Injection Concentrate are stable 
until the date indicated o n the package when stored under refrigeration, 2° ‐ 8°C (36°47°  
F). Refrigeration is not required for shipping. Freezing does not adversely affect the 
concentrate. Solutions for infusion which are prepared as recommended are stable at 
ambient temperature an d lighting for up to 27 hours.  
 
Administration : Paclitaxel should be given after the subject  has received the appropriate 
premedication as per institutional standards. Paclitaxel: supplied in 5 ml vials containing 
30 mg of drug (6mg/ml). Please refer to the package insert  for information on preparation 
and for full prescribing information.  
Drug i nteractions: There is a potential for interaction with Ketoconazole, which might 
interfere with paclitaxel metabolism.  
Contraindications: Known hypersensitivity to either paclitaxel or Cremaphor EL.  
 
7.6 Cisplatin  
Formulation: Cisplatin is a sterile aqueous solution, each mL containing 1 mg cisplatin 
and 9 mg sodium chloride. Cisplatin is supplied in multidose vials of 50 mg and 100 mg 
cisplatin. Please refer to package insert for information on preparation.  
NOTE: Aluminum reacts with cisplatin causin g precipitate formation and loss of potency; 
therefore, needles or intravenous sets containing aluminum parts that may come in 
contact with the drug must not be used for the preparation or administration of cisplatin.  
Storage: Store at 15° to 20°C. Do not refrigerate. Protect unopened container from light. 
The cisplatin remaining in the amber vial following initial entry is stable for 28 days 
protected from light or for 7 days under fluorescent room light.  
Side effects are listed in section 6.1.6. Please re fer to the package insert for full 
prescribing information.  
Availability: Cisplatin is commercially available from Bristol Laboratories Oncology 
Products.  
Administration  should follow institutional guidelines and may depend on renal function, 
and ability t o give pre - and post -hydration as appropriate . Typically a bolus injection will 
be given over 2 -3 hours, but injection time may be extended to minimize adverse events. 
Pre- and post -hydration is required.  
 
 
 
SPONSOR: The University of Chicago  
 
76 
Version 4Apr2019  7.7 Filgrastim (Neupogen ) Drug Information  
Packaging and Formulation  
 
G-CSF (Filgrastim) is commercially available. Filgrastim is a sterile, clear, colorless, 
preservative -free liquid for parenteral administration, containing Filgrastim at a specific 
activity of 1.0 ± 0.6 x 108 U/mg (as  measured by a cell mitogenesis assay).  The product 
is available in single use vial form and prefilled syringe.  The single use vial contains 480 
mcg Filgrastim at a fill volume of 1.6 mL.  The formulation is: 480 mcg of Filgrastim (r -
methHuG -CSF), contai ning acetate (0.94 mg), sorbitol (80.0 mg), Tween® 80 (0.004%), 
sodium (0.056 mg) in water for injection, USP q.s. ad (1.6 mL).  The single use prefilled 
syringe contains 0.6 mg Filgrastim at a fill volume of 0.8 mL.  The formulation is: 480 mcg 
of Filgras tim (r -methHuG -CSF), containing acetate (0.472 mg), sorbitol (40.0 mg), 
Tween® 80 (0.004%), sodium (0.028 mg) in water for injection, USP q.s. ad (0.8 mL).   
 
Storage Conditions and Stability  
 
Filgrastim should be stored in the refrigerator at 2o to 8oC (36o to 46oF).  Avoid shaking.  
Prior to injection, Filgrastim may be allowed to reach room temperature for a maximum 
of 24 hours.  Any vial or pre -filled syringe left at room temperature for greater than 24 
hours should be discarded.  Parenteral drug produc ts should be inspected visually for 
particulate matter and discoloration prior to administration, whenever solution and 
container permit; if particulate or discoloration are observed, the container should not be 
used.  At a concentration of 5 mcg/ml or gre ater in D5W, filgrastim is stable for 7 days at 
room or refrigerator temperatures.  At dilutions from 5 to 15 mcg/ml, albumin in a final 
concentration if 2mg/ml should be added to protect against adsorption to plastic materials.  
Addition of albumin is unn ecessary when the drug is diluted to a concentration greater 
than 15 mcg/ml in D5W.  Dilutions in D5W are stable in glass bottles, polyvinyl chloride, 
polyolefin or polypropylene bags and IV sets, and Travenol Infusors.  
 
Dilution of Neupogen® to a final concentration of less than 5 mcg/mL is not recommended 
at any time.  Do not dilute with saline at any time because the product may precipitate.  
 
Preparation and Administration  
 
If using the vial, draw the appropriate dose into a syringe for subcutane ous injection.  If 
using the pre -filled syringe, select the appropriate pre -filled syringe for subcutaneous 
injection.  Inject only the appropriate dose, discard the unused drug.  Incompatibilities : 
Normal saline.  
 
Adverse Reactions  
 
The following events are associated with Filgrastim and meet the regulatory definition of 
“expected”.  The only consistently observed clinical toxicity described with Filgrastim is 
medullary bone pain.  Other clinical adverse events that have been described include skin  
rash, and cutaneous vasculitis.  Since commercial introduction of Neupogen®, there have 
SPONSOR: The University of Chicago  
 
77 
Version 4Apr2019  been rare reports of allergic -type reactions.  Biochemical abnormalities that may occur 
include increases in alkaline phosphatase, uric acid, and lactate dehydrogenase . 
 
Overdosage  
 
The maximum amount of Filgrastim that can be safely administered has not been 
determined.  Efficacy was demonstrated at doses of 4 to 8 mcg/kg/day in the phase 3 
study of nonmyeloablative chemotherapy.  Subject s in  bone marrow transplant st udies 
received up to 138 mcg/kg/day without toxic effects, although there was a flattening of the 
dose response curve above daily doses of greater than 10 mcg/kg/day.   
 
In Fligrastim clinical trials of cancer subject s receiving myelosuppressive chemothera py, 
WBC > 100,000/mm3 have been reported in less than 5% of subject s, but were not 
associated with any reported adverse clinical effects.  
 
In cancer subject s receiving myelosuppressive chemotherapy, discontinuation of 
Filgrastim therapy usually results in  a 50% decrease in circulating neutrophils within 1 to 
2 days, with a return to pretreatment levels in 1 to 7 days.  
 
Toxicity/Warnings  
 
Filgrastim is contraindicated inpatient s with known hypersensitivity to E coli -derived 
proteins, pegfilgrastim, Neupogen ®, or any other component of the product.  
 
Rare cases of splenic rupture have been reported following the administration of colony -
stimulating factors, including Filgrastim, for peripheral blood progenitor cell (PBPC) 
mobilization in both healthy donors an d subject s with cancer.  Some of these cases were 
fatal.  Individuals receiving Filgrastim who report abdominal or shoulder tip pain, 
particularly healthy donors receiving Filgrastim for PBPC mobilization, should be 
evaluated for an enlarged spleen or sple nic rupture.     
 
Adult respiratory distress syndrome (ARDS) has been reported in neutropenic subject s 
with sepsis receiving Filgrastim, and is postulated to be secondary to an influx of 
neutrophils to sites of inflammation in the lungs.  Neutropenic subje cts receiving 
Filgrastim who develop fever, lung infiltrates, or respiratory distress should be evaluated 
for the possibility of ARDS.  In the event that ARDS occurs, Filgrastim should be 
discontinued until resolution of ARDS and subject s should receive ap propriate medical 
management for this condition.  
 
Allergic -type reactions occurring on initial or subsequent treatment have been reported in 
< 1 in 4000 subject s treated with Filgrastim.  These have generally been characterized 
by systemic symptoms involvi ng at least 2 body systems, most often skin (rash, urticaria, 
facial edema), respiratory (wheezing, dyspnea), and cardiovascular (hypotension,  
tachycardia).  Some reactions occurred on initial exposure.  Reactions tended to occur 
within the first 30 minut es after administration and appeared to occur more frequently in 
subject s receiving Filgrastim IV.  Rapid resolution of symptoms occurred in most cases 
SPONSOR: The University of Chicago  
 
78 
Version 4Apr2019  after administration of anti -histamines, steroids, bronchodilators, and/or epinephrine.  
Symptoms recurr ed in more than half the subject s who were rechallenged.  
 
Severe sickle cell crisis have been reported in subject s with sickle cell disease 
(specifically homozygous sickle cell anemia, sickle/hemoglobin C disease, and sickle/
 + 
thalassemia) who received Filgrastim for PBPC mobilization or following chemotherapy. 
One of these cases was fatal.   
 
PREGNANCY AND LACTATION  
Since there are no adequate and well -controlled studies in pregnant women, the effect, if 
any, of Filgrastim o n the developing fetus or the reproductive capacity of the mother is 
unknown.     
 
It is not known whether Filgrastim is excreted in human milk.  Because many drugs are 
excreted in human milk, caution should be exercised when Filgrastim is administered to 
a nursing woman.  
 
DRUG INTERACTIONS  
 
No formal drug interaction studies between pegfilgrastim and other drugs have been 
performed.  Drugs which may potentiate the release of neutrophils, such as lithium, 
should be used with caution.  Subject s receiving lithium and Filgrastim should have more 
frequent monitoring of neutrophil counts.  
 
Nursing Guidelines  
 
Filgrastim should be kept in the refrigerator until needed and the vials or Pre -filled Syringe 
should not be shaken.  The drug should be administered at the same time each day.  Vials 
and Pre -filled Syringes of filgrastim are single -dose and the remaining drug should be 
discarded.  Refer to protocol text for information regarding requirements for 
documentation of doses administered, temperatures, side effects, etc. Acetaminophen is 
the recommend ed analgesic for mild bone pain. Duration of therapy will be determined 
by the return of blood counts (WBC/ANC) to specific values.  
 
7.8 Nivolumab  
Nivolumab is supplied by BMS.  
Nivolumab Storage Conditions and Handling  
Nivolumab should be stored at between 2 -8 degrees Celsius (36 -46 degrees Fahrenheit), and 
protected from light and freezing.  If any temperature excursions are encountered during storage, 
they should be reported to BMS.  As with all injectable drugs, care should be taken when handling 
and prepari ng Nivolumab.  Whenever possible, Nivolumab should be prepared in a laminar flow 
hood or safety cabinet using standard precautions for the safe handling of intravenous agents 
SPONSOR: The University of Chicago  
 
79 
Version 4Apr2019  applying aseptic technique.  Partially used vials should be disposed at the time following 
procedures for the disposal of anticancer drugs.  
Nivolumab Use Time/Stability  
Once transferred to IV bags, the solution may be stored for up to 20 hrs in a refrigerator at 2 -8 
degrees Celsius and used within 8 hours at room temperature and under room light inclusive of 
administration time.  The maximum 8-hour period under room tempe rature and room light 
conditions for undiluted and diluted solutions of Nivolumab injection in the IV bag should be 
inclusive of the product administration period . 
Pharmacy supplies required  
• Empty IV bags -50mg, 100mL, 200 mL  
• 0.9% NaCl bags  
• 0.2 or 1.2 micron in line filter and infusion tubing  
• Volumetric infusion pumps.  
Nivolumab Preparation and Administration:  
• Nivolumab injection is to be administered using a volumetric pump with a 0.2/ 1.2 micron 
pore size, low protein binding polyethersulfon e membrane in -line filter at the protocol -
specific doses  and infusion times . 
• The line should be flushed at the end of the infusion with sufficient quantity of normal 
saline per institution SOC.  
• Nivolumab is not to be administered as an IV push or bolus inj ection.  
• At the dose of 3 60 or 480 mg, the total dose needed will be diluted to a minimum total 
volume of 100 ml in 0.9% Sodium Chloride injection solution.  
• Care must be taken to assure sterility of the prepared solution as the produce not contain 
any anti-microbial preservative or bacteriostatic agent.  
• Nivolumab should be administered over a 1 -hour period; infusions will be controlled by a 
volumetric pump.  
• Nivolumab infusins are compatible with polyolefin containers and infusion sets, and glass 
bottles  .  I 
• Allow the appropriate number of vials of Nivolumab to stand at room temperature for 
approximately 5 minutes before preparation.  
• Ensure that Nivolumab solution is clear, colorless, and essentially free from particulate 
matter.  
• Aseptically withdraw the  require volume of Nivolumab into a syringe and dispense into an 
IV bag.   
o Add the appropriate volume of 0.9% Sodium Chloride injection solution.  
o Mix by gently inverting several times. DO NOT shake.  
o Record the time the Nivolumab was prepared on the IV bag label.  
o Attach the IV bag containing the Nivolumab solution to the infusion set, in -line filter, 
and infusion pump.  
SPONSOR: The University of Chicago  
 
80 
Version 4Apr2019  o The infusion rate of the infusion pump should be adjus ted to allow for a total 
infusion time of 30 minutes.  
o At the end of the infusion period, flush the line with a sufficient quantity of 0.9% 
Sodium Chloride injection solution.  
 
SPONSOR: The University of Chicago  
 
81 
Version 4Apr2019  8 CORRELATIVE/SPECIAL STUDI ES 
8.1 Objective s 
Correlative studies will be explorative in nature and will focus on tissue (serial samples) 
as we ll as blood based markers. The overreaching goal is in a descriptive manner to 
identify changes to the tumor / microenvironment with treatment with nivolumab + 
chemotherapy using serial samples, and also evaluate potential predictive candidate 
biomarkers.  
 
We will collect plasma samples to monitor treatment progress  using  cell free circulating 
tumor DNA (ctDNA). This will be done by measuring the HPV DNA titer and /or somatic 
mutations. In addition to providing a marker of treatment efficacy e.g. during induction 
with nivolumab + chemotherapy, it will also be used to assess subject s after treatment 
serially to assess any evidence of early recurrence but will not be use d for clinical 
decision making at this point.  
 
8.2 Correlative analysis  
8.2.1  Tissue:  
Baseline  archival (or if not available alternatively fresh)  tissue will be collected on all 
subject s as well as a biopsy at week 2 -3 to assess synergistic/immunotherapy relevant 
changes in the tumor micro -environment. In the curative intent setting biopsy is readily 
doable in virtually all head and neck cancer subject s with stage IV HNC as enrolled in this 
trial. 
8.2.1.1  Multicolor IF  based assessment of immune microenvironment  
Using both a rchival or fresh tumor samples (tissue digest or fresh frozen/OTC tissue) and 
then the on -treatment paired biopsy during induction (nivolumab+chemotherapy) , we will 
analyze dynamic changes in the immune microenvironment .  
 
The analyses may include determination of CD8, PD -L1, FOXP3, IDO, CD168, and other 
immune related markers that will be determined by immunofluorescence . Results will be 
digitally assessed, and results descriptively compared with results from  flow cytometry 
(cell digest)  and mRNA a nalysis (see below) . 
 
8.2.1.2  mRNA analysis / Immune Signatures (Nanostring or similar)  
Analysis will be performed using the Nanostring nCounter (or similar approach) using the 
Nanostring immune panel. Briefly from 3 -5 FFPE slides RNA will be extracted using the 
Qiagen RNA/DNA FFPE kit and protocol.  
SPONSOR: The University of Chicago  
 
82 
Version 4Apr2019  8.2.1.3  Tumor DNA Analysis  
Exome sequencing from tumor and normal blood white cells will be performed on the 
tumor samples for an exploratory analysis of correlation of genetic aberrations, immune 
phenotype and tumor response.  In addition tumor RNAseq analysis will be performed 
from tumor tissue. Specific processing information will be made available in a 
continually updated SOP for tissue collection and processing.  
 
8.2.1.4  Germline DNA analysis  
Blood will be obtained from all subject s for exome sequencing of normal DNA (see 
above). Specific processing information will be made available in a continually updated 
SOP for tissue collection and processing.  
 
8.2.1.5  Analysis of Tumor Digests  
Fresh tumor sampl es will be digested using a protocol for tumor digestion employing the 
Miltenyi GentleMACS system available in the HIM Core facility. Single cell suspension 
will be stored for subsequent FACS or similar analysis.  Specific processing information 
will be ma de available in a continually updated SOP for tissue collection and 
processing.  
 
8.2.2  Blood:   
8.2.2.1  ctDNA analysis   
Using cell free  circulating  DNA (ctDNA) we measure HPV DNA titers  and somatic 
mutations. This will be assessed as a candidate marker of treatment efficacy e.g. during 
induction with nivolumab + chemotherapy (baseline versus 2 -3 weeks into treatment).  
 
Furthermore, it will also be used to assess subject s after treatment serially to assess 
any evidence of early recurrence (early detection)  but will not be used for clinical 
decision making at this point. Especially as part of a de -escalation protocol early 
detection in the future may prove invaluable in order to identify subject s at ri sk for 
recurrence, who may benefit from additional therapy.  
 
8.2.2.2  RNA analysis from blood  
Blood samples will be obtained at baseline and after 3 weeks (administration of cycle 2 
nivolu mab dose). Samples will be processed for RNA extraction (e.g. using the PAXge ne 
RNA kit/tubes). RNA will be analyses by Nanostring (see above) or RNAseq in an 
exploratory fashion comparing baseline with on -treatment inflammatory markers. Specific 
processing information will be made available in a continually updated SOP for tissue 
collection and processing.  
SPONSOR: The University of Chicago  
 
83 
Version 4Apr2019   
8.3 Sample and Tissue Procurement  
8.3.1  Archival tumor collection  
 
All subject s at the time of enrollment need to provide ≥10 5 -micron un -stained slides for 
correlative analysis. Subject s who cannot fulfill this requirement  will need to  undergo a 
new biopsy prior to enrollment on study.  
 
8.3.2  Tissue Biopsy  
Tumor biopsy will be performed prior to starting therapy or archival tissue will be obtained 
for all subject s. At the time of surgical resection or biopsy, tissue in excess of what is 
necessary for diagnostic purposes will be obtained <15 min after removal  from the 
subject . Furthermore , an on -treatment biopsy during nivolumab induction chemotherapy 
will be performed at 2 -3 weeks post start of treatment as clinically feasible  and subject  
consents to the procedure .  
 
Tissues will be instantaneously frozen and stored anonymously with a unique barcode at 
-80C in a locked freezer in Biospecimen Shared Resource (Tissue Bank) at The 
University of Chicago. Additional alternative processing (e.g. tissue digestion, and cell 
suspension generation for flow analyses is also acceptable).  
  
• Write study number, subject  initials and date on plastic cryomold.  
• Weigh or estimate sample weight and slice sample into less than 0.5 cm 
thick fragments.  
• Place tissue into cryotube labeled with  study number, subject  initials and 
date filled with RNAlater reagent from Qiagen.  
• Freeze over liquid nitrogen vapors or in -80 C freezer.  
 
8.3.3  Blood Isolation  
Blood will be obtained from all subject s enrolled in the study for pharmacogenomics and 
biomarker ev aluation. Investigation of the relevant polymorphisms will take place in 
germline DNA extracted from peripheral whole blood (10 ml) collected in EDTA (purple 
top) plastic vacutainer tubes (i.e. BD catalog #366643). Investigation of cytokine markers 
will be  from peripheral blood (10 ml) collected in a red top vacutainer tubes. Blood should 
be stored at -80 C and sent to Biospecimen Shared Resource (Tissue Bank) at The 
University of Chicago for DNA extraction and plasma  isolation  following standard HTRC 
proto cols 
 
Isolated DNA will be store anonymously with a unique barcode at -80 C at the University 
at Chicago for future genotype analysis.  
SPONSOR: The University of Chicago  
 
84 
Version 4Apr2019   
Subject s will have blood samples for genotyping and plasma  analysis collected prior to 
induction ch emotherapy. Samples for serum analysis will be collected prior to 
radiotherapy initiation, and then after the first week and at the completion of radiotherapy 
and will be collected at 2 months after radiotherapy.  
 
Plasma will be used for identification of  cell free circulating  tumor DNA, e.g. for HPV titer 
and somatic mutations to be assessed as a candidate biomarker for monitoring during 
treatment for efficacy and surveillance after completion of treatment for detection of early 
recurrence.  
 
SPONSOR: The University of Chicago  
 
85 
Version 4Apr2019  9 STUDY CALENDAR / FLOWCHART  
SPONSOR: The University of Chicago  
 
86 
Version 4Apr2019   

SPONSOR: The University of Chicago  
 
87 
Version 4Apr2019   
 
  

SPONSOR: The University of Chicago  
 
88 
Version 4Apr2019  Subgroup A 1: TORS  
 
 
 

SPONSOR: The University of Chicago  
 
89 
Version 4Apr2019  Subgroup A2: RT Only  
 
 
 
  

SPONSOR: The University of Chicago  
 
90 
Version 4Apr2019  Subgroup B: CRT 3 Cyles  
 
   
 

SPONSOR: The University of Chicago  
 
91 
Version 4Apr2019  Subgroup C: CRT 5 Cycles  
 
 

SPONSOR: The University of Chicago  
 
92 
Version 4Apr2019  10 MEASUREMENT OF EFFECT  
For the purposes of this study, subject s should have both pre - and post -induction 
chemotherapy imaging of the head and neck with either CT or MRI for determination of 
response.  
 
Measurement of target lesions will be evaluated in this study using the international 
criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST  v1.1) 
Committee .90  
 
10.1 Measurement of Target Lesions  
 Tumo r lesions : Must be accurately measured in at least one dimension ( longest  diameter 
in the plane of measurement is to be recorded) with a  minimum  size of 10 mm by CT scan 
(CT scan slice thickness no greater than 5  mm). 
In cases where based on discussion in tumor board the target lesions cannot be 
accurately measured by RECIST a volumetric measurement may be used IF agree upon 
by the tumor board and PI.  
 
Malignant lymph nodes : To be considered patholog ically enlarged  and measurable, a 
lymph node must be ⩾15 mm in  short  axis when assessed by CT scan (CT scan slice 
thickness recommended to be no greater than 5  mm).  At baseline and in  follow -up, only 
the short axis will be measured and followed . 
 
10.2 Measureme nt of Response  
Target lesion measurements will be summated on pre - and post -induction chemotherapy 
imaging. The percentage change will be calculated and the response used for treatment 
stratification as previously described.  
 
10.2.1  Details about diagnostic imagi ng 
Diagnostic imaging plays an important role in the assessment of head and neck 
squamous cell carcinomas before and after treatment. Currently, computed tomography 
(CT) with contrast, fluorodeoxyglucose positron emission tomography (FDG -PET), and 
magnetic  resonance imaging (MRI) are routinely used to evaluate subject s with this type 
of cancer. However, CT and FDG -PET often yield false positive or false negative 
findings for early assessment of treatment response. In particular, increased FDG 
uptake by activated inflammatory cells occurs in irradiated tissue and can result in false 
positive results during the early post -treatment period, which limits the utility of 18FDG -
PET for the detection of residual tumor prior to 12 weeks (Meng et al). This is beyo nd 
the “safe window” for performing surgery in cases of residual tumor that has been 
described at 4 to 12 weeks following chemoradiation, which is between the period of 
resolution of acute tissue injury and the onset of chronic tissue injury induced by 
chemoradiation that results in relatively normal wound healing, and is associated with a 
reduced incidence of surgical complications.  
SPONSOR: The University of Chicago  
 
93 
Version 4Apr2019  On the other hand, measurements derived from diffusion weighted imaging perfusion 
MRI are promising techniques that can serve  as potentially accurate imaging 
biomarkers of early treatment response for head and neck tumors. In particular, ADC, 
which is a measure of the magnitude of diffusion of water molecules within tissue, and is 
commonly clinically calculated using MRI with DW I, and K -trans, which is a measure of 
capillary permeability obtained using dynamic contrast enhanced (DSC) MRI, a 
perfusion weighted imaging MRI sequence, are potentially useful biomarkers for 
predicting treatment response.  
 
Indeed, DWI has been one of t he most investigated biologic imaging modalities in head 
and neck cancer, primarily due to its ability to acquire reproducible images in a short 
sequence that can be incorporated into any head and neck MRI protocol. Studies have 
demonstrated that changes i n ADC and percentage change in tumor volumes between 
baseline DWI and 3 -weeks mid -therapy DWI showed correlation with outcomes, as 
opposed to percentage change in mean ADC, which did not correlate with tumor control 
at 6 months. Results from these studies imply that ADC values may be more accurate in 
detecting changes in tumor architecture, possibly at an earlier stage, compared with 
conventional measures such as alterations in tumor volume or enhancement. Both 
baseline ADC and change in ADC during therapy have proved useful as predictors of 
response in a recent study in which the authors showed that tumors that responded 
completely to chemoradiation had decreased baseline ADC values compared with 
tumors that responded only partially; in this study, change i n the ADC during therapy 
served as a better predictor than baseline ADC alone. Ultimately, the true value of ADC 
in prediction and monitoring of response likely lies in a combination of pre -, intra -, and 
post-therapy ADC values, which needs to be evaluated  in larger samples to establish its 
utility.  
 
Diffusion -weighted MR imaging (DWI) and dynamic contrast -enhanced perfusion -
weighted imaging parameters can potentially serve as biomarkers for predicting 
treatment response in subject s with head and neck squam ous cell carcinomas ( Kuang 
et al, Imanishi et al, Sumi et al, Srinivasan et al, Trojanowska et al, Padhani et al, 
Surlan -Popovic et al, Galban et al, Cao et al) . DWI allows quantification of the diffusion 
of water molecules in tissues using the apparent di ffusion coefficient (ADC), which can 
reflect tumor cellularity. Previous studies demonstrated that tumors with high ADC 
values are less likely to respond to chemoradiation, possibly because a high ADC value 
may reflect the presence of micronecrosis and, co nsequently, increased resistance to 
the delivery of cytotoxic drugs as well as oxygen during chemoradiation. DWI has also 
been used in the prediction of response to chemoradiation in head and neck squamous 
cell carcinomas.  
 
The subject s in this study will  undergo a standardized 3T MRI protocol at baseline 
before induction chemotherapy and approximately 1 month after immunotherapy. The 
MRI sequences included in the protocol consist of multiplanar T1, T2, post -contrast T1, 
diffusion -weighted imaging, and per fusion -weighted imaging, with the same slice 
thickness, matrix sizes, and echo and repetition times implemented for each subject . 
The detailed protocol available to the performing technologists is provided in the 
Appendix.  
 
SPONSOR: The University of Chicago  
 
94 
Version 4Apr2019  ADC maps are automatically gener ated from the DWI sequences and measurement of 
the ADC values of the tumors will be made by drawing regions of interest at the PACS 
viewing station in the University of Chicago radiology computers. Post -processing 
software (Olea) available in the radiology  reading room workstations is necessary to 
derive Ktrans measurement of the tumors from the raw perfusion images.  
 
10.3 Progression -Free and Overall Survival  
  
Progression -Free Survival : From the date of registration to the date of progressive 
disease  or death  (whichever is first) or last follow -up if censored . 
  
Overall Survival : From the date of registration to the date of death or date of last 
follow -up if censored.  
 
Assessment of Local/Distant Failure : If disease progression is documented, 
subject s should have full assessment of sites of failure (i.e. local and distant). Local 
failure should be assessed by radiographic imaging and physical examination. 
Distant failure should be assessed by radiographic imaging. Further assessment 
of local and dista nt failure can be performed if warranted by subject  symptoms.  
 
Patients should be followed for a minimum of 3 years post completion, but optional 
follow -up as aligned with clinical care is acceptable.  
 
SPONSOR: The University of Chicago  
 
95 
Version 4Apr2019  11 REGULATORY AND REPORTING REQUIREMENTS  
11.1 Regulatory Guide lines  
11.1.1  Food and Drug Administration (FDA) Approval  
This study will be conducted under an IND held by Dr. Tanguy Seiwert at the University 
of Chicago.  The University of Chicago CCTO will be responsible for facilitating all 
communications with the FDA on beh alf of the IND holder.    
 
11.2 Expedited Adverse  Event Reporting  
Adverse events (AEs) will use the descriptions and grading scales found in the revised 
NCI Common Terminology Criteria for Adverse Events (CTCAE)  version  4. All appropriate 
treating areas will ha ve access to a copy of the CTC AE version 4. A copy of the CTC AE 
version 4. A copy of the CTC AE version 4 can be downloaded from the CTEP web site 
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-
14_QuickReference_5x7.pdf ). 
 
11.3 Adverse Event Definitions  
11.3.1  Adverse Event  
 
An adverse event is any untoward medical occurrence in a subject  or clinical 
investigation subject administered a pharmaceutical product that does not necessarily 
have a causal relationship with the treatment. An adverse event can be any 
unfavorable and unintended sign (including a laboratory finding), symptom or disea se 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.  
 
At each evaluation subject s should be interviewed in a non -directed manner to elicit 
potential adverse react ions from the subject . The occurrence of an adverse event will 
be based on changes in the subject ’s physical examination, laboratory results, and/or 
signs and symptoms, and review of the subject ’s own record of adverse events.  
 
Adverse events will be follo wed until resolution while the subject  remains on -study. 
Once the subject  is removed from study, events thought to be related to the study 
medication will be followed until resolution or stabilization of the adverse event, or until 
the subject  starts a new  treatment regimen, or death, whichever comes first.  Subjects 
will be followed for AEs/SAEs for 100 days after their last dose of study drug(s).  
 
11.3.2  Serious Adverse Event (SAE)   
An adverse event is considered serious if it results in ANY of the following outcomes:  
 
SPONSOR: The University of Chicago  
 
96 
Version 4Apr2019  1) Death  
2) Life-threatening (e.g. places subject at immediate  risk of death, this does 
not include events that might have caused death if they occurred a greater 
severity)  
3) Results in inpatient  hospitalization or prolongation of existing 
hospitalization for ≥ 24 hours  
4) A persistent or significant incapacity or substantial disruption of the ability 
to conduct normal life functions  
5) A congenital anomaly/birth defect.  
 
Adverse events must be reported to regulatory authorities according to the definitions 
and timelines specified in the local laws and regulations.  
 
Important Medical Events (IME) that may not result in death, be life threatening, or 
require hospitalization may be considered serious when, based upon medical judgment, 
they may jeopardize the subject  or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.   Examples of such 
events are intensive treatm ent in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or 
development of drug dependency or drug abuse.   
 
In addition to those events meeting the definitions above, the followin g will be 
considered an SAE for the purposes of this study:  
 
• Potential drug induced liver injury (DILI ) 
• Suspected transmission of an infectious agent (e.g. pathogenic or 
nonpathogenic) via the study drug  
• Pregnancy occurring within the period defined in sec tion 4.1  
• Overdose  
• Death due to Disease Progression occurring within 100 days of last dose of 
study drug  
 
11.3.3  Relatedness  
The definition of “related” being that there is a reasonable possibility that the drug caused 
the adverse experience . 
 
11.3.4  Adverse Reactions  
An adverse event is considered to be an adverse reaction if there evidence to suggest a 
causal relationship to the study agent.  This may include a single occurrence of an 
event strongly associated with drug exposure (e.g. Stevens -Johnson Syndrome), one or 
more occurrence of an event otherwise uncommon is the study population, or an 
aggregate analysis of specific events occurring at greater than expected frequency.  
 
SPONSOR: The University of Chicago  
 
97 
Version 4Apr2019  11.4 Adverse Event Reporting  
11.4.1  Routine Adverse Event Reporting  
 
All Adverse Events must  be reported in routine study data submissions.  AEs reported 
using the Serious Event Reporting Form and/or MedWatch Form discussed below 
must also be reported in routine study data submissions.   
 
All adverse events (except grade 1 a nd 2 laboratory abnormalities that do not require an 
intervention), regardless of causal relationship, are to be recorded in the case report 
form and source documentation. The Investigator must determine the intensity of any 
adverse events according to the  NCI Common Terminology Criteria for Adverse Events 
(CTCAE) Version 4.0 and their causal relationship.  
 
11.4.2  Serious Adverse Event Reporting  
All serious adverse events  (as defined in sectio n 11.1.2 ) occurring on this study require  
expedited  reporting to the University of Chicago Comprehensive Cancer Center (UC  
CCC) .  The responsible Research Nurse or Clinical Research Coordinator  should report 
the SAE to the Principal  Investigator ,CCTO  and enter  into Velos  by the end of the 
business day when  team  becomes aware of the event.  Events occurring after business 
hours should be reported to the CCTO by 12pm (noon) the next business day  via email 
to qaccto@bsd.uchicago.edu . Reports  in Velos  should be made using the ‘Serious 
Event Report’ Form.    
 
All unexpected adverse reactions must be reported to  the University of Chicago CCTO 
for FDA reporting .  The responsible Research Nurse or Clinical Research Coordinator  
should provide a complete written report using the FDA MedWatch 3500A form.  The 
completed form should be sent to the CCTO within the specified timelines below 
regardless of whether all information regarding the event is available.  If applicab le, a 
follow -up report should be provided to the CCTO if additional information on the event 
becomes available .   
 
Clinical staff  should not forward any adverse event reports directly to the FDA.  
The CCTO will report all events to the FDA as per the curre nt FDA guidelines.   
 
All serious adverse events should  also be reported to the local IRB of record according 
to their policies and procedures.  
   
 
11.4.3  Serious Adverse Event Reporting to BMS  
SAEs, whether related or not related to study drug, and pregnancies must be reported 
to BMS within 24 hours  of investigator knowledge of the event . SAEs must be recorded 
on BMS or an approved form; pregnancies on a Pregnancy Surveillance Form.  
 
SPONSOR: The University of Chicago  
 
98 
Version 4Apr2019  SAE Email Address:  Worldwide.Safety@BMS.com  
 
SAE Facsimile Number:  609-818-3804  
 
If only limited information is initially available, follow -up reports are required. (Note: 
Follow -up SAE reports should include the same investigator term(s) initially reported.)  
 
If an ongoing SAE changes in its intensity or relationship to study drug or if new 
information becomes available, a follow -up SAE report should be sent within 24 hours to 
the BMS (or designee) using the same procedure used for transm itting the initial SAE 
report.  
 
All SAEs should be followed to resolution or stabilization.  
 
Global Pharmacovigilance & Epidemiology  
Bristol -Myers Squibb Company  
Fax Number: 609 -818-3804  
Email: Worldwide.safet y@bms.com  
 
If the investigator believes that an SAE is not related to study drug, but is potentially 
related to the conditions of the study (such as withdrawal of previous therapy or a 
complication of a study procedure),  the relationship should be specified in the narrative 
section of the SAE Report Form.  
 
11.4.4  Serious Adverse Event Reporting to Celgene  
Serious adverse events (SAE) are defined above.  The investigator must inform Celgene 
in writing using a Celgene SAE form or MEDWATCH 3500A form  of any SAE within 24 
hours of being aware of the event .  The written report must be completed and supplied to 
Celgene by facsimile or email within 24 hours/1 business day .  The initial report must be 
as complete as possible, including an assessment of the causal relationship between the 
event and the investig ational product(s), if available.  Information not available at the time 
of the initial report (e.g., an end date for the adverse event or laboratory values received 
after the report) must be documented on a follow -up report.  A final report to document 
resolution of the SAE is required.  The Celgene tracking number (AX -CL-HN-PI-004235) 
and the institutional protocol number should be included on SAE reports (or on the fax 
cover letter) sent to Celgene .  A copy of the fax transmission confirmation  or email  of the 
SAE report to Celgene should be attached to the SAE and retained with the subject  
records.  
 
Celgene Drug Safety Contact Information:  
Celgene  Corporation       
Global Drug Safety and  Risk Management     
Connell  Corporate  Park      
SPONSOR: The University of Chicago  
 
99 
Version 4Apr2019  300 Connell Dr.   Suite  6000      
Berkeley Heights, NJ   07922         
Fax:(908) 673 -9115  
E-mail: drugsafety@celgene.com  
 
11.5 Subject  registration and data submission  
11.5.1  Registration  
All patients must be registered with the University of Chicago Head and Neck Clinical 
Research Coordinator (CRC)  prior to the commencement of treatment. PI, Research 
nurse and CRC will c onfirm all selection criteria listed in Section 4. Confirmation is 
documented with signatures and date.  
 
11.5.2  Data management  
The investigator  or qualified  designee  is responsible  for recording  and verifying  
the accuracy  of subject  data.  
 
All required data must be recorded at the completion of each cycle  as stated above in 
section 11.4.2.  
 
11.6 Data and safety monitoring  
Data Safety and Monitoring will occur at the weekly University of Chicago Head and 
Neck Research Program meetings, which are led by senior level medical oncologists.  At  
each meeting, the study will be reviewed for safety and progress toward  completion . 
Toxicities and adverse events will be reviewed at each meeting.  
 
11.7 Auditing  
The Univer sity of Chicago Comprehensive Cancer  Center  will perform routine  Quality  
Assurance  Audits  of investig ator-initiated clinical  trials as described in the NCI -approved 
UC CCC DSM Plan.  Audits  provide  assurance  that trials  are conducted  and study  data 
are collected,  docu mented  and reported  in compliance with the protocol.  Further,  quality 
assurance audits  ensure that  study  data are collected,  docu mented  and reported  in 
compliance  with Good Clinical Practices  (GCP)  Guidelines  and regulatory  require ments.  
The audit  will review  subjects  enrolled  at the University  of Chicago in accorda nce with 
audit procedures specified in the UC CCC Data  and Safety  Monitoring  plan. 
   
A regulatory authority (e.g. FDA) may also wish to conduct an inspection of the study, 
during its conduct or even after its completion. If an inspection has been requested by a 
regulatory authority, the site investigator must immediately inform the Univers ity of 
Chicago Cancer Clinical Trials Office and Regulatory Manager that such a request has 
SPONSOR: The University of Chicago  
 
100 
Version 4Apr2019  been made.  
 
11.8 Record Reten tion 
Study documentation includes all CRFs, data correction forms or queries, source 
documents, Sponsor -Investigator correspondence, monitor ing logs/letters, and regulatory 
documents (e.g., protocol and amendments, IRB correspondence and approval, signed 
subject  consent forms).  
Source documents include all recordings of observations or notations of clinical activities 
and all reports and recor ds necessary for the evaluation and reconstruction of the clinical 
research study.  
Government agency regulations and directives require that all study documentation 
pertaining to the conduct of a clinical trial must be retained by the study investigator.  In 
the case of a study with a drug seeking regulatory approval and marketing, these 
documents shall be retained for at least two years after the last approval of marketing 
application in an International Conference on Harmonization (ICH) region.  In all ot her 
cases, study documents should be kept on file until three years after the completion and 
final study report of this investigational study.  
 
11.9 Obligations of Study Site Investigations  
The Study Principal Investigator is responsible for the conduct of the clinical trial in 
accordance with Title 21 of the Code of Federal Regulations and/or the Declaration of 
Helsinki.  The Principal Investigator is responsible for personally overseeing th e 
treatment of all study subject s.  He/she must assure that all study personnel, including 
sub-investigators and other study staff members, adhere to the study protocol and all 
FDA/GCP/NCI regulations and guidelines regarding clinical trials both during an d after 
study completion.  
 
The Study Principal Investigator will be responsible for assuring that all the required 
data will be collected and entered into the CRFs. Periodically, monitoring visits or audits 
will be conducted and he/she must provide access  to original records to permit 
verification of proper entry of data.  
 
SPONSOR: The University of Chicago  
 
101 
Version 4Apr2019  12 STATISTICAL CONSIDERATIONS  
12.1 Statistical methods  
12.1.1  Primary Endpoint : Deep Response Rate (DRR)  
Overall Primary Objective:  To demonstrate an increased rate of deep responses (deep 
response rat e=DRR) to induction chemotherapy with the addition of nivolumab to the 
carboplatin/nab -paclitaxel backbone used in the Optima I trial.  
• In the predecessor Optima  1 study , deep responses were defined as ≥50% tumor 
shrinkage by RECIST  1.1 and this is believed to be equivalent to a clinical complete 
response (CR) as utilized in the ECOG 1308 study (which was the primary 
outcome for E1308). Hence in this study , deep responses are also defined as 
≥50% tumor shrinkage by RECIST 1.1.  
• We will employ a superiority  test in which the objective is to establish that the 
response rate to  carboplatin /nab-paclitaxel/nivolumab induction chemotherapy is 
15% higher than the response rate of 6 0% in Optima I which utilized a  
carboplatin /nab-paclitaxel induction regimen.  
• We will test: H 0: DRR=60% (based on data from Optima 1 trial)  vs H A: DRR=75% 
with addition of nivolumab to the carboplatin/nab -paclitaxel induction regimen.  
• Using Power Analysis and Sample Size (PA SS v11) software, a sample of  
subject s will provide 87 % power to test this hypothesis using a (one -sided) type I 
error rate of 0.10. Essentially, H 0 will be rejected and nivolumab/carboplatin/nab -
paclitaxel  based induction regi men declared superior if the lower, one -sided 90% 
confidence limit for the response rate exceeds 75%. No interim analysis will be 
conducted.  
 
NB: A minimum of 10 patients will be enrolled on the RT only and also TORS arm to allow 
for descriptive interpreta tion of the pathology results in tabular form. The overall trial may 
overenroll up to 18 patient s (N=74) to fulfill this enrollment goal for the RT -only and TORS 
arms . 
 
12.1.2  Secondary Endpoint s  
Secondary objectives, respective endpoints, and analyses:  
• To determine the tolerability of the nivolumab/carboplatin/nab -paclitaxel  induction 
chemotherapy regimen and its impact on subsequent receipt of definitive 
chemoradiotherapy.  
o Endpoint will be CTCAE v4.0 adverse events  
o The safety analysis will be performed in all treated subjects. Descriptive 
statistics of safety will be presented using the National Cancer Institute (NCI) 
SPONSOR: The University of Chicago  
 
102 
Version 4Apr2019  Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 by 
treatment arm. All AEs, drug -related AEs, SAEs and drug -related SAEs will 
be tabulated using the worst grade per NCI CTCAE v 4.0 criteria by system 
organ class and preferred term. On -study lab parameters including 
hematology, coagulation, chemistry, liver function and renal function will be 
summarized using worse  grade per NCI CCAE v 4.0 criteria.  
o All recorded adverse events will be listed and tabulated by system organ 
class, preferred term and treatment. Vital signs and clinical laboratory test 
results will be listed and summarized by treatment. Any significant p hysical 
examination findings, and clinical laboratory results will be listed. ECG 
readings will be evaluated by the investigator and abnormalities, if present, 
will be listed.  
• To determine  2-year progression -free survival (PFS) for the entire cohort and a ll arms 
and compare them to the entire cohort and corresponding arms in Optima I.  
o PFS is defined as the time from registration  to the date of first documented 
disease progression, as assessed by the IRC using RECIST 1.1 criteria, or 
death due to any cause,  whichever occurs first. Subjects who died without a 
reported progression will be considered to have progressed on the date of their 
death. Subjects who did not progress or die will be censored on the date of 
their last evaluable tumor assessment. Subjects  who did not have any on study 
tumor assessments and did not die will be censored on the date they were 
registered . Subjects who started any subsequent anti -cancer therapy, including 
tumor -directed radiotherapy and tumor -directed surgery, without a prior 
reported progression will be censored at the last evaluable tumor assessment 
prior to/on initiation of the subsequent anti -cancer therapy.  
o PFS will be estimated by Kaplan -Meier methodology  and comparisons will be 
made using the log -rank test. PF S analyses will include subjects in the overall 
cohort and in each of the three arms.  
• To determine 2 -year overall survival (OS) for the entire cohort and all arms and 
compare them to the entire cohor t and corresponding arms in Optima I.  
o OS is defined as the time between the date of registration  and the date of death. 
For subjects without documentation of death, OS will be censored on the last 
date the subject was known to be alive.  
o OS will be estimated by Kaplan -Meier methodology  and comparisons will be 
made using the log -rank test . OS analyses will include subjects in the  overall  
cohort  and in each of the three arms.  
• To determine 2 -year rates of locoregional and distant control for the entire cohort and 
all arms and compare them to the entire cohort and corresponding arms in Optima I.  
o Locoregion al failure is defined as the time from registration  to the date of first 
documented disease progression  in the head and neck , as assessed by the 
IRC using RECIST 1.1 criteria .  
SPONSOR: The University of Chicago  
 
103 
Version 4Apr2019  o Distant  failure is defined as the time from registration  to the date of first 
documented disease progression  below the clavicles , as assessed by the IRC 
using RECIST 1.1 criteria .  
o Time to locoregional and distant failure rates will be estimated by the Kaplan -
Meier methodology and comparisons will be made using the log -rank test. 
Time to LRF and DF analyses will include  subjects in the overall cohort and in 
each of the three arms.  
 
12.1.3  Exploratory Objectives/ Endpoint s/Analyses  
• To determine rates of acute and late toxicity using CTCAE v4.0 and compare them to 
rates of acute and late toxicity  on the Optima I and RAVD trials.  
o Endpoint will be CTCAE v4.0 adverse events  
o Results will be tabulated and comparisons will be made using the chi -square, 
Fisher’s exact, or t -test as appropriate.  
• To deter mine quality of life scores  in subject s and compare them to quality of life 
scores on the RAVD trial.  
o Endpoint s will be overall and domain subset scores on the QOL instruments 
used.  
o Results will be tabulated and comparisons will be made using the chi -squar e, 
Fisher’s exact, or t -test as appropriate.  
• To determine the comparative efficacy and toxicity profiles of TORS versus RT for 
management of low risk disease  will be exploratory and dependent  on number of 
subject s that are treated . 
o Endpoints  for efficacy  will include progression -free and overall survival, as 
calculated above. Comparisons will be made using the log -rank test.  
o Endpoint for toxicity will be CTCAE v4.0 adverse events. R esults will be 
tabulated and comparisons will be made using t he chi -square, Fisher’s exact, 
or t-test as appropriate.  
 
12.1.4  Laboratory /Translational  Objectives  
We will interrogate  the immune micro -environment at baseline, and 2 -3 weeks into 
induction therapy with nivolumab and chemotherapy with an optional  on-treatment biopsy. 
This will be exploratory  as previously described with descriptive statistical analyses 
summarized in tabular format.  
 
12.1.5  Visual Aid Objectives  
We will administer anonymous and optional subject  questionnaires after the 
SPONSOR: The University of Chicago  
 
104 
Version 4Apr2019  multidisciplinary consultation and prior to allocation to treatme nt arm. These may be 
administered during the induction therapy. We will also distribute anonymous and 
optional questionnaires to providers in surgery, medical oncology, and radiation 
oncology at Head and Neck Multidisciplinary Tumor Board once subject  enrollment is 
discontinued.  
SPONSOR: The University of Chicago  
 
105 
Version 4Apr2019  13 REFERENCES:  
 
 1. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and 
rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology 
29:4294 -4301, 2011  
 2. Ang KK, Harris  J, Wheeler R, et al: Human papillomavirus and survival of 
patient s with oropharyngeal cancer. N Engl J Med 363:24 -35, 2010  
 3. O'Sullivan B, Huang SH, Siu LL, et al: Deintensification candidate 
subgroups in human papillomavirus -related oropharyngeal cance r according to minimal 
risk of distant metastasis. J Clin Oncol 31:543 -50, 2013  
 4. Marur S, Li S, Cmelak A, et al: E 1308: A phase II trial of induction 
chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in 
patient s with human  papilloma virus (HPV) -associated resectable squamous cell 
carcinoma of the oropharynx (OPSCC). J Clin Oncol 31, 2013  
 5. Villaflor VM, Melotek JM, Karrison TG, et al: Response -Adapted Volume 
De-escalation (RAVD) in Locally Advanced Head and Neck Cancer. A nn Oncol, 2016  
 6. Salama JK, Stenson KM, Kistner EO, et al: Induction chemotherapy and 
concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a 
multi -institutional phase II trial investigating three radiotherapy dose levels. Ann On col 
19:1787 -94, 2008  
 7. Nab-paclitaxel and Carboplatin Followed by Response -Based Local 
Therapy in Treating Patient s With Stage III or IV HPV -Related Oropharyngeal Cancer 
(OPTIMA), [STUDY_ID_REMOVED]  
 8. Ferris RL, Blumenschein G, Jr., Fayette J, et al: Nivoluma b for Recurrent 
Squamous -Cell Carcinoma of the Head and Neck. N Engl J Med, 2016  
 9. Seiwert TY, Burtness B, Mehra R, et al: Safety and clinical activity of 
pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the 
head and neck  (KEYNOTE -012): an open -label, multicentre, phase 1b trial. Lancet Oncol 
17:956 -65, 2016  
 10. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J 
Clin 62:10 -29, 2012  
 11. Kramer S, Gelber RD, Snow JB, et al: Combined radiation therapy and  
surgery in the management of advanced head and neck cancer: final report of study 73 -
03 of the Radiation Therapy Oncology Group. Head Neck Surg 10:19 -30, 1987  
 12. Laramore GE, Scott CB, al -Sarraf M, et al: Adjuvant chemotherapy for 
resectable squamous ce ll carcinomas of the head and neck: report on Intergroup Study 
0034. Int J Radiat Oncol Biol Phys 23:705 -13, 1992  
 13. Tupchong L, Phil D, Scott CB, et al: Randomized study of preoperative 
versus postoperative radiation therapy in advanced head and neck ca rcinoma: Long -term 
follow -up of RTOG study 73 -03. International Journal of Radiation 
Oncology*Biology*Physics 20:21 -28, 1991  
 14. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. 
N Engl J Med 328:184 -94, 1993  
 15. Group* TDoVALCS: Induct ion Chemotherapy plus Radiation Compared 
with Surgery plus Radiation in Patient s with Advanced Laryngeal Cancer. New England 
Journal of Medicine 324:1685 -1690, 1991  
SPONSOR: The University of Chicago  
 
106 
Version 4Apr2019   16. Spaulding MB, Fischer SG, Wolf GT: Tumor response, toxicity, and survival 
after neoadj uvant organ -preserving chemotherapy for advanced laryngeal carcinoma. 
The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin 
Oncol 12:1592 -9, 1994  
 17. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or 
without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J 
Med 338:1798 -804, 1998  
 18. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy 
versus concomitant chemotherapy and radiation therapy for advance d-stage oropharynx 
carcinoma. J Natl Cancer Inst 91:2081 -6, 1999  
 19. El-Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the 
management of squamous cell carcinoma of the head and neck region. A meta -analysis 
of prospective and randomized trials.  J Clin Oncol 14:838 -47, 1996  
 20. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy 
with or without concurrent low -dose daily cisplatin in locally advanced squamous cell 
carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458 -
64, 2000  
 21. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to 
locoregional treatment for head and neck squamous -cell carcinoma: three meta -analyses 
of updated individual data. MACH -NC Collaborative Group . Meta -Analysis of 
Chemotherapy on Head and Neck Cancer. Lancet 355:949 -55, 2000  
 22. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous 
radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a 
randomized multicenter study. J Cl in Oncol 16:1318 -24, 1998  
 23. Seiwert TY, Salama JK, Vokes EE: The chemoradiation paradigm in head 
and neck cancer. Nat Clin Pract Oncol 4:156 -71, 2007  
 24. Eisbruch A: Intensity -modulated radiation therapy in the treatment of head 
and neck cancer. Nat Cl in Pract Oncol 2:34 -9, 2005  
 25. Nguyen -Tan PF, Zhang Q, Ang KK, et al: Randomized Phase III Trial to 
Test Accelerated Versus Standard Fractionation in Combination With Concurrent 
Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Gro up 0129 
Trial: Long -Term Report of Efficacy and Toxicity. Journal of Clinical Oncology, 2014  
 26. Langendijk JA, Doornaert P, Verdonck -de Leeuw IM, et al: Impact of late 
treatment -related toxicity on quality of life among patient s with head and neck cancer  
treated with radiotherapy. J Clin Oncol 26:3770 -6, 2008  
 27. Eisbruch A, Schwartz M, Rasch C, et al: Dysphagia and aspiration after 
chemoradiotherapy for head -and-neck cancer: which anatomic structures are affected 
and can they be spared by IMRT? Int J Ra diat Oncol Biol Phys 60:1425 -39, 2004  
 28. Setton J, Caria N, Romanyshyn J, et al: Intensity -Modulated Radiotherapy 
in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan -Kettering 
Cancer Center Experience. International Journal of Radia tion Oncology • Biology • 
Physics 82:291 -298 
 29. Adelstein DJ, Li Y, Adams GL, et al: An intergroup phase III comparison of 
standard radiation therapy and two schedules of concurrent chemoradiotherapy in 
patient s with unresectable squamous cell head and n eck cancer. J Clin Oncol 21:92 -8, 
2003  
SPONSOR: The University of Chicago  
 
107 
Version 4Apr2019   30. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and 
radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 
349:2091 -8, 2003  
 31. Vokes EE, Haraf DJ, Mick R, et al: Intens ified concomitant 
chemoradiotherapy with and without filgrastim for poor -prognosis head and neck cancer. 
J Clin Oncol 12:2351 -9, 1994  
 32. Vokes EE, Panje WR, Schilsky RL, et al: Hydroxyurea, fluorouracil, and 
concomitant radiotherapy in poor -prognosis hea d and neck cancer: a phase I -II study. J 
Clin Oncol 7:761 -8, 1989  
 33. Vokes EE, Beckett M, Karrison T, et al: The interaction of 5 -fluorouracil, 
hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology 
49:454 -60, 1992  
 34. Vokes E E, Weichselbaum RR: Concomitant chemoradiotherapy: rationale 
and clinical experience in patient s with solid tumors. J Clin Oncol 8:911 -34, 1990  
 35. Moran RG, Danenberg PV, Heidelberger C: Therapeutic response of 
leukemic mice treated with fluorinated pyri midines and inhibitors of deoxyuridylate 
synthesis. Biochem Pharmacol 31:2929 -35, 1982  
 36. Brockstein B, Haraf DJ, Stenson K, et al: Phase I study of concomitant 
chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony -
stimulating factor support for patient s with poor -prognosis cancer of the head and neck. 
J Clin Oncol 16:735 -44, 1998  
 37. Brockstein B, Haraf DJ, Stenson K, et al: A phase I -II study of concomitant 
chemoradiotherapy with paclitaxel (one -hour infusion), 5 -fluorouracil and hydroxyurea 
with granulocyte colony stimulating factor support for patient s with poor prognosis head 
and neck cancer. Ann Oncol 11:721 -8, 2000  
 38. Kies MS, Haraf DJ, Rosen F, et al: Concomitant infusional paclitaxel and 
fluorouracil, oral hyd roxyurea, and hyperfractionated radiation for locally advanced 
squamous head and neck cancer. J Clin Oncol 19:1961 -9, 2001  
 39. Vokes EE, Kies MS, Haraf DJ, et al: Concomitant chemoradiotherapy as 
primary therapy for locoregionally advanced head and neck c ancer. J Clin Oncol 18:1652 -
61, 2000  
 40. Rosen FR, Haraf DJ, Kies MS, et al: Multicenter randomized Phase II study 
of paclitaxel (1 -hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily 
radiation with or without erythropoietin for advance d head and neck cancer. Clin Cancer 
Res 9:1689 -97, 2003  
 41. Haraf DJ, Rosen FR, Stenson K, et al: Induction chemotherapy followed by 
concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head 
and neck cancer. Clin Cancer Res 9:5936 -43, 2003  
 42. Vokes EE, Stenson K, Rosen FR, et al: Weekly carboplatin and paclitaxel 
followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: 
curative and organ -preserving therapy for advanced head and neck cancer. J Clin Oncol 
21:320 -6, 2003  
 43. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction 
chemotherapy with cisplatin and 5 -fluorouracil with or without docetaxel for larynx 
preservation. J Natl Cancer Inst 101:498 -506, 2009  
 44. Posner MR, Hershock DM, Bla jman CR, et al: Cisplatin and fluorouracil 
alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705 -15, 2007  
SPONSOR: The University of Chicago  
 
108 
Version 4Apr2019   45. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and 
docetaxel in unresectable head and neck cancer. N Eng l J Med 357:1695 -704, 2007  
 46. Cohen EEW KT, Kocherginsky M, et al.: DeCIDE: A phase III randomized 
trial of docetaxel (D), cisplatin (P), 5 -fluorouracil (F) (TPF) induction chemotherapy (IC) in 
patient s with N2/N3 locally advanced squamous cell carcinoma  of the head and neck 
(SCCHN). J Clin Oncol 30, 2012  
 47. Haddad R, O'Neill A, Rabinowits G, et al: Induction chemotherapy followed 
by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent 
chemoradiotherapy alone in locally advanced  head and neck cancer (PARADIGM): a 
randomised phase 3 trial. Lancet Oncol 14:257 -64, 2013  
 48. Hitt R, Grau JJ, López -Pousa A, et al: A randomized phase III trial 
comparing induction chemotherapy followed by chemoradiotherapy versus 
chemoradiotherapy alone as treatment of unresectable head and neck cancer. Annals of 
Oncology, 2013  
 49. Herman LC, Chen L, Garnett A, et al: Comparison of carboplatin -paclitaxel 
to docetaxel -cisplatin -5-flurouracil induction chemotherapy followed by concu rrent 
chemoradiation for locally advanced head and neck cancer. Oral Oncol 50:52 -8, 2014  
 50. Cohen EEW, Karrison TG, Kocherginsky M, et al: Phase III Randomized 
Trial of Induction Chemotherapy in Patient s With N2 or N3 Locally Advanced Head and 
Neck Cance r. Journal of Clinical Oncology, 2014  
 51. Surapaneni MS, Das SK, Das NG: Designing Paclitaxel Drug Delivery 
Systems Aimed at Improved Patient  Outcomes: Current Status and Challenges. ISRN 
Pharmacology 2012:623139, 2012  
 52. Hansson BG, Rosenquist K, Anton sson A, et al: Strong association between 
infection with human papillomavirus and oral and oropharyngeal squamous cell 
carcinoma: a population -based case -control study in southern Sweden. Acta Otolaryngol 
125:1337 -44, 2005  
 53. Mork J, Lie AK, Glattre E, e t al: Human papillomavirus infection as a risk 
factor for squamous -cell carcinoma of the head and neck. N Engl J Med 344:1125 -31, 
2001  
 54. Marur S, D'Souza G, Westra WH, et al: HPV -associated head and neck 
cancer: a virus -related cancer epidemic. Lancet O ncol 11:781 -9, 2010  
 55. Furniss CS, McClean MD, Smith JF, et al: Human papillomavirus 16 and 
head and neck squamous cell carcinoma. Int J Cancer 120:2386 -92, 2007  
 56. Hammarstedt L, Lindquist D, Dahlstrand H, et al: Human papillomavirus as 
a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119:2620 -3, 
2006  
 57. Rampias T, Sasaki C, Weinberger P, et al: E6 and e7 gene silencing and 
transformed phenotype of human papillomavirus 16 -positive oropharyngeal cancer cells. 
J Natl Cancer  Inst 101:412 -23, 2009  
 58. Sturgis EM, Ang KK: The epidemic of HPV -associated oropharyngeal 
cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw 
9:665 -73, 2011  
 59. Gillison ML, D'Souza G, Westra W, et al: Distinct risk fac tor profiles for 
human papillomavirus type 16 -positive and human papillomavirus type 16 -negative head 
and neck cancers. J Natl Cancer Inst 100:407 -20, 2008  
SPONSOR: The University of Chicago  
 
109 
Version 4Apr2019   60. Posner MR, Lorch JH, Goloubeva O, et al: Survival and human 
papillomavirus in oropharynx cancer  in TAX 324: a subset analysis from an international 
phase III trial. Ann Oncol 22:1071 -7, 2011  
 61. Rischin D, Young RJ, Fisher R, et al: Prognostic significance of p16INK4A 
and human papillomavirus in patient s with oropharyngeal cancer treated on TROG 02.02 
phase III trial. J Clin Oncol 28:4142 -8, 2010  
 62. O'Sullivan B, Huang SH, Perez -Ordonez B, et al: Outcomes of HPV -related 
oropharyngeal cancer patient s treated by radiotherapy alone using altered fractionation. 
Radiother Oncol 103:49 -56, 2012  
 63. Huang SH, Xu W, Waldron J, et al: Refining American Joint Committee on 
Cancer/Union for International Cancer Control TNM stage and prognostic groups for 
human papillomavirus -related oropharyngeal carcinomas. J Clin Oncol 33:836 -45, 2015  
 64. O'Sullivan  B, Huang SH, Su J, et al: Development and validation of a 
staging system for HPV -related oropharyngeal cancer by the International Collaboration 
on Oropharyngeal cancer Network for Staging (ICON -S): a multicentre cohort study. 
Lancet Oncol 17:440 -51, 2016  
 65. Bratman SV, Bruce JP, O’Sullivan B, et al: HUman papillomavirus genotype 
association with survival in head and neck squamous cell carcinoma. JAMA Oncology 
2:823 -826, 2016  
 66. Dawson LA, Anzai Y, Marsh L, et al: Patterns of local -regional recurrence 
following parotid -sparing conformal and segmental intensity -modulated radiotherapy for 
head and neck cancer. Int J Radiat Oncol Biol Phys 46:1117 -26, 2000  
 67. O'Sullivan B, Warde P, Grice B, et al: The benefits and pitfalls of ipsilateral 
radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 51:332 -43, 
2001  
 68. Spencer CR, Gay HA, Haughey BH, et al: Eliminating radiotherapy to the 
contralateral retropharyngeal and high level II lymph nodes in head and neck squamous 
cell carcinoma  is safe and improves quality of life. Cancer 120:3994 -4002, 2014  
 69. Chera BS, Amdur RJ, Tepper J, et al: Phase 2 Trial of De -intensified 
Chemoradiation Therapy for Favorable -Risk Human Papillomavirus -Associated 
Oropharyngeal Squamous Cell Carcinoma. Int  J Radiat Oncol Biol Phys 93:976 -85, 2015  
 70. Holsinger FC, Ferris RL: Transoral Endoscopic Head and Neck Surgery and 
Its Role Within the Multidisciplinary Treatment Paradigm of Oropharynx Cancer: Robotics, 
Lasers, and Clinical Trials. Journal of Clinical  Oncology, 2015  
 71. Morisod B, Simon C: Meta -analysis on survival of patient s treated with 
transoral surgery versus radiotherapy for early -stage squamous cell carcinoma of the 
oropharynx. Head & Neck 38:E2143 -E2150, 2016  
 72. Chen AM, Daly ME, Luu Q, et a l: Comparison of functional outcomes and 
quality of life between transoral surgery and definitive chemoradiotherapy for 
oropharyngeal cancer. Head & Neck 37:381 -385, 2015  
 73. Nichols AC, Yoo J, Hammond JA, et al: Early -stage squamous cell 
carcinoma of the  oropharynx: Radiotherapy vs. Trans -Oral Robotic Surgery (ORATOR) – 
study protocol for a randomized phase II trial. BMC Cancer 13:133 -133, 2013  
 74. Sadeghi N, Li NW, Taheri MR, et al: Neoadjuvant chemotherapy and 
transoral surgery as a definitive treatmen t for oropharyngeal cancer: A feasible novel 
approach. Head Neck, 2016  
 75. Bernier J, Cooper JS, Pajak TF, et al: Defining risk levels in locally 
advanced head and neck cancers: a comparative analysis of concurrent postoperative 
SPONSOR: The University of Chicago  
 
110 
Version 4Apr2019  radiation plus chemotherap y trials of the EORTC (#22931) and RTOG (# 9501). Head 
Neck 27:843 -50, 2005  
 76. [STUDY_ID_REMOVED]: Transoral Surgery Followed By Low -Dose or Standard -
Dose Radiation Therapy With or Without Chemotherapy in Treating Patient s With HPV 
Positive Stage III -IVA Oropharyngeal Cancer.  
 77. Ma DJ, Price KA, Moore EJ, et al: Abstract CT227: MC1273: P hase II 
evaluation of aggressive dose de -escalation for adjuvant chemoradiation in HPV 
associated oropharynx cancer. Cancer Research 75:CT227 -CT227, 2015  
 78. Stenson KM, Haraf DJ, Pelzer H, et al: The role of cervical 
lymphadenectomy after aggressive conc omitant chemoradiotherapy: the feasibility of 
selective neck dissection. Arch Otolaryngol Head Neck Surg 126:950 -6, 2000  
 79. Liauw SL, Mancuso AA, Amdur RJ, et al: Postradiotherapy neck dissection 
for lymph node -positive head and neck cancer: the use of c omputed tomography to 
manage the neck. J Clin Oncol 24:1421 -7, 2006  
 80. Mehanna H, Wong W -L, McConkey CC, et al: PET -CT Surveillance versus 
Neck Dissection in Advanced Head and Neck Cancer. New England Journal of Medicine 
374:1444 -1454, 2016  
 81. Berman D , Korman A, Peck R, et al: The development of 
immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The 
Bristol -Myers Squibb experience. Pharmacology & Therapeutics 148:132 -153, 2015  
 82. Pardoll DM: The blockade of immune checkp oints in cancer 
immunotherapy. Nat Rev Cancer 12:252 -264, 2012  
 83. [STUDY_ID_REMOVED]: Chemotherapy +/ - Nivolumab in Patient s With Intermediate 
and High -Risk Local -Regionally Advanced Head and Neck Squamous Cell Carcinoma.  
 84. George B, Kelly K, Ko A, et al: A BI-007-ST-001 A  Phase I study of 
nivolumab  and nab-paclitaxel  regimen in solid tumors: Results from the Pancreatic 
Cnacer and Non -Small Cell Lung Cancer Cohort , ESMO 2016  abstract 2027  
 85. [STUDY_ID_REMOVED]: Reduced -Dose Intensity -Modulated Radiation Therapy 
With or Without Cisplatin in Treating Patient s With Advanced Oropharyngeal Cancer.  
 86. [STUDY_ID_REMOVED]: Radiation Therapy With Cisplatin or Cetuximab in Treating 
Patient s With Oropharyngeal Cancer.  
 87. [STUDY_ID_REMOVED]: Weekly Cetuximab/RT Versus Weekly Cisplatin /RT in HPV -
Associated Oropharyngeal Squamous Cell Carcinoma (HPVOropharynx).  
 88. [STUDY_ID_REMOVED]: Nab -paclitaxel and Carboplatin Followed by Response -
Based Local Therapy in Treating patient s With Stage III or IV HPV -Related 
Oropharyngeal Cancer (OPTIMA).  
 89. Jordan RC, Lingen MW, Perez -Ordonez B, et al: Validation of methods for 
oropharyngeal cancer HPV status determination in US cooperative group trials. Am J 
Surg Pathol 36:945 -54, 2012  
 90. Eisenhauer E, Therasse P, Bogaerts J, et al: New response evaluat ion 
criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of 
cancer 45:228 -247, 2009  
           91. Ali FM, Johns N, Finlay AY, Salek MS, Piguet V. Comparison of the paper -
based and electronic versions of the Dermatology Life Quality Index: evidence of 
equivalence. Br J Dermatol. 2017.   
SPONSOR: The University of Chicago  
 
111 
Version 4Apr2019  .    92.Campbell N, Ali F, Finlay AY, Salek SS. Equivalence of electronic and paper -based 
patient -reported outcome measures. Qual Life Res. 2015;24(8):1949 -61. 
 
 
 
SPONSOR: The University of Chicago  
 
112 
Version 4Apr2019  APPENDIX A : PERFORMANCE STA TUS CRITERIA  
 
ECOG Performance Status 
Scale   Karnofsky 
Performance Status 
scale   
0 Normal activity. Fully active, 
able to carry on all pre -
disease performance 
without restriction  100 Normal. No complaints, no 
evidence of disease.  
  90 Able to carry on normal 
activit y; minor signs or 
symptoms of disease.  
1 Symptoms, but ambulatory. 
Restricted in physically 
strenuous activity, but 
ambulatory and able to carry 
out work of a light or 
sedentary nature (e.g., light 
housework, office work).  80 Normal activity with effort; 
some signs or symptoms of 
disease.  
  70 Cares for self, unable to 
carry on normal activity or do 
active work.  
2 In bed < 50% of the time. 
Ambulatory and capable of 
all self -care, but unable to 
carry out any work activities. 
Up and about more than 
50% of waking hours.  60 Requires occasional 
assistance, but is able to 
care for most of his/her 
needs.  
  50 Requires considerable 
assistance and frequent 
medical care.  
3 In bed >50% of the time. 
Capable of only limited self -
care, confined to bed or 
chair more t han 50% of 
waking hours.  40 Disabled, requires special 
care and assistance.  
  30 Severely disabled, 
hospitalization indicated. 
Death not imminent.  
4 100% bedridden. 
Completely disabled. 
Cannot carry on any self -
care. Totally confined to bed 
or chair.  20 Very sick, hospitalization 
indicated. Death not 
imminent.  
  10 Moribund, fatal processes 
progressing rapidly.  
5 Dead  0 Dead  
 
  
SPONSOR: The University of Chicago  
 
113 
Version 4Apr2019  APPENDIX B : RTOG /NRG  EARLY TOXICITY GRADING  
 
Tissue  Grade 1  2 3 4 
Skin Follicular, faint or dull 
erythema / epilation / dry 
desquam ation / decreased 
sweating  Tender or bright 
erythema, patchy 
moist 
desquamation / 
moderate edema  Confluent, moist 
desquamation other 
than skin folds, pitting 
edema  Ulceration, 
hemorrhage, necrosis  
Mucous 
membrane  Injection / may experience 
mild pain not r equiring 
analgesic  Patchy mucositis 
that may produce 
an inflammatory 
serosanguinous 
discharge / may 
experience 
moderate pain 
requiring analgesia  Confluent fibrinous 
mucositis / may include 
severe pain requiring 
narcotic  Ulceration, 
hemorrhage or 
necrosis  
Eye Mild conjunctivitis w/ or w/o 
scleral injection / in creased 
tearing  Moderate 
conjunctivitis w/ or 
w/o keratitis 
requiring steroids 
and/or antibiotics / 
dry eye requiring 
artificial tears / iritis 
with photophobia  Severe keratitis with 
corneal ulceratio n / 
objective decrease in 
visual acuity or in visual 
fields / acute glaucoma / 
panophthalmitis  Loss of vision (uni or 
bilateral)  
Ear Mild external otitis with 
erythema, pruritus, 
secondary to dry 
desquamation not requiring 
medication. Audiogram 
unchanged from baseline  Moderate external 
otitis requiring 
topical medication / 
serous otitis media 
/ hypoacusis on 
testing only  Severe external otitis 
with discharge or moist 
desquamation / 
symptomatic hypoacusis 
/ tinnitus, not drug 
related  Deafness  
Salivary 
gland Mild mouth dryness / 
slightly thickened saliva / 
may have slightly altered 
taste such as metallic taste 
/ these changes not 
reflected  
in alteration in baseline 
feeding behavior, such as 
increased use of liquids 
with meals  Moderate to 
complete dryness / 
thick, sticky saliva / 
markedly altered 
taste  (none)  Acute salivary gland 
necrosis  
Pharynx & 
esophagus  Mild dysphagia or 
odynophagia / may require 
topical anesthetic or non -
narcotic analgesics / may 
require soft diet  Moderate 
dysphagia or 
odynophagia / ma y 
require narcotic 
analgesics / may 
require puree or 
liquid diet  Severe dysphagia or 
odynophagia with 
dehydration or weight 
loss > 15% from 
pretreatment baseline 
requiring NG feeding 
tube, IV fluids, or 
hyperalimentation  Complete obstructio n, 
ulceration, perforation, 
fistula  
Larynx  Mild or intermittent 
hoarseness / cough not 
requiring antitussive / 
erythema of mucosa  Persistent 
hoarseness but 
able to vocalize / 
referred ear pain, 
sore throat, patchy 
fibrinous exudate Whispered speech, 
throat pain or referred 
ear pain requiring 
narcotic / conf luent 
fibrinous exudate, Marked dyspnea, 
stridor or hemoptysis 
with tracheostomy or 
intubation necessary  
SPONSOR: The University of Chicago  
 
114 
Version 4Apr2019  or mild arytenoid 
edema not 
requiring narcotic / 
cough  
requiring 
antitussive  marked arytenoid 
edema  
HEME  1 2 3 4 
WBC  3.0 - < 4.0  2.0 - < 3.0  1.0 - < 2.0  < 1.0  
Platelets  75 - < 100  50 - < 75 25 - < 50 <25 or spontaneous 
bleeding  
Neutrophils  1.5 - < 1.9  1.0 - < 1.5  0.5 - < 1.0  < 0.5 or sepsis  
Hgb / Hct  11 - 9.5 (28% - < 32%)  < 9.5 - 7.5 ( < 28%)  < 7.5 - 5.0 (Packe d cell 
transfusion required)  (none)  
 
 
 
SPONSOR: The University of Chicago  
 
115 
Version 4Apr2019  APPENDIX C : RTOG LATE TOXICITY GRADING  
 
Tissue  Grade 1  Grade 2 Grade 3 Grade 4 
Skin Slight atrophy; 
pigmentation 
change; some hair 
loss Patch atrophy; 
moderate 
telangiectasia; total 
hair loss  Marked atrophy; gross 
telangiectasia  Ulceration  
Subcutaneous tissue  Slight induration 
(fibrosis) and loss 
of subcutaneous fat  Moderate fibrosis but 
asymptomatic; slight 
field contracture; <10% 
linear reduction  Severe induration and loss of 
subcutaneous tissue; field 
contracture > 10% linear 
measurement  Necrosis  
Mucous membrane  Slight atrophy and 
dryness  Moderate atrophy and 
telangiectasia; little 
mucous  Marked atrophy with complete 
dryness  Ulceration  
Salivary glands  Slight dryness of 
mouth; good 
response on 
stimulation  Moderate dryness of 
mout h; poor response 
on stimulation  Complete dryness of mouth; no 
response on stimulation  Fibrosis  
Spinal cord  Mild L'Hermitte's 
syndrome  Severe L'Hermitte's 
syndrome  Objective neurological findings 
at or below cord level treated  Mono, para 
quadraplegia  
Brain Mild headache; 
slight lethargy  Moderate headache; 
great lethargy  Severe headache; severe CNS 
dysfunction (partial loss of 
power or dyskinesia)  Coma  
Eye Asymptomatic 
cataract; minor 
corneal ulceration 
or keratitis  Symptomatic cataract; 
moderate corneal 
ulceration; minor 
retinopathy or 
glaucoma  Severe keratitis; severe 
retinopathy or detachment  Panophthalmitis 
/ blindness  
Larynx  Hoarseness; slight 
arytenoid edema  Moderate arytenoid 
edema; chondritis  Severe edema; severe 
chondritis  Necrosis  
Esophagus  Mild fibrosis; slight 
difficulty in 
swallowing solids; 
no pain on 
swallowing  Unable to take solid 
food normally; 
swallowing semisolid 
food; dilatation may be 
indicated  Severe fibrosis; able to swallow 
only liquids; may have pain on 
swallowing; dilatation requi red Necrosis / 
perforation 
fistula  
Bone  Asymptomatic; no 
growth retardation; 
reduced bone 
density  Moderate pain or 
tenderness; growth 
retardation; irregular 
bone sclerosis  Severe pain or tenderness; 
complete arrest of bone growth; 
dense bone sclerosis  Necrosis / 
spontaneous 
fracture  
 
jhjhv  
SPONSOR: The University of Chicago  
 
116 
Version 4Apr2019  APPENDIX D:  SAMPLE TRANSMISSION FORM AND INSTRUCTIONS  
Tissue and Blood Sample Collection Form  
 
Clinician/Research Nurse: Please Fill Out  
Tissue Samples  
Subject  Name: ___________________             UC MR # (if applicable): _______________  
Subject  Protocol ID #:______________              Date Tissue Obtained: _________________  
Date of Birth: ______________________________  Attending Physician: __________________  
Site of Biopsy: ___________________________  Institution: _________________  
Date consent was signed: ___________________      Diagnosis:__________________  
Pre/Post Therapy   (Please circle)    Day started on clinical protocol:__________  
Did Surgical Pathology receive tissue for diagnosis?  Yes   No 
Contact Person’s Phone Number and email Address at Affiliate : 
Blood Samples  
  date drawn  time date shipped    
Pre-Therapy , 
during, and 
post-therapy    1 Tiger Top for 
Plasma         
Pre-therapy  
and 2 -3 weeks 
into induction  1 RNA collection 
tube     
Pre-therapy  1 lavender top/DNA      
 
Researcher: Please Fill Out  
Date Samples received: _________________   Data entered into Database:  Yes
 No 
Name of Data Manager informed: _______________________  Date Informed:_________  
Location in –80C freezer  - _________________  
Approximate size of tissue: _____________________________________________  
Notes:  
 
SPONSOR: The University of Chicago  
 
117 
Version 4Apr2019  Questions or Problems? Please contact:  
HTRC , University of Chicago, 5841 S Maryland, MC 3083, Chicago, IL 60637  
Phone   773-702-0119 , Pager 773 -753-1880 -9747  
 
 
 
 
118 
 APPENDIX E: ACCEPTED FORMS OF BIRTH CONTROL  
HIGHLY EFFECTIVE METHODS OF CONTRACEPTION  
• Hormonal methods of contraception including combined oral contraceptive 
pills, vaginal ring, injectables, implants and intrauterine devices (IUDs) 
such as Mirena® by WOCBP subject or mal e subject’s WOCBP partner   
• IUDs, such as ParaGard®   
• Bilateral Tubal ligation   
• Vasectom ized partner    
• Complete Abstinence*   
  
 *Complete abstinence is defined as complete avoidance of heterosexual 
intercourse and is an acceptable form of contraception for all study drugs. 
Female subjects must continue to have pregnancy tests. Acceptable 
alternate methods of highly effective contraception must be discussed in 
the event that the subject chooses to forego complete abstinence.   
  
 Subjects are encouraged to  use two methods of contraception, with one 
method being highly effective and the other method being eit her highly 
effective or less effective as listed below:   
 
LESS EFFECTIVE  METHODS OF CONTRACEPTION  
• Diaphragm with spermicide   
• Male condoms and spermicide   
• Male condom without spermicide   
• Female condom*         
*A male and female condom must not be used together  
 
 
UNACCEPTABLE METHODS OF CONTRACEPTION:  
o Vaginal sponge  
o Progestin only pills  
o Cervical cap with spermicide  
o Periodic abstinence (calendar, symptothermal, post -ovulation 
methods)  
o Withdrawal (coitus interruptus)  
o Spermicide only  
o Lactat ion amenorrhea method (LAM)  
o A male and a female condom must not be used together  
  
  

 
 
119 
 APPENDIX F: QUALITY OF LIFE FORMS AND PERFORMANCE 
MEASURES  
 
 
 
120 
  
 
 

 
 
121 
  

 
 
122 
  
 
 
 

 
 
123 
 

 
 
124 
 

 
 
125 
 

 
 
126 
 

 
 
127 
 

 
 
128 
 

 
 
129 
 

 
 
130 
 

 
 
131 
 

 
 
132 
 

 
 
133 
 

 
 
134 
  

 
 
135 
  
 